[
  {
    "id": "EP1919899B1",
    "text": "Macrocyclic inhibitors of hepatitis c virus AbstractInhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from formula (II) wherein said ring system may optionally be substituted with 1-3 substituents; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each of which may be optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from N, O or S, and being optionally substituted with 1-3 substituents pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided. Claims (\n12\n)\n\n\n\n\n \n\n\nA compound having the formula\n\n \n \n\nan \nN\n-oxide, salt, or stereoisomer thereof,\n\nwherein each dashed line (represented by -----) represents an optional double bond;\n\n \nX\n is N, CH and where \nX\n bears a double bond it is C;\n\n\n \nR\n1\n \n is -OR\n6\n, -NH-SO\n2\nR\n7\n;\n\n\n \nR\n2\n \n is hydrogen, and where \nX\n is C or CH, \nR\n2\n \n may also be C\n1-6\nalkyl;\n\n\n \nR\n3\n \n is hydrogen, C\n1-6\nalkyl, C\n1-6\nalkoxyC\n1-6\nalkyl, or C\n3-7\ncycloalkyl;\n\n\n \nn\n is 3, 4, 5, or 6;\n\n\n \nR\n4\n \n and \nR\n5\n \n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein said ring system may optionally be substituted with one, two or three substituents independently selected from halo, hydroxy, oxo, nitro, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, C\n1-6\nalkoxycarbonyl, amino, azido, mercapto, polyhaloC\n1-6\nalkyl;\n\n\n \nR\n6\n \n is hydrogen; aryl; Het; C\n3-7\ncycloalkyl optionally substituted with C\n1-6\nalkyl; or C\n1-6\nalkyl optionally substituted with C\n3-7\ncycloalkyl, aryl or with Het;\n\n\n \nR\n7\n \n is aryl; Het; C\n3-7\ncycloalkyl optionally substituted with C\n1-6\nalkyl; or C\n1-6\nalkyl optionally substituted with C\n3-7\ncycloalkyl, aryl or with Het;\n\n\n \naryl\n as a group or part of a group is phenyl or naphthyl, each of which may be optionally substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, amino, mono- or diC\n1-6\nalkylamino, azido, mercapto, polyhaloC\n1-6\nalkyl, polyhaloC\n1-6\nalkoxy, C\n3-7\ncycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C\n1-6\nalkyl-piperazinyl, 4-C\n1-6\nalkylcarbonyl-piperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C\n1-6\nalkyl radicals;\n\n\n \nHet\n as a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, amino, mono- or di-C\n1-6\nalkylamino, azido, mercapto, polyhaloC\n1-6\nalkyl, polyhaloC\n1-6\nalkoxy, C\n3-7\ncycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C\n1-6\nalkyl-piperazinyl, 4-C\n1-6\nalkylcarbonyl-piperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C\n1-6\nalkyl radicals.\n \n\n\n\n\n \n \n\n\nA compound according to claim 1, wherein the compound has the formula (I-c), (I-d), or (I-e):\n\n \n \n\n\n \n \n \n\n\n\n\n \n \n\n\nA compound according to any one of claims 1-2, wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein the phenyl of said bicyclic ring system is optionally substituted with one or two substituents independently selected from halo, hydroxy, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxy-carbonyl, amino, and polyhaloC\n1-6\nalkyl.\n\n\n\n\n \n \n\n\nA compound according to any one of claims 1-2, wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein the pyrrolidine, piperidine, or morpholine rings of said bicyclic ring system are optionally substituted with one or two substituents independently selected from C\n1-6\nalkyl, C\n1-6\nalkoxy, and C\n1-6\nalkoxyC\n1-6\nalkyl.\n\n\n\n\n \n \n\n\nA compound according to any one of claims 1-4, wherein\n\n(a) R\n1\n is -OR\n6\n, wherein R\n6\n is C\n1-6\nalkyl or hydrogen; or\n\n\n(b) R\n1\n is NHS(=O)\n2\nR\n7\n, wherein R\n7\n is methyl, cyclopropyl, or phenyl.\n \n\n\n\n\n \n \n\n\nA compound according to any of claims 1-5 other than an N-oxide, or salt.\n\n\n\n\n \n \n\n\nA combination comprising\n\n(a) a compound as defined in any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof; and\n\n\n(b) ritonavir, or a pharmaceutically acceptable salt thereof.\n \n\n\n\n\n \n \n\n\nA pharmaceutical composition comprising a carrier, and as active ingredient an anti-virally effective amount of a compound as claimed in any one of claims 1-6 or a combination according to claim 7.\n\n\n\n\n \n \n\n\nA compound according to any of claims 1-6 or a combination according to claim 7, for use as a medicament.\n\n\n\n\n \n \n\n\nUse of a compound according to any of claims 1-6 or a combination according to claim 7, for the manufacture of a medicament for inhibiting HCV replication.\n\n\n\n\n \n \n\n\nA compound according to any of claims 1-6 or an effective amount of each component of the combination according to claim 7 for use in a method of inhibiting HCV replication.\n\n\n\n\n \n \n\n\nA process for preparing a compound as claimed in any of claims 1 - 6, wherein said process comprises:\n\n(a) preparing a compound of formula (I) wherein the bond between C\n7\n and C\n8\n is a double bond, which is a compound of formula (I-i), by forming a double bond between C\n7\n and C\n8\n, in particular via an olefin metathesis reaction, with concomitant cyclization to the macrocycle as outlined in the following reaction scheme:\n\n \n \n\nwherein in the above and following reaction schemes R\n8\n represents a radical\n\n \n \n \n\n\n(b) converting a compound of formula (I-i) to a compound of formula (I) wherein the link between C7 and C8 in the macrocycle is a single bond, i.e. a compound of formula (I-j):\n\n \n \n\nby a reduction of the C7-C8 double bond in the compounds of formula (I-j);\n\n\n(c) preparing a compound of formula (I) wherein R\n1\n represents -NHSO\n2\nR\n7\n, said compounds being represented by formula (I-k-1), by forming an amide bond between a intermediate (2a) and an sulfonylamine (2b), or preparing a compound of formula (I) wherein R\n1\n represents -OR\n6\n, i.e. a compound (I-k-2), by forming an ester bond between an intermediate (2a) and an alcohol (2c) as outlined in the following scheme wherein G represents a group:\n\n \n \n\n\n \n \n\n\n \n \n \n\n\n(d) preparing a compound of formula (I) wherein R\n3\n is hydrogen, said compound being represented by (I-l), from a corresponding nitrogen-protected intermediate (3a), wherein PG represents a nitrogen protecting group:\n\n \n \n \n\n\n(e) reacting an intermediate (4a) with an amine (4b) in the presence of a carbamate forming reagent as outlined in the following reaction scheme:\n\n \n \n \n\n\n(f) converting compounds of formula (I) into each other by a functional group transformation reaction; or\n\n\n(g) preparing a salt form by reacting the free form of a compound of formula (I) with an acid or a base. Description\n\n\n\n\n \n \n \nThe present invention is concerned with macrocylic compounds having inhibitory activity on the replication of the hepatitis C virus (HCV). It further concerns compositions comprising these compounds as active ingredients as well as processes for preparing these compounds and compositions.\n\n\n \n \n \n \nHepatitis C virus is the leading cause of chronic liver disease worldwide and has become a focus of considerable medical research. HCV is a member of the \nFlaviviridae\n family of viruses in the \nhepacivirus\n genus, and is closely related to the \nflavivirus\n genus, which includes a number of viruses implicated in human disease, such as dengue virus and yellow fever virus, and to the animal \npestivirus\n family, which includes bovine viral diarrhea virus (BVDV). HCV is a positive-sense, single-stranded RNA virus, with a genome of around 9,600 bases. The genome comprises both 5' and 3' untranslated regions which adopt RNA secondary structures, and a central open reading frame that encodes a single polyprotein of around 3,010-3,030 amino acids. The polyprotein encodes ten gene products which are generated from the precursor polyprotein by an orchestrated series of co- and posttranslational endoproteolytic cleavages mediated by both host and viral proteases. The viral structural proteins include the core nucleocapsid protein, and two envelope glycoproteins E1 and E2. The non-structural (NS) proteins encode some essential viral enzymatic functions (helicase, polymerase, protease), as well as proteins of unknown function. Replication of the viral genome is mediated by an RNA-dependent RNA polymerase, encoded by non-structural protein 5b (NS5B). In addition to the polymerase, the viral helicase and protease functions, both encoded in the bifunctional NS3 protein, have been shown to be essential for replication of HCV RNA. In addition to the NS3 serine protease, HCV also encodes a metalloproteinase in the NS2 region.\n\n\n \n \n \n \nFollowing the initial acute infection, a majority of infected individuals develop chronic hepatitis because HCV replicates preferentially in hepatocytes but is not directly cytopathic. In particular, the lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection. Chronic hepatitis can progress to liver fibrosis leading to cirrhosis, end-stage liver disease, and HCC (hepatocellular carcinoma), making it the leading cause of liver transplantations.\n\n\n \n \n \n \nThere are 6 major HCV genotypes and more than 50 subtypes, which are differently distributed geographically. HCV type 1 is the predominant genotype in Europe and the US. The extensive genetic heterogeneity of HCV has important diagnostic and clinical implications, perhaps explaining difficulties in vaccine development and the lack of response to therapy.\n\n\n \n \n \n \nTransmission of HCV can occur through contact with contaminated blood or blood products, for example following blood transfusion or intravenous drug use. The introduction of diagnostic tests used in blood screening has led to a downward trend in post-transfusion HCV incidence. However, given the slow progression to the end-stage liver disease, the existing infections will continue to present a serious medical and economic burden for decades.\n\n\n \n \n \n \nCurrent HCV therapies are based on (pegylated) interferon-alpha (IFN-α) in combination with ribavirin. This combination therapy yields a sustained virologic response in more than 40% of patients infected by genotype 1 viruses and about 80% of those infected by genotypes 2 and 3. Beside the limited efficacy on HCV type 1, this combination therapy has significant side effects and is poorly tolerated in many patients. Major side effects include influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms. Hence there is a need for more effective, convenient and better tolerated treatments.\n\n\n \n \n \n \nRecently, two peptidomimetic HCV protease inhibitors have gained attention as clinical candidates, namely BILN-2061 disclosed in \n \nWO00/59929\n \n and VX-950 disclosed in \n \nWO03/87092\n \n. A number of similar HCV protease inhibitors have also been disclosed in the academic and patent literature. It has already become apparent that the sustained administration of BILN-2061 or VX-950 selects HCV mutants which are resistant to the respective drug, so called drug escape mutants. These drug escape mutants have characteristic mutations in the HCV protease genome, notably D168V, D168A and/or A156S. Accordingly, additional drugs with different resistance patterns are required to provide failing patients with treatment options, and combination therapy with multiple drugs is likely to be the norm in the future, even for first line treatment.\n\n\n \n \n \n \nExperience with HIV drugs, and HIV protease inhibitors in particular, has further emphasized that sub-optimal pharmacokinetics and complex dosage regimes quickly result in inadvertent compliance failures. This in turn means that the 24 hour trough concentration (minimum plasma concentration) for the respective drugs in an HIV regime frequently falls below the IC\n90\n or ED\n90\n threshold for large parts of the day. It is considered that a 24 hour trough level of at least the IC\n50\n, and more realistically, the IC\n90\n or ED\n90\n, is essential to slow down the development of drug escape mutants.\n\n\n \n \n \n \nAchieving the necessary pharmacokinetics and drug metabolism to allow such trough levels provides a stringent challenge to drug design. The strong peptidomimetic nature of prior art HCV protease inhibitors, with multiple peptide bonds poses pharmacokinetic hurdles to effective dosage regimes.\n\n\n \n \n \n \nThere is a need for HCV inhibitors which may overcome the disadvantages of current HCV therapy such as side effects, limited efficacy, the emerging of resistance, and compliance failures.\n\n\n \n \n \n \n \n \nWO05/0372\n \n relates to macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication, as well as pharmaceutical compositions, methods of treating a Hepatitis C virus infection and methods of treating liver fibrosis.\n\n\n \n \n \n \nThe present invention concerns HCV inhibitors which are superior in one or more of the following pharmacological related properties, i.e. potency, decreased cytotoxicity, improved pharmacokinetics, improved resistance profile, acceptable dosage and pill burden.\n\n\n \n \n \n \nIn addition, the compounds of the present invention have relatively low molecular weight and are easy to synthesize, starting from starting materials that are commercially available or readily available through art-known synthesis procedures.\n\n\n \n \n \n \nThe present invention concerns inhibitors of HCV replication, which can be represented by formula (I):\n\nand the \nN\n-oxides, salts, and stereoisomers thereof, wherein\n\neach dashed line (represented by - - - - -) represents an optional double bond;\n\n \n \n \n \nX\n \n \nis N, CH and where X bears a double bond it is C;\n \n \nR\n1\n \n \n \nis -OR\n6\n, -NH-SO\n2\nR\n7\n;\n \n \nR\n2\n \n \n \nis hydrogen, and where \nX\n is C or CH, \nR\n2\n \n may also be C\n1-6\nalkyl;\n \n \nR\n3\n \n \n \nis hydrogen, C\n1-6\nalkyl, C\n1-6\nalkoxyC\n1-6\nalkyl, or C\n3-7\ncycloalkyl;\n \n \nn\n \n \nis 3, 4, 5, or 6;\n \n \nR\n4\n \n and \nR\n5\n \n \n \ntaken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein said ring system may optionally be substituted with one, two or three substituents independently selected from halo, hydroxy, oxo, nitro, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarlbonyl, C\n1-6\nalkoxycarbonyl, amino, azido, mercapto, polyhaloC\n1-6\nalkyl;\n \n \nR\n6\n \n \n \nis hydrogen; aryl; Het; C\n3-7\ncycloalkyl optionally substituted with C\n1-6\nalkyl; or C\n1-6\nalkyl optionally substituted with C\n3-7\ncycloalkyl, aryl or with Het;\n \n \nR\n7\n \n \n \nis aryl; Het; C\n3-7\ncycloalkyl optionally substituted with C\n1-6\nalkyl; or C\n1-6\nalkyl optionally substituted with C\n3-7\ncycloalkyl, aryl or with Het;\n \n \naryl\n \n \nas a group or part of a group is phenyl or naphthyl, each of which may be optionallysubstituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, amino, mono- or diC\n1-6\nalkylamino, azido, mercapto, polyhaloC\n1-6\nalkyl, polyhaloC\n1-6\nalkoxy, C\n3-7\ncycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C\n1-6\nalkyl-piperazinyl, 4-C\n1-6\nalkylcarbonyl-piperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C\n1-6\nalkyl radicals;\n \n \nHet\n \n \nas a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, amino, mono- or di-C\n1-6\nalkylamino, azido, mercapto, polyhaloC\n1-6\nalkyl, polyhaloC\n1-6\nalkoxy, C\n3-7\ncycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C\n1-6\nalkyl-piperazinyl, 4-C\n1-6\nalkylcarbonyl-piperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C\n1-6\nalkyl radicals.\n \n\n\n \n \n \nThe invention further relates to methods for the preparation of the compounds of formula (I), the \nN\n-oxides, addition salts, and stereochemically isomeric forms thereof, their intermediates, and the use of the intermediates in the preparation of the compounds of formula (I).\n\n\n \n \n \n \nThe invention relates to the compounds of formula (I) \nper se,\n the \nN\n-oxides, addition salts, and stereochemically isomeric forms thereof, for use as a medicament. The invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The pharmaceutical compositions may comprise combinations of the aforementioned compounds with other anti-HCV agents.\n\n\n \n \n \n \nThe invention also relates to the use of a compound of formula (I), or a \nN\n-oxide, addition salt, or stereochemically isomeric forms thereof, for the manufacture of a medicament for inhibiting HCV replication. Or the disclosure relates to a method of inhibiting HCV replication in a warm-blooded animal said method comprising the administration of an effective amount of a compound of formula (I), or a \nN\n-oxide, addition salt, or stereochemically isomeric forms thereof.\n\n\n \n \n \n \nAs used in the foregoing and hereinafter, the following definitions apply unless otherwise noted.\n\n\n \n \n \n \nThe term halo is generic to fluoro, chloro, bromo and iodo.\n\n\n \n \n \n \nThe term \"polyhaloC\n1-6\nalkyl\" as a group or part of a group, e.g. in polyhalo-C\n1-6\nalkoxy, is defined as mono- or polyhalo substituted C\n1-6\nalkyl, in particular C\n1-6\nalkyl substituted with up to one, two, three, four, five, six, or more halo atoms, such as methyl or ethyl with one or more fluoro atoms, for example, difluoromethyl, trifluoromethyl, trifluoroethyl. Preferred is trifluoromethyl. Also included are perfluoroC\n1-6\nalkyl groups, which are C\n1-6\nalkyl groups wherein all hydrogen atoms are replaced by fluoro atoms, e.g. pentafluoroethyl. In case more than one halogen atom is attached to an alkyl group within the definition ofpolyhaloC\n1-6\nalkyl, the halogen atoms may be the same or different.\n\n\n \n \n \n \nAs used herein \"C\n1-4\nalkyl\" as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as for example methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-1-propyl; \"C\n1-6\nalkyl\" encompasses C\n1-4\nalkyl radicals and the higher homologues thereof having 5 or 6 carbon atoms such as, for example, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 2-methyl-1-butyl, 2-methyl-1-pentyl, 2-ethyl-1-butyl, 3-methyl-2-pentyl, and the like. Of interest amongst C\n1-6\nalkyl is C\n1-4\nalkyl.\n\n\n \n \n \n \nThe term \"C\n2-6\nalkenyl\" as a group or part of a group defines straight and branched chained hydrocarbon radicals having saturated carbon-carbon bonds and at least one double bond, and having from 2 to 6 carbon atoms, such as, for example, ethenyl (or vinyl), 1-propenyl, 2-propenyl (or allyl), 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 2-methyl-2-butenyl, 2-methyl-2-pentenyl and the like. Of interest amongst C\n2-6\nalkenyl is C\n2-4\nalkenyl.\n\n\n \n \n \n \nThe term \"C\n2-6\nalkynyl\" as a group or part of a group defines straight and branched chained hydrocarbon radicals having saturated carbon-carbon bonds and at least one triple bond, and having from 2 to 6 carbon atoms, such as, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 2-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl and the like. Of interest amongst C\n2-6\nalkynyl is C\n2-4\nalkynyl.\n\n\n \n \n \n \nC\n3-7\ncycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.\n\n\n \n \n \n \nC\n1-6\nalkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methylene, ethylene, 1,3-propanediyl, 1,4-butanediyl, 1,2-propanediyl, 2,3-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the like. Of interest amongst C\n1-6\nalkanediyl is C\n1-4\nalkanediyl.\n\n\n \n \n \n \nC\n1-6\nalkoxy means C\n1-6\nalkyloxy wherein C\n1-6\nalkyl is as defined above.\n\n\n \n \n \n \nAs used herein before, the term (=O) or oxo forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom. Whenever a ring or ring system is substituted with an oxo group, the carbon atom to which the oxo is linked is a staturated carbon.\n\n\n \n \n \n \nThe radical Het is a heterocycle as specified in this specification and claims. Examples ofHet comprise, for example, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, thiazinolyl, isothiazinolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl (including 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, furanyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazolyl, triazinyl, and the like. Of interest amongst the Het radicals are those which are non-saturated, in particular those having an aromatic character. Of further interest are those Het radicals having one or two nitrogens.\n\n\n \n \n \n \nEach of the Het radicals mentioned in this and the following paragraphs may be optionally substituted with the number and kind of substituents mentioned in the definitions of the compounds of formula (I) or any of the subgroups of compounds of formula (I). Some of the Het radicals mentioned in this and the following paragraphs may be substituted with one, two or three hydroxy substituents. Such hydroxy substituted rings may occur as their tautomeric forms bearing keto groups. For example a 3-hydroxypyridazine moiety can occur in its tautomeric form 2\nH\n-pyridazin-3-one. Where Het is piperazinyl, it preferably is substituted in its 4-position by a substituent linked to the 4-nitrogen with a carbon atom, e.g. 4-C\n1-6\nalkyl, 4-polyhalo-C\n1-6\nalkyl, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkylcarbonyl, C\n3-7\ncycloalkyl.\n\n\n \n \n \n \nInteresting Het radicals comprise, for example pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl (including 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, furanyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazolyl, triazinyl, or any of such heterocycles condensed with a benzene ring, such as indolyl, indazolyl (in particular 1H-indazolyl), indolinyl, quinolinyl, tetrahydroquinolinyl (in particular 1,2,3,4-tetrahydroquinolinyl), isoquinolinyl, tetrahydroisoquinolinyl (in particular 1,2,3,4-tetrahydroisoquinolinyl), quinazolinyl, phthalazinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzofuranyl, benzothienyl.\n\n\n \n \n \n \nThe Het radicals pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, 4-substituted piperazinyl preferably are linked via their nitrogen atom (i.e. 1-pyrrolidinyl, 1-piperidinyl, 4-thiomorpholinyl, 4-morpholinyl, 1-piperazinyl, 4-substituted 1-piperazinyl).\n\n\n \n \n \n \nIt should be noted that the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable. Radicals used in the definitions of the variables include all possible isomers unless otherwise indicated. For instance pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.\n\n\n \n \n \n \nWhen any variable occurs more than one time in any constituent, each definition is independent.\n\n\n \n \n \n \nWhenever used hereinafter, the term \"compounds of formula (I)\", or \"the present compounds\" or similar terms, it is meant to include the compounds of formula (I), each and any of the subgroups thereof, their \nN\n-oxides, addition salts, and stereochemically isomeric forms. One embodiment comprises the compounds of formula (I) or any subgroup of compounds of formula (I) specified herein, as well as the \nN\n-oxides, salts, as the possible stereoisomeric forms thereof. Another embodiment comprises the compounds of formula (I) or any subgroup of compounds of formula (I) specified herein, as well as the salts as the possible stereoisomeric forms thereof.\n\n\n \n \n \n \nThe compounds of formula (I) have several centers of chirality and exist as stereochemically isomeric forms. The term \"stereochemically isomeric forms\" as used herein defines all the possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess.\n\n\n \n \n \n \nWith reference to the instances where (\nR\n) or (\nS\n) is used to designate the absolute configuration of a chiral atom within a substituent, the designation is done taking into consideration the whole compound and not the substituent in isolation.\n\n\n \n \n \n \nUnless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms, which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or mixed with each other are intended to be embraced within the scope of the present invention.\n\n\n \n \n \n \nPure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term \"stereoisomerically pure\" concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e. minimum 90% of one isomer and maximum 10% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a stereoisomeric excess of 97% up to 100%. The terms \"enantiomerically pure\" and \"diastereomerically pure\" should be understood in a similar way, but then having regard to the enantiomeric excess, and the diastereomeric excess, respectively, of the mixture in question.\n\n\n \n \n \n \nPure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.\n\n\n \n \n \n \nThe diastereomeric racemates of the compounds of formula (I) can be obtained separately by conventional methods. Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.\n\n\n \n \n \n \nFor some of the compounds of formula (I), their \nN\n-oxides, salts, solvates, and the intermediates used in the preparation thereof, the absolute stereochemical configuration was not experimentally determined. A person skilled in the art is able to determine the absolute configuration of such compounds using art-known methods such as, for example, X-ray diffraction.\n\n\n \n \n \n \nThe present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.\n\n\n \n \n \n \nThe present disclosure is also intended to include prodrugs of the compounds of formula (I). The term \"prodrug\" as used throughout this text means the pharmacologically acceptable derivatives such as esters, amides and phosphates, such that the resulting \nin vivo\n biotransformation product of the derivative is the active drug as defined in the compounds of formula (I). The reference by \nGoodman and Gilman (The Pharmacological Basis of Therapeutics, 8th ed, McGraw-Hill, Int. Ed. 1992, \"\nBiotransformation of Drugs\n\", p 13-15\n) describing prodrugs generally is hereby incorporated. Prodrugs preferably have excellent aqueous solubility, increased bioavailability and are readily metabolized into the active inhibitors \nin vivo.\n Prodrugs of a compound of the present invention may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either by routine manipulation or \nin vivo,\n to the parent compound.\n\n\n \n \n \n \nPreferred are pharmaceutically acceptable ester prodrugs that are hydrolysable \nin vivo\n and are derived from those compounds of formula (I) having a hydroxy or a carboxyl group. An \nin vivo\n hydrolysable ester is an ester, which is hydrolyzed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C\n1-6\nalkoxymethyl esters for example methoxymethyl, C\n1-6\nalkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C\n3-8\ncycloalkoxycarbonyloxyC\n1-6\nalkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C\n1-6\nalkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl which may be formed at any carboxy group in the compounds of this invention.\n\n\n \n \n \n \nAn \nin vivo\n hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a result of the \nin vivo\n hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of \nin vivo\n hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4-position of the benzoyl ring.\n\n\n \n \n \n \nFor therapeutic use, salts of the compounds of formula (I) are those wherein the counter-ion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.\n\n\n \n \n \n \nThe pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, \np\n-toluenesulfonic, cyclamic, salicylic, \np\n-aminosalicylic, pamoic and the like acids.\n\n\n \n \n \n \nConversely said salt forms can be converted by treatment with an appropriate base into the free base form.\n\n\n \n \n \n \nThe compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, \nN\n-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.\n\n\n \n \n \n \nThe term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.\n\n\n \n \n \n \nThe term \"quaternary amine\" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl \np\n-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion of choice can be introduced using ion exchange resins.\n\n\n \n \n \n \nThe \nN\n-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called \nN\n-oxide.\n\n\n \n \n \n \nIt will be appreciated that the compounds of formula (I) may have metal binding, chelating, complex forming properties and therefore may exist as metal complexes or metal chelates. Such metalated derivatives of the compounds of formula (I) are intended to be included within the scope of the present disclosure.\n\n\n \n \n \n \nSome of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.\n\n\n \n \n \n \nAs mentioned above, the compounds of formula (I) have several asymmetric centers. In order to more efficiently refer to each of these asymmetric centers, the numbering system as indicated in the following structural formula will be used.\n\n \n \n \n\n\n \n \n \n \nAsymmetric centers are present at positions 1, 4 and 6 of the macrocycle as well as at the carbon atom 3' in the 5-membered ring, carbon atom 2' when the R\n2\n substituent is C\n1-6\nalkyl, and at carbon atom 1' when X is CH. Each of these asymmetric centers can occur in their R or S configuration.\n\n\n \n \n \n \nThe stereochemistry at position 1 preferably corresponds to that of an L-amino acid configuration, i.e. that of L-proline.\n\n\n \n \n \n \nWhen X is CH, the 2 carbonyl groups substituted at positions 1' and 5' of the cyclopentane ring preferably are in a trans configuration. The carbonyl substituent at position 5' prferably is in that configuration that cooresponds to an L-proline configuration. The carbonyl groups substituted at positions 1' and 5' preferably are as depicted below in the structure of the following formula\n\n \n \n \n\n\n \n \n \n \nThe compounds of formula (I) include a cyclopropyl group as represented in the structural fragment below:\n\n \n \n\nwherein C\n7\n represents the carbon at position 7 and carbons at position 4 and 6 are asymmetric carbon atoms of the cyclopropane ring.\n\n\n \n \n \n \nNotwithstanding other possible asymmetric centers at other segments of the compounds offormula (I), the presence of these two asymmetric centers means that the compounds can exist as mixtures of diastereomers, such as the diastereomers of compounds of formula (I) wherein the carbon at position 7 is configured either syn to the carbonyl or syn to the amide as shown below.\n\n \n \n\n\n \n \n \n\n\n \n \n \n \nOne embodiment concerns compounds of formula (I) wherein the carbon at position 7 is configured syn to the carbonyl. Another embodiment concerns compounds of formula (I) wherein the configuration at the carbon at position 4 is R. A specific subgroup of compounds of formula (I) are those wherein the carbon at position 7 is configured syn to the carbonyl and wherein the configuration at the carbon at position 4 is R.\n\n\n \n \n \n \nThe compoundsof formula (I) may include a proline residue (when X is N) or a cyclopentyl or cyclopentenyl residue (when X is CH or C).. Preferred are the compounds of formula (I) wherein the substituent at the 1 (or 5') position and the carbamate substituent at position 3' are in a trans configuration. Of particular interest are the compounds of formula (I) wherein position 1 has the configuration corresponding to L-proline and the carbamate substituent at position 3' is in a trans configuration in respect of position 1. Preferably the compounds of formula (I) have the stereochemistry as indicated in the structures of formulae (I-a) and (I-b) below:\n\n \n \n \n\n\n \n \n \n \nOne embodiment of the present invention concerns compounds of formula (I) or of formula (I-a) or of any subgroup of compounds of formula (I), wherein one or more of the following conditions apply:\n\n \n \n \n(a) R\n2\n is hydrogen;\n \n(b) X is nitrogen;\n \n(c) a double bond is present between carbon atoms 7 and 8.\n \n\n\n \n \n \nOne embodiment of the present invention concerns compounds of formula (I) or of formulae (I-a), (I-b), or of any subgroup of compounds of formula (I), wherein one or more of the following conditions apply:\n\n \n \n \n(a) R\n2\n is hydrogen;\n \n(b) X is CH;\n \n(c) a double bond is present between carbon atoms 7 and 8.\n \n\n\n \n \n \nParticular subgroups of compounds of formula (I) are those represented by the following structural formulae:\n\n \n \n \n\n\n \n \n \n \nAmongst the compounds of formula (I-c) and (I-d), those having the stereochemical configuration of the compounds of formulae (I-a), and (I-b), respectively, are of particular interest.\n\n\n \n \n \n \nThe double bond between carbon atoms 7 and 8 in the compounds of formula (I), or in any subgroup of compounds of formula (I), may be in a \ncis\n or in a \ntrans\n configuration. Preferably the double bond between carbon atoms 7 and 8 is in a \ncis\n configuration, as depicted in formulae (I-c) and (I-d).\n\n\n \n \n \n \nA double bond between carbon atoms 1' and 2' may be present in the compounds of formula (I), or in any subgroup of compounds of formula (I), as depicted in formula (I-e) below.\n\n \n \n \n\n\n \n \n \n \nYet another particular subgroup of compounds of formula (I) are those represented by the following structural formulae:\n\n \n \n\n\n \n \n \n\n\n \n \n \n \nAmongst the compounds of formulae (I-f), (I-g) or (I-h), those having the stereochemical configuration of the compounds of formulae (I-a) and (I-b) are of particular interest.\n\n\n \n \n \n \nIn (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h), where applicable, X, n, R\n1\n, R\n2\n, R\n3\n, R\n4\n and R\n5\n are as specified in the definitions of the compounds of formula (I) or in any of the subgroups of compounds of formula (I) specified herein.\n\n\n \n \n \n \nIt is to be understood that the above defined subgroups of compounds of formulae (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h), as well as any other subgroup defined herein, are meant to also comprise any prodrugs, \nN\n-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms of such compounds.\n\n\n \n \n \n \nWhen n is 2, the moiety -CH\n2\n- bracketed by \"n\" corresponds to ethanediyl in the compounds of formula (I) or in any subgroup of compounds of formula (I). When n is 3, the moiety -CH\n2\n- bracketed by \"n\" corresponds to propanediyl in the compounds of formula (I) or in any subgroup of compounds of formula (I). When n is 4, the moiety -CH\n2\n- bracketed by \"n\" corresponds to butanediyl in the compounds of formula (I) or in any subgroup of compounds of formula (I). When n is 5, the moiety-CH\n2\n-bracketed by \"n\" corresponds to pentanediyl in the compounds of formula (I) or in any subgroup of compounds of formula (I). When n is 6, the moiety -CH\n2\n- bracketed by \"n\" corresponds to hexanediyl in the compounds of formula (I) or in any subgroup of compounds of formula (I). Particular subgroups of the compounds of formula (I) are those compounds wherein n is 4 or 5.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein\n\n \n \n \n(a) R\n1\n is -OR\n6\n, in particular wherein R\n6\n is C\n1-6\nalkyl, such as methyl, ethyl, or \ntert\n-butyl and most preferably where R\n6\n is hydrogen; or\n \n(b) R\n1\n is -NHS(=O)\n2\nR\n7\n, in particular wherein R\n7\n is C\n1-6\nalkyl, C\n3-\nC\n7\ncycloalkyl, or aryl, e.g. wherein R\n7\n is methyl, cyclopropyl, or phenyl; or\n \n(c) R\n1\n is -NHS(=O)\n2\nR\n7\n, in particular wherein R\n7\n is C\n3-7\ncycloalkyl substituted with C\n1-6\nalkyl, preferably wherein R\n7\n is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, any of which is substituted with C\n1-4\nalkyl, i.e. with methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or isobutyl.\n \n\n\n \n \n \nFurther embodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n1\n is -NTS(=O)\n2\nR\n7\n, in particular wherein R\n7\n is cyclopropyl substituted with C\n1-4\nalkyl, i.e. with methyl, ethyl, propyl, or isopropyl.\n\n\n \n \n \n \nFurther embodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n1\n is -NHS(=O)\n2\nR\n7\n, in particular wherein R\n7\n is 1-methylcyclopropyl.\n\n\n \n \n \n \nFurther embodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein\n\n \n \n \n(a) R\n2\n is hydrogen;\n \n(b) R\n2\n is C\n1-6\nalkyl, preferably methyl.\n \n\n\n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein\n\n \n \n \n(a) X is N, C (X being linked via a double bond) or CH (X being linked via a single bond) and R\n2\n is hydrogen;\n \n(b) X is C (X being linked via a double bond) and R\n2\n is C\n1-6\nalkyl, preferably methyl.\n \n\n\n \n \n \nFurther embodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein\n\n \n \n \n(a) R\n3\n is hydrogen;\n \n(b) R\n3\n is C\n1-6\nalkyl;\n \n(d) R\n3\n is C\n1-6\nalkoxyC\n1-6\nalkyl or C\n3-7\ncycloalkyl.\n \n\n\n \n \n \nPreferred embodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n3\n is hydrogen, or C\n1-6\nalkyl, more preferably hydrogen or methyl.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein said ring system may optionally be substituted with one or two substituents independently selected from halo, hydroxy, oxo, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxyC\n1-6\nalkyl, C\n1-6\nalkoxycarbonyl, amino, and polyhaloC\n1-6\nalkyl.\n\n\n \n \n \n \nOther subgroups of the compounds of formula (I) are those compounds of formula (I), or any subgroup of compounds of formula (I) specified herein, wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein said ring system may optionally be substituted with one or two substituents independently selected from fluoro, chloro, hydroxy, oxo, cyano, carboxyl, methyl, ethyl, isopropyl, t-butyl, methoxy, ethoxy, isopropoxy, \ntert\n-butoxy, methoxyethyl, ethoxymethyl, methoxycarbonyl, ethoxycarbonyl, amino, and trifluoromethyl.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein the phenyl of said bicyclic ring system is optionally substituted with one or two substituents independently selected from halo, hydroxy, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxy-carbonyl, amino, and polyhaloC\n1-6\nalkyl.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\n\n \n \n\nwherein said bicyclic ring system is optionally substituted on the phenyl part, preferably at the positions above indicated with dotted lines with one or two substituents independently selected from halo, hydroxy, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxy-carbonyl, amino, and polyhalo-C\n1-6\nalkyl.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein the pyrrolidine, piperidine, or morpholine rings of said bicyclic ring system are optionally substituted with one or two substituents independently selected from C\n1-6\nalkyl, C\n1-6\nalkoxy, and C\n1-6\nalkoxyC\n1-6\nalkyl.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\nwherein the phenyl of said bicyclic ring system is optionally substituted with one substituent independently selected from halo, hydroxy, cyano, carboxyl, C\n1-6\nalkyl, C\n1-6\nalkoxy, C\n1-6\nalkoxy-carbonyl, amino, and polyhaloC\n1-6\nalkyl; and wherein the pyrrolidine, piperidine, or morpholine rings of said bicyclic ring system are optionally substituted with one substituent independently selected from C\n1-6\nalkyl, C\n1-6\nalkoxy, and C\n1-6\nalkoxyC\n1-6\nalkyl.\n\n\n \n \n \n \nEmbodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n\n\n \n \n\nwherein said bicyclic ring system is optionally substituted on the positions above indicated with one or two substituents independently selected from C\n1-6\nalkyl, C\n1-6\nalkoxy, and C\n1-6\nalkoxyC\n1-6\nalkyl.\n\n\n \n \n \n \nPreferred embodiments of the invention are compounds of formula (I) or any of the subgroups of compounds of formula (I) wherein R\n4\n and R\n5\n taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from\n\n \n \n \n\n\n \n \n \n \nThe compounds of formula (I) consist of three building blocks P1, P2, P3. Building block P1 further contains a P1' tail. The carbonyl group marked with an asterisk in compound (I-c) below may be part of either building block P2 or of building block P3.\n\n\n \n \n \n \nFor reasons of chemistry, building block P2 of the compounds of formula (I) wherein X is C incorporates the carbonyl group attached to the position 1'.\n\n\n \n \n \n \nThe linking of building blocks P1 with P2, P2 with P3, and P1 with P1' (when R\n1\n is -NH-SO\n2\nR\n7\n) involves forming an amide bond. The linking of blocks P1 and P3 involves double bond formation. The linking of building blocks P1, P2 and P3 to prepare compounds (I-i) or (I-j) can be done in any given sequence. One of the steps involves a cyclization whereby the macrocycle is formed.\n\n\n \n \n \n \nRepresented herebelow are compounds (I-i) which are compounds of formula (I) wherein carbon atoms C7 and C8 are linked by a double bond, and compounds (I-j) which are compounds of formula (I) wherein carbon atoms C7 and C8 are linked by a single bond. The compounds of formula (I-j) can be prepared from the corresponding compounds of formula (I-I) by reducing the double bond in the macrocycle.\n\n \n \n \n\n\n \n \n \n \nThe synthesis procedures described hereinafter are meant to be applicable for as well the racemates, stereochemically pure intermediates or end products, as any stereoisomeric mixtures. The racemates or stereochemical mixtures may be separated into stereoisomeric forms at any stage of the synthesis procedures. In one embodiment, the intermediates and end products have the stereochemistry specified above in the compounds of formula (I-a) and (I-b).\n\n\n \n \n \n \nIn the synthesis procedures described hereinafter, R\n8\n represents a radical\n\n \n \n\nwherein the dotted line represents the bond by which the radical is linked to the remainder of the molecule.\n\n\n \n \n \n \nIn a preferred embodiment, compounds (I) wherein the bond between C\n7\n and C\n8\n is a double bond, which are compounds of formula (I-i), as defined above, may be prepared as outlined in the following reaction scheme:\n\n \n \n \n\n\n \n \n \n \nFormation of the macrocycle can be carried out via an olefin metathesis reaction in the presence of a suitable metal catalyst such as e.g. the Ru-based catalyst reported by \nMiller, S.J., Blackwell, H.E., Grubbs, R.H. J. Am. Chem. Soc. 118, (1996), 9606-9614\n; \nKingsbury, J. S., Harrity, J. P. A., Bonitatebus, P. J., Hoveyda, A. H., J. Am. Chem. Soc. 121, (1999), 791-799\n; and \nHuang et al., J. Am. Chem. Soc. 121, (1999), 2674-2678\n; for example a Hoveyda-Grubbs catalyst.\n\n\n \n \n \n \nAir-stable ruthenium catalysts such as bis(tricyclohexylphosphine)-3-phenyl-1H-inden-1-ylidene ruthenium chloride (Neolyst M1\n®\n) or bis(tricyclohexylphosphine)-[(phenylthio)methylene]ruthenium (IV) dichloride can be used. Other catalysts that can be used are Grubbs first and second generation catalysts, i.e. Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium and (1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)-(tricyclohexylphosphine)ruthenium, respectively. Of particular interest are the Hoveyda-Grubbs first and second generation catalysts, which are dichloro(\no\n-isopropoxyphenylmethylene)(tricyclohexylphosphine)-ruthenium(II) and 1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro-(\no\n-isopropoxyphenylmethylene)ruthenium respectively. Also other catalysts containing other transition metals such as Mo can be used for this reaction.\n\n\n \n \n \n \nThe metathesis reactions may be conducted in a suitable solvent such as for example ethers, e.g. THF, dioxane; halogenated hydrocarbons, e.g. dichoromethane, CHCl\n3\n, 1,2-dichloroethane and the like, hydrocarbons, e.g. toluene. In a preferred embodiment, the metathesis reaction is conducted in toluene. These reactions are conducted at increased temperatures under nitrogen atmosphere.\n\n\n \n \n \n \nCompounds of formula (I) wherein the link between C7 and C8 in the macrocycle is a single bond, i.e. compounds of formula (I-j), can be prepared from the compounds of formula (I-i) by a reduction of the C7-C8 double bond in the compounds of formula (I-i): This reduction may be conducted by catalytic hydrogenation with hydrogen in the presence of a noble metal catalyst such as, for example, Pt, Pd, Rh, Ru or Raney nickel. Of interest is Rh on alumina. The hydrogenation reaction preferably is conducted in a solvent such as, e.g. an alcohol such as methanol, ethanol, or an ether such as THF, or mixtures thereof. Water can also be added to these solvents or solvent mixtures.\n\n\n \n \n \n \nThe R\n1\n group can be connected to the P1 building block at any stage of the synthesis, i.e. before or after the cyclization, or before or after the cyclization and reduction as descibed herein above. The compounds of formula (I) wherein R\n1\n represents -NHSO\n2\nR\n7\n, said compounds being represented by formula (I-k-1), can be prepared by linking the R\n1\n group to P1 by forming an amide bond between both moieties. Similarly, the compounds of formula (I) wherein R\n1\n represents -OR\n6\n, i.e. compounds (I-k-2), can be prepared by linking the R\n1\n group to P1 by forming an ester bond. In one embodiment, the -OR\n6\n groups are introduced in the last step of the synthesis of the compounds (I) as outlined in the following reaction schemes wherein G represents a group:\n\n \n \n\n\n \n \n\n\n \n \n \n\n\n \n \n \n \nIntermediate (2a) can be coupled with the amine (2b) by an amide forming reaction such as any of the procedures for the formation of an amide bond described hereinafter. In particular, (2a) may be treated with a coupling agent, for example \nN,N\n'-carbonyldiimidazole (CDI), EEDQ, IIDQ, EDCI or benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (commercially available as PyBOP®), in a solvent such as an ether, e.g. THF, or a halogenated hydrocarbon, e.g. dichloromethane, chlorophorm, dichloroethane, and reacted with the desired sulfonamide (2b), preferably after reacting (2a) with the coupling agent. The reactions of (2a) with (2b) preferably are conducted in the presence of a base, for example a trialkylamine such as triethylamine or diisopropylethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Intermediate (2a) can also be converted into an activated form, e.g. an activated form of general formula G-CO-Z, wherein Z represents halo, or the rest of an active ester, e.g. Z is an aryloxy group such as phenoxy, p.nitrophenoxy, pentafluorophenoxy, trichlorophenoxy, pentachlorophenoxy and the like; or Z can be the rest of a mixed anhydride. In one embodiment, G-CO-Z is an acid chloride (G-CO-C1) or a mixed acid anhydride (G-CO-O-CO-R or G-CO-O-CO-OR, R in the latter being e.g. C\n1-4\nalkyl, such as methyl, ethyl, propyl, i.propyl, butyl, t.butyl, i.butyl, or benzyl). The activated form G-CO-Z is reacted with the sulfonamide (2b).\n\n\n \n \n \n \nThe activation of the carboxylic acid in (2a) as described in the above reactions may lead to an internal cyclization reaction to an azalactone intermediate of formula\n\n \n \n\nwherein X, R\n2\n, R\n3\n, R\n4\n, R\n5\n, n are as specified above and wherein the stereogenic centers may have the stereochemical configuration as specified above, for example as in (I-a) or (I-b). The intermediates (2a-1) can be isolated from the reaction mixture, using conventional methodology, and the isolated intermediate (2a-1) is then reacted with (2b), or the reaction mixture containing (2a-1) can be reacted further with (2b) without isolation of (2a-1). In one embodiment, where the reaction with the coupling agent is conducted in a water-immiscible solvent, the reaction mixture containing (2a-1) may be washed with water or with slightly basic water in order to remove all water-soluble side products. The thus obtained washed solution may then be reacted with (2b) without additional purification steps. The isolation of intermediates (2a-1) on the other hand may provide certain advantages in that the isolated product, after optional further purification, may be reacted with (2b), giving rise to less side products and an easier work-up of the reaction.\n\n\n \n \n \n \nIntermediate (2a) can be coupled with the alcohol (2c) by an ester forming reaction. For example, (2a) and (2c) are reacted together with removal of water either physically, e.g. by azeotropical water removal, or chemically by using a dehydrating agent. Intermediate (2a) can also be converted into an activated form G-CO-Z, such as the activated forms mentioned above, and subsequently reacted with the alcohol (2c). The ester forming reactions preferably are conducted in the presence of a base such as an alkali metal carbonate or hydrogen carbonate, e.g. sodium or potassium hydrogen carbonate, or a tertiary amine such as the amines mentioned herein in relation to the amide forming reactions, in particular a trialkylamine, e.g. triethylamine. Solvents that can be used in the ester forming recations comprise ethers such as THF; halogenated hydrocarbons such as dichoromethane, CH\n2\nCl\n2\n; hydrocarbons such as toluene; polar aprotic solvents such as DMF, DMSO, DMA; and the like solvents.\n\n\n \n \n \n \nThe compounds of formula (I) wherein R\n3\n is hydrogen, said compounds being represented by (I-1), can also be prepared by removal of a protecting group PG, from a corresponding nitrogen-protected intermediate (3a), as in the following reaction scheme. The protecting group PG in particular is any of the nitrogen protecting groups mentioned hereinafter and can be removed using procedures also mentioned hereinafter:\n\n \n \n \n\n\n \n \n \n \nThe starting materials (3a) in the above reaction can be prepared following the procedures for the preparation of compounds of formula (I), but using intermediates wherein the group R\n3\n is PG.\n\n\n \n \n \n \nThe compounds of formula (I) can also be prepared by reacting an intermediate (4a) with an amine (4b) in the presence of a carbamate forming reagent as outlined in the following reaction scheme wherein the various radicals have the meanings specified above:\n\n \n \n \n\n\n \n \n \n \nThe reaction of intermediates (4a) with the carbamate forming reagent is conducted in the same solvents and bases as those used for the amide bond formation as described hereinafter.\n\n\n \n \n \n \nCarbamate forming reactions may be conducted using a variety of methods, in particular by reaction of amines with alkyl chloroformates; by reaction of alcohols with carbamoyl chlorides or isocyanates; via reactions involving metal complexes or acyl transfer agents. See for example, \nGreene, T. W. and Wuts, P. G. M., \"\nProtective Groups in Organic Synthesis\n\"; 1999; Wiley and Sons, p. 309-348\n. Carbon monoxide and certain metal catalysts can be used to synthesize carbamates from several starting compounds, including amines. Metals such as palladium, iridium, uranium, and platinum may be used as catalysts. Methods using carbon dioxide for synthesis of carbamates that have been also been reported, can also be used (see for example, \nYoshida, Y., et al., Bull. Chem. Soc . Japan 1989, 62, 1534\n; and \nAresta, M., et al., Tetrahedron, 1991, 47, 9489\n).\n\n\n \n \n \n \nOne approach for the preparation of carbamates involves the use of intermediates\n\n \n \n\nwherein Q is leaving group such as halo, in particular chloro and bromo, or a group used in active esters for amide bond formation, such as those mentioned above, for example phenoxy or substituted phenoxy such as p.chloro and p.nitrophenoxy, trichlorophenoxy, pentachlorophenoxy, N-hydroxy-succinimidyl, and the like. Intermediates (4b) can be derived from alcohols (4a) and phosgene, thus forming a chloroformate, or by transferring the chloro in the latter to intermediates (5a) which are intermediates of formula (5) wherein Q is Q\n1\n. In this and the following reaction procedures, Q\n1\n represents any of the active ester moieties such as those mentioned above. Intermediates (4b) are reacted with (4a), obtaining compounds (I).\n\n\n \n \n \n \nIntermediates (4b-1), which are intermediates (4b) wherein Q is Q', can also be prepared by reacting the alcohol (4a) with carbonates Q\n1\n-CO-Q\n1\n such as e.g. bisphenol, bis-(substituted phenol) or bis N-hydroxy-succinimidyl carbonates:\n\n \n \n \n\n\n \n \n \n \nThe reagents (5a) may also be prepared from chloroformates Cl-CO-Q\n1\n as follows:\n\n \n \n \n\n\n \n \n \n \nThe above reactions to prepare reagents (4b-1) may be conducted in the presence of the bases and solvents mentioned hereinafter for the synthesis of amide bonds, in particular triethylamine and dichloromethane.\n\n\n \n \n \n \nAlternatively, in order to prepare the compounds of formula (I), first an amide bond between building blocks P2 and P1 is formed, followed by coupling of the P3 building block to the P1 moiety in P1-P2, and a subsequent carbamate or ester bond formation between P3 and the P2 moiety in P2-P1-P3 with concomitant ring closure.\n\n\n \n \n \n \nYet another alternative synthetic methodology is the formation of an amide bond between building blocks P2 and P3, followed by the coupling of building block P1 to the P3 moiety in P3-P2, and a last amide bond formation between P1 and P2 in P1-P3-P2 with concomitant ring closure.\n\n\n \n \n \n \nBuilding blocks P1 and P3 can be linked to a P1-P3 sequence. If desired, the double bond linking P1 and P3 may be reduced. The thus formed P1-P3 sequence, either reduced or not, can be coupled to building block P2 and the thus forming sequence P1-P3-P2 subsequently cyclized, by forming an amide bond.\n\n\n \n \n \n \nBuilding blocks P1 and P3 in any of the previous approaches can be linked via double bond formation, e.g. by the olefin metathesis reaction described hereinafter, or a Wittig type reaction. If desired, the thus formed double bond can be reduced, similarly as described above for the conversion of (I-i) to (I-j). The double bond can also be reduced at a later stage, i.e. after addition of a third building block, or after formation of the macrocycle. Building blocks P2 and P1 are linked by amide bond formation and P3 and P2 are linked by carbamate or ester formation.\n\n\n \n \n \n \nThe tail P1' can be bonded to the P1 building block at any stage of the synthesis of the compounds of formula (I), for example before or after coupling the building blocks P2 and P1; before or after coupling the P3 building block to P1; or before or after ring closure.\n\n\n \n \n \n \nThe individual building blocks can first be prepared and subsequently coupled together or alternatively, precursors of the building blocks can be coupled together and modified at a later stage to the desired molecular composition.\n\n\n \n \n \n \nThe formation of amide bonds can be carried out using standard procedures such as those used for coupling amino acids in peptide synthesis. The latter involves the dehydrative coupling of a carboxyl group of one reactant with an amino group of the other reactant to form a linking amide bond. The amide bond formation may be performed by reacting the starting materials in the presence of a coupling agent or by converting the carboxyl functionality into an active form such as an active ester, mixed anhydride or a carboxyl acid chloride or bromide. General descriptions of such coupling reactions and the reagents used therein can be found in general textbooks on peptide chemistry, for example, \nM. Bodanszky, \"\nPeptide Chemistry\n\", 2nd rev. ed., Springer-Verlag, Berlin, Germany, (1993\n).\n\n\n \n \n \n \nExamples of coupling reactions with amide bond formation include the azide method, mixed carbonic-carboxylic acid anhydride (isobutyl chloroformate) method, the carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimide such as \nN\n-ethyl-\nN'\n-[(3-dimethylamino)propyl]carbodiimide) method, the active ester method (e.g. \np\n-nitrophenyl, \np\n-chlorophenyl, trichlorophenyl, pentachlorophenyl, pentafluorophenyl, \nN\n-hydroxysuccinic imido and the like esters), the Woodward reagent K-method, the 1,1-carbonyldiimidazole (CDI or N,N'-carbonyl-diimidazole) method, the phosphorus reagents or oxidation-reduction methods. Some of these methods can be enhanced by adding suitable catalysts, e.g. in the carbodiimide method by adding 1-hydroxybenzotriazole, DBU (1,8-diazabicyclo[5.4.0]undec-7-ene), or 4-DMAP. Further coupling agents are (benzotriazol-1-yloxy)tris-(dimethylamino) phosphonium hexafluorophosphate, either by itself or in the presence of 1-hydroxybenzotriazole or 4-DMAP; or 2-(1\nH-\nbenzotriazol-1-yl)-\nN\n,\nN\n,\nN\n',\nN\n'-tetra-methyluronium tetrafluoroborate, or O-(7-azabenzotriazol-1-yl)-\nN\n,\nN\n,\nN\n',\nN\n'-tetramethyluronium hexafluorophosphate. These coupling reactions can be performed in either solution (liquid phase) or solid phase.\n\n\n \n \n \n \nA preferred amide bond formation is performed employing N-ethyloxycarbonyl-2-ethyloxy-1,2-dihydroquinoline (EEDQ) or N-isobutyloxy-carbonyl-2-isobutyloxy-1,2-dihydroquinoline (IIDQ). Unlike the classical anhydride procedure, EEDQ and IIDQ do not require base nor low reaction temperatures. Typically, the procedure involves reacting equimolar amounts of the carboxyl and amine components in an organic solvent (a wide variety of solvents can be used). Then EEDQ or IIDQ is added in excess and the mixture is allowed to stir at room temperature.\n\n\n \n \n \n \nThe coupling reactions preferably are conducted in an inert solvent, such as halogenated hydrocarbons, e.g. dichloromethane, chloroform, dipolar aprotic solvents such as acetonitrile, dimethylformamide, dimethylacetamide, DMSO, HMPT, ethers such as tetrahydrofuran (THF).\n\n\n \n \n \n \nIn many instances the coupling reactions are done in the presence of a suitable base such as a tertiary amine, e.g. triethylamine, diisopropylethylamine (DIPEA), \nN\n-methylmorpholine, \nN\n-methylpyrrolidine, 4-DMAP or 1,8-diazabicycle[5.4.0]undec-7-ene (DBU). The reaction temperature may range between 0 °C and 50 °C and the reaction time may range between 15 min and 24 h.\n\n\n \n \n \n \nThe functional groups in the building blocks that are linked together may be protected to avoid formation of undesired bonds. Appropriate protecting groups that can be used are listed for example in \nGreene, \"\nProtective Groups in Organic Chemistry\n\", John Wiley & Sons, New York (1999\n) and \"\nThe Peptides: Analysis, Synthesis, Biology\", Vol. 3, Academic Press, New York (1987\n).\n\n\n \n \n \n \nCarboxyl groups can be protected as an ester that can be cleaved off to give the carboxylic acid. Protecting groups that can be used include 1) alkyl esters such as methyl, trimethylsilyl and \ntert\n-butyl; 2) arylalkyl esters such as benzyl and substituted benzyl; or 3) esters that can be cleaved by a mild base or mild reductive means such as trichloroethyl and phenacyl esters.\n\n\n \n \n \n \nAmino groups can be protected by a variety of N-protecting groups, such as:\n\n \n \n \n1) acyl groups such as formyl, trifluoroacetyl, phthalyl, and \np\n-toluenesulfonyl;\n \n2) aromatic carbamate groups such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls, and 9-fluorenylmethyloxycarbonyl (Fmoc);\n \n3) aliphatic carbamate groups such as \ntert\n-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxy-carbonyl, and allyloxycarbonyl;\n \n4) cyclic alkyl carbamate groups such as cyclopentyloxycarbonyl and adamantyloxycarbonyl;\n \n5) alkyl groups such as triphenylmethyl, benzyl or substituted benzyl such as 4-methoxybenzyl;\n \n6) trialkylsilyl such as trimethylsilyl or t.Bu dimethylsilyl; and\n \n7) thiol containing groups such as phenylthiocarbonyl and dithiasuccinoyl. Interesting amino protecting groups are Boc and Fmoc.\n \n\n\n \n \n \nPreferably the amino protecting group is cleaved off prior to the next coupling step. Removal ofN-protecting groups can be done following art-known procedures. When the Boc group is used, the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCl in dioxane or in ethyl acetate. The resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or acetonitrile or dimethylformamide. When the Fmoc group is used, the reagents of choice are piperidine or substituted piperidine in dimethylformamide, but any secondary amine can be used. The deprotection is carried out at a temperature between 0 °C and room temperature, usually around 15-25 °C, or 20-22 °C.\n\n\n \n \n \n \nOther functional groups that can interfere in the coupling reactions of the building blocks may also be protected. For example hydroxyl groups may be protected as benzyl or substituted benzyl ethers, e.g. 4-methoxybenzyl ether, benzoyl or substituted benzoyl esters, e.g. 4-nitrobenzoyl ester, or with trialkylsilyl goups (e.g. trimethylsilyl or \ntert\n-butyldimethylsilyl).\n\n\n \n \n \n \nFurther amino groups may be protected by protecting groups that can be cleaved off selectively. For example, when Boc is used as the α-amino protecting group, the following side chain protecting groups are suitable: p-toluenesulfonyl (tosyl) moieties can be used to protect further amino groups; benzyl (Bn) ethers can be used to protect hydroxy groups; and benzyl esters can be used to protect further carboxyl groups. Or when Fmoc is chosen for the α-amino protection, usually \ntert\n-butyl based protecting groups are acceptable. For instance, Boc can be used for further amino groups; \ntert-\nbutyl ethers for hydroxyl groups; and \ntert-\nbutyl esters for further carboxyl groups.\n\n\n \n \n \n \nAny of the protecting groups may be removed at any stage of the synthesis procedure but preferably, the protecting groups of any of the functionalities not involved in the reaction steps are removed after completion of the build-up of the macrocycle. Removal of the protecting groups can be done in whatever manner is dictated by the choice of protecting groups, which manners are well known to those skilled in the art.\n\n\n \n \n \n \nThe intermediates of formula (1a) wherein X is N, said intermediates being represented by formula (1a-1), may be prepared using an urea forming reaction, starting from intermediates (5a) which are reacted with an alkenamine (5b) in the presence of a carbonyl introducing agent as outlined in the following reaction scheme.\n\n \n \n \n\n\n \n \n \n \nCarbonyl (CO) introducing agents include phosgene, or phosgene derivatives such as carbonyl diimidazole (CDI), and the like. In one embodiment (5a) is reacted with the CO introducing agent in the presence of a suitable base and a solvent, which can be the bases and solvents used in the amide forming reactions as described above. Thereafter, the amine (5b) is added thereby obtaining intermediates (1a-1) as in the above scheme. In a particular embodiment, the base is a hydrogencarbonate, e.g. NaHCO\n3\n, or a tertiary amine such as triethylamine and the like, and the solvent is an ether or halogenated hydrocarbon, e.g. THF, CH\n2\nCl\n2\n, CHCl\n3\n, and the like. An alternative route using similar reaction conditions involves first reacting the CO introducing agent with the amine (5b) and then reacting the thus formed intermediate with (5a).\n\n\n \n \n \n \nThe intermediates (1a-1) can alternatively be prepared as follows:\n\n \n \n \n\n\n \n \n \n \nPG\n1\n is an O-protecting group, which can be any of the groups mentioned herein and in particular is a benzoyl or substituted benzoyl group such as 4-nitrobenzoyl. In the latter instance this group can be removed by reaction with a an alkali metal hydroxide (LiOH, NaOH, KOH), in particular where PG\n1\n is 4-nitrobenzoyl, with LiOH, in an aqueous medium comprising water and a water-soluble organic solvent such as an alkanol (methanol, ethanol) and THF.\n\n\n \n \n \n \nIntermediates (6a) are reacted with (5b) in the presence of a carbonyl introducing agent, similar as described above, and this reaction yields intermediates (6c). These are deprotected, in particular using the reaction conditions mentioned above. The resulting alcohol (6d) is reacted with intermediates (4b) in a carbamate forming reaction, as described above for the reaction of (4a) with (4b), and this reaction results in intermediates (1a-1).\n\n\n \n \n \n \nThe intermediates of formula (1a) wherein X is C, said intermediates being represented by formula (1a-2), may be prepared by an amide forming reaction starting from intermediates (7a) which are reacted with an alkenamine (5b) as shown in the following reaction scheme, using reaction conditions for preparing amides such as those described above.\n\n \n \n \n\n\n \n \n \n \nThe intermediates (1a-1) can alternatively be prepared as follows:\n\n \n \n \n\n\n \n \n \n \nPG\n1\n is an O-protecting group as described above. The same reaction conditions as described above may be used: amide formation as described above, removal of PG\n1\n as in the description of the protecting groups and introduction of R\n8\n as in the reactions of (4a) with the amine s (4b).\n\n\n \n \n \n \nThe intermediates of formula (2a) may be prepared by first cyclizing an open amide (9a) to a macrocyclic ester (9b), which in turn is converted to an intermediate (2a) as follows:\n\n \n \n \n\n\n \n \n \n \nPG\n2\n is a carboxyl protecting group, e.g. one of the carboxyl protecting groups mentioned above, in particular a C\n1-4\nalkyl or benzyl ester, e.g. a methyl, ethyl or t.butyl ester. The reaction of (9a) to (9b) is a metathesis reaction and is conducted as described above. Removal of PG\n2\n as described above, yields intermediates (2a). Where PG\n1\n is a C\n1-4\nalkyl ester, it is removed by alkaline hydrolysis, e.g. with NaOH or preferably LiOH, in an aqueous solvent, e.g. a C\n1-4\nalkanol/water mixture, such as methanol/water or ethanol/water. A benzyl group can be removed by catalytic hydrogenation.\n\n\n \n \n \n \nIn an alternative synthesis, intermediates (2a) can be prepared as follows:\n\n \n \n \n\n\n \n \n \n \nThe PG\n1\n group is selected such that it is selectively cleavable towards PG\n2\n. PG\n2\n may be e.g. methyl or ethyl esters, which can be removed by treatment with an alkali metal hydroxide in an aqueous medium, in which case PG\n1\n e.g. is t.butyl or benzyl. Or alternatively, PG\n2\n may be t.butyl esters removable under weakly acidic conditions or PG\n1\n may be benzyl esters removable with strong acid or by catalytic hydrogenation, in the latter two cases PG\n1\n e.g. is a benzoic ester such as a 4-nitrobenzoic ester.\n\n\n \n \n \n \nFirst, intermediates (10a) are cyclized to the macrocyclic esters (10b), the latter are deprotected by removal of the PG\n1\n group to intermediates (10c), which are reacted with amine s (4b), followed by removal of the carboxyl protecting group PG\n2\n. The cyclization, deprotection of PG\n1\n and PG\n2\n, and the coupling with (4b) are as described above.\n\n\n \n \n \n \nThe R\n1\n groups can be introduced at any stage of the synthesis, either as the last step as described above, or earlier, before the macrocycle formation, as illustrated in the following scheme:\n\n \n \n \n\n\n \n \n \n \nIn the above scheme, R\n2\n, R\n6\n, R\n7\n, R\n8\n, X and PG\n2\n are as defined above and L\n1\n is a P3 group\n\n \n \n\nwherein n and R\n3\n are as defined above and where X is N, L\n1\n may also be a nitrogen-protecting group (PG, as defined above) and where X is C, L\n1\n may also be a group -COOPG\n2a\n, wherein the group PG\n2a\n is a carboxyl protecting group similar as PG\n2\n, but wherein PG\n2a\n is selectively cleavable towards PG\n2\n. In one embodiment PG\n2a\n is t.butyl and PG\n2\n is methyl or ethyl.\n\n\n \n \n \n \nThe intermediates (11c) and (11d) wherein L\n1\n represents a group (b) correspond to the intermediates (1a) and may be processed further as specified above.\n\n\n \n\n\nCoupling of P1 and P2 building blocks\n\n\n\n\n \n \n \nThe P1 and P2 building blocks are linked using an amide forming reaction following the procedures described above. The P1 building block may have a carboxyl protecting group PG\n2\n (as in (12b)) or may already be linked to P1' group (as in (12c)). L\n2\n is a N-protecting group (PG), or a group (b), as specified above. L\n3\n is hydroxy, -OPG\n1\n or a group -O-R\n8\n as specified above. Where in any of the following reaction schemes L\n3\n is hydroxy, prior to each reaction step, it may be protected as a group -OPG\n1\n and, if desired, subsequently deprotected back to a free hydroxy function. Similarly as described above, the hydroxy function may be converted to a group -O-R\n8\n.\n\n \n \n \n\n\n \n \n \n \nIn the procedure of the above scheme, a cyclopropyl amino acid (12b) or (12c) is coupled to the acid function of the P2 building block (12a) with the formation of an amide linkage, following the procedures described above. Intermediates (12d) or (12e) are obtained. Where in the latter L\n2\n is a group (b), the resulting products are P3-P2-P1 sequences encompassing some of the intermediates (11c) or (11d) in the previous reaction scheme. Removal of the acid protecting group in (12d), using the appropriate conditions for the protecting group used, followed by coupling with an amine H\n2\nN-SO\n2\nR\n7\n (2b) or with HOR\n6\n (2c) as described above, again yields the intermediates (12e), wherein -COR\n1\n are amide or ester groups. Where L\n2\n is a N-protecting group, it can be removed yielding intermediates (5a) or (6a). In one embodiment, PG in this reaction is a BOC group and PG\n2\n is methyl or ethyl. Where additionally L\n3\n is hydroxy, the starting material (12a) is Boc-L-hydroxyproline. In a particular embodiment, PG is BOC, PG\n2\n is methyl or ethyl and L\n3\n is -O-R\n8\n.\n\n\n \n \n \n \nIn one embodiment, L\n2\n is a group (b) and these reactions involve coupling P1 to P2-P3, which results in the intermediates (1a-1) or (1a) mentioned above. In another embodiment, L\n2\n is a N-protecting group PG, which is as specified above, and the coupling reaction results in intermediates (12d-1) or (12e-1), from which the group PG can be removed, using reaction conditions mentioned above, obtaining intermediates (12-f) or respectively (12g), which encompass intermediates (5a) and (6a) as specified above:\n\n \n \n\n\n \n \n \n\n\n \n \n \n \nIn one embodiment, the group L\n3\n in the above schemes represents a group -O-PG\n1\n which can be introduced on a starting material (12a) wherein L\n3\n is hydroxy. In this instance PG\n1\n is chosen such that it is selectively cleavable towards group L\n2\n being PG.\n\n\n \n \n \n \nIn a similar way, P2 building blocks wherein X is C, which are cyclopentane or cyclopentene derivatives, can be linked to P1 building blocks as outlined in the following scheme wherein R\n1\n, R\n2\n, L\n3\n, PG\n2\n and PG\n2a\n are carboxyl protecting groups. PG\n2a\n typically is chosen such that it is selectively cleavable towards group PG\n2\n. Removal of the PG\n2a\n group in (13c) yields intermediates (7a) or (8a), which can be reacted with (5b) as described above.\n\n \n \n \n\n\n \n \n \n \nIn one particular embodiment, where X is C, R\n2\n is H, and where X and the carbon bearing R\n2\n are linked by a single bond (P2 being a cyclopentane moiety), PG\n2a\n and L\n3\n taken together form a bond and the P2 building block is represented by formula:\n\n \n \n \n\n\n \n \n \n \nBicyclic acid (14a) is reacted with (12b) or (12c) similar as described above to (14b) and (14c) respectively, wherein the lactone is opened to give intermediates (14c) and (14e). The lactone can be opened using ester hydrolysis procedures, for example using the reaction conditions described above for the alkaline removal of a PG\n1\n group in (9b), in particular using basic conditions such as an alkali metal hydroxide, e.g. NaOH, KOH, in particular LiOH.\n\n \n \n \n\n\n \n \n \n \nIntermediates (14c) and (14e) can be processed further as described hereinafter.\n\n\n \n\n\nSynthesis of P2 building blocks\n\n\n\n\n \n \n \nThe P2 building blocks contain either a pyrrolidine, a cyclopentane, or a cyclopentene moiety substituted with a group -O-R\n8\n.\n\n\n \n \n \n \nP2 building blocks containing a pyrrolidine moiety can be derived from commercially available hydroxy proline.\n\n\n \n \n \n \nThe preparation of P2 building blocks that contain a cylopentane ring may be performed as shown in the scheme below.\n\n \n \n \n\n\n \n \n \n \nThe bicyclic acid (17b) can be prepared, for example, from 3,4-bis(methoxycarbonyl)-cyclopentanone (17a), as described by \nRosenquist et al. in Acta Chem. Scand. 46 (1992) 1127-1129\n. A first step in this procedure involves the reduction of the keto group with a reducing agent like sodium borohydride in a solvent such as methanol, followed by hydrolysis of the esters and finally ring closure to the bicyclic lactone (17b) using lactone forming procedures, in particular by using acetic anhydride in the presence of a weak base such as pyridine. The carboxylic acid functionality in (17b) can then be protected by introducing an appropriate carboxyl protecting group, such as a group PG\n2\n, which is as specified above, thus providing bicyclic ester (17c). The group PG\n2\n in particular is acid-labile such as a t.butyl group and is introduced e.g. by treatment with isobutene in the presence of a Lewis acid or with di-\ntert\n-butyl dicarbonate in the presence of a base such as a tertiary amine like dimethylaminopyridine or triethylamine in a solvent like dichloromethane. Lactone opening of (17c) using reaction conditions described above, in particular with lithium hydroxide, yields the acid (17d), which can be used further in coupling reactions with P1 building blocks. The free acid in (17d) may also be protected, preferably with an acid protecting group PG\n2a\n that is selectively cleavable towards PG\n2\n, and the hydroxy function may be converted to a group -OPG\n1\n or to a group -O-R\n8\n. The products obtained upon removal of the group PG\n2\n are intermediates (17g) and (17i) which correspond to intermediates (13a) or (16a) specified above.\n\n\n \n \n \n \nIntermediates with specific stereochemistry may be prepared by resolving the intermediates in the above reaction sequence. For example, (17b) may be resolved following art-known procedures, e.g. by salt form action with an optically active base or by chiral chromatography, and the resulting stereoisomers may be processed further as described above. The OH and COOH groups in (17d) are in cis position. Trans analogs can be prepared by inverting the stereochemistry at the carbon bearing the OH function by using specific reagents in the reactions introducing OPG\n1\n or O-R\n8\n that invert the stereochemistry, such as, e.g. by applying a Mitsunobu reaction.\n\n\n \n \n \n \nIn one embodiment, the intermediates (17d) are coupled to P1 blocks (12b) or (12c), which coupling reactions correspond to the coupling of (13a) or (16a) with the same P1 blocks, using the same conditions. Subsequent introduction of a -O-R\n8\n-substituent as described above followed by removal of the acid protection group PG\n2\n yields intermediates (8a-1), which are a subclass of the intermediates (7a), or part of the intermediates (16a). The reaction products of the PG\n2\n removal can be further coupled to a P3 building block. In one embodiment PG\n2\n in (17d) is t.butyl which can be removed under acidic conditions, e.g. with trifluoroacetic acid.\n\n \n \n \n\n\n \n \n \n \nAn unsaturated P2 building block, i.e. a cyclopentene ring, may be prepared as illustrated in the scheme below.\n\n \n \n \n\n\n \n \n \n \nA bromination-elimination reaction of 3,4-bis(methoxycarbonyl)cyclopentanone (17a) as described by \nDolby et al. in J. Org. Chem. 36 (1971) 1277-1285\n followed by reduction of the keto functionality with a reducting agent like sodium borohydride provides the cyclopentenol (19a). Selective ester hydrolysis using for example lithium hydroxide in a solvent like a mixture of dioxane and water, provides the hydroxy substituted monoester cyclopentenol (19b).\n\n\n \n \n \n \nAn unsaturated P2 building block wherein R\n2\n can also be other than hydrogen, may be prepared as shown in the scheme below.\n\n \n \n \n\n\n \n \n \n \nOxidation of commercially available 3-methyl-3-buten-1-ol (20a), in particular by an oxidizing agent like pyridinium chlorochromate, yields (20b), which is converted to the corresponding methyl ester, e.g. by treatment with acetyl chloride in methanol, followed by a bromination reaction with bromine yielding the α-bromo ester (20c). The latter can then be condensed with the alkenyl ester (20e), obtained from (20d) by an ester forming reaction. The ester in (20e) preferably is a t.butyl ester which can be prepared from the corresponding commercially available acid (20d), e.g. by treatment with di-\ntert\n-butyl dicarbonate in the presence of a base like dimethylaminopyridine. Intermediate (20e) is treated with a base such as lithium diisopropyl amide in a solvent like tetrahydrofuran, and reacted with (20c) to give the alkenyl diester (20f). Cyclisation of (20f) by an olefin metathesis reaction, performed as described above, provides cyclopentene derivative (20g). Stereoselective epoxidation of (20g) can be carried out using the Jacobsen asymmetric epoxidation method to obtain epoxide (20h). Finally, an epoxide opening reaction under basic conditions, e.g. by addition of a base, in particular DBN (1,5-diazabicyclo-[4.3.0]non-5-ene), yields the alcohol (20i). Optionally, the double bond in intermediate (20i) can be reduced, for example by catalytic hydrogenation using a catalyst like palladium on carbon, yielding the corresponding cyclopentane compound. The t.butyl ester may be removed to the corresponding acid, which subsequently is coupled to a P1 building block.\n\n\n \n \n \n \nThe -O-R\n8\n group can be introduced on the pyrrolidine, cyclopentane or cyclopentene rings at any convenient stage of the synthesis of the compounds according to the present invention. One approach is to first introduce the -O-R\n8\n group to the said rings and subsequently add the other desired building blocks, i.e. P1 (optionally with the P1' tail) and P3, followed by the macrocycle formation. Another approach is to couple the building blocks P2, bearing no -O-R\n8\n substituent, with each P1 and P3, and to add the -O-R\n8\n group either before or after the macrocycle formation. In the latter procedure, the P2 moieties have a hydroxy group, which may be protected by a hydroxy protecting group PG\n1\n.\n\n\n \n \n \n \nR\n8\n groups can be introduced on building blocks P2 by reacting hydroxy substituted intermediates (21a) or (21b) with intermediates (4b) similar as described above for the synthesis of (I) starting from (4a). These reactions are represented in the schemes below, wherein L\n2\n is as specified above and L\n5\n and L\n5a\n independently from one another, represent hydroxy, a carboxyl protecting group -OPG\n2\n or -OPG\n2a\n, or L\n5\n may also represent a P1 group such as a group (d) or (e) as specified above, or L\n5a\n may also represent a P3 group such as a group (b) as specified above The groups PG\n2\n and PG\n2a\n are as specified above. Where the groups L\n5\n and L\n5a\n are PG\n2\n or PG\n2a\n, they are chosen such that each group is selectively cleavable towards the other. For example, one of L\n5\n and L\n5a\n may be a methyl or ethyl group and the other a benzyl or t.butyl group.\n\n\n \n \n \n \nIn one embodiment in (21a), L\n2\n is PG and L\n5\n is -OPG\n2\n, or in (21d), L\n5a\n is -OPG\n2\n and L\n5\n is -OPG\n2\n and the PG\n2\n groups are removed as described above.\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n \n\n\n \n \n \n \nIn another embodiment the group L\n2\n is BOC, L\n5\n is hydroxy and the starting material (21a) is commercially available BOC-hydroxyproline, or any other stereoisomeric form thereof, e.g. BOC-L-hydroxyproline, in particular the trans isomer of the latter. Where L\n5\n in (21b) is a carboxyl-protecting group, it may be removed following procedures described above to (2 1 c). In still another embodiment PG in (21b-1) is Boc and PG\n2\n is a lower alkyl ester, in particular a methyl or ethyl ester. Hydrolysis of the latter ester to the acid can be done by standard procedures, e.g. acid hydrolysis with hydrochloric acid in methanol or with an alkali metal hydroxide such as NaOH, in particular with LiOH. In another embodiment, hydroxy substituted cyclopentane or cyclopentene analogs (21d) are converted to (21e), which, where L\n5\n and L\n5a\n are -OPG\n2\n or -OPG\n2a\n, may be converted to the corresponding acids (21f) by removal of the group PG\n2\n. Removal of PG\n2a\n in (21e-1) leads to similar intermediates.\n\n\n \n \n \n \nIntermediates (4b), which are amino derivatives, are known compounds or can be easily prepared using art-known procedures.\n\n\n \n\n\nSynthesis of P1 building blocks\n\n\n\n\n \n \n \nThe cyclopropane amino acid used in the preparation of the P1 fragment is commercially available or can be prepared using art-known procedures.\n\n\n \n \n \n \nIn particular the amino-vinyl-cyclopropyl ethyl ester (12b) may be obtained according to the procedure described in \n \nWO 00/09543\n \n or as illustrated in the following scheme, wherein PG\n2\n is a carboxyl protecting group as specified above:\n\n \n \n \n\n\n \n \n \n \nTreatment of commercially available or easily obtainable imine (31a) with 1,4-dihalobutene in presence of a base produces (31b), which after hydrolysis yields cyclopropyl amino acid (12b), having the allyl substituent \nsyn\n to the carboxyl group. Resolution of the enantiomeric mixture (12b) results in (12b-1). The resolution is performed using art-known procedures such as enzymatic separation; crystallization with a chiral acid; or chemical derivatization; or by chiral column chromatography. Intermediates (12b) or (12b-1) may be coupled to the appropriate P2 derivatives as described above.\n\n\n \n \n \n \nP1 building blocks for the preparation of compounds according to general formula (I) wherein R\n1\n is -OR\n6\n or NH-SO\n2\nR\n7\n can be prepared by reacting amino acids (32a) with the appropriate alcohol or amine respectively under standard conditions for ester or amide formation. Cyclopropyl amino acids (32a) are prepared by introducing a N-protecting group PG, and removal of PG\n2\n and the amino acids (32a) are converted to the amides (12c-1) or esters (12c-2), which are subgroups of the intermediates (12c), as outlined in the following reaction scheme, wherein PG is as specified above.\n\n \n \n \n\n\n \n \n \n \nThe reaction of (32a) with amine (2b) is an amide forming procedure. The similar reaction with (2c) is an ester forming reaction. Both can be performed following the procedures described above. This reaction yields intermediates (32b) or (32c) from which the amino protecting group is removed by standard methods such as those described above. This in turn results in the desired intermediate (12c-1). Starting materials (32a) may be prepared from the above mentioned intermediates (12b) by first introducing a N-protecting group PG and subsequent removal of the group PG\n2\n.\n\n\n \n \n \n \nIn one embodiment the reaction of (32a) with (2b) is done by treatment of the amino acid with a coupling agent, for example N,N'-carbonyl-diimidazole (CDI) or the like, in a solvent like THF followed by reaction with (2b) in the presence of a base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Alternatively the amino acid can be treated with (2b) in the presence of a base like diisopropylethylamine followed by treatment with a coupling agent such as benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (commercially available as PyBOP®) to effect the introduction of the sulfonamide group.\n\n\n \n \n \n \nIntermediates (12c-1) or (12c-2) in turn may be coupled to the appropriate proline, cyclopentane or cyclopentene derivatives as described above.\n\n\n \n\n\nSynthesis of the P3 building blocks\n\n\n\n\n \n \n \nThe P3 building blocks are available commercially or can be prepared according to methodologies known to the skilled in the art. One of these methodologies is shown in the scheme below and uses monoacylated amines, such as trifluoroacetamide or a Boc-protected amine.\n\n \n \n \n\n\n \n \n \n \nIn the above scheme, R together with the CO group forms a N-protecting group, in particular R is \nt\n-butoxy, trifluoromethyl; R\n3\n and n are as defined above and LG is a leaving group, in particular halogen, e.g. chloro or bromo.\n\n\n \n \n \n \nThe monoacylated amines (33a) are treated with a strong base such as sodium hydride and are subsequently reacted with a reagent LG-C\n5-8\nalkenyl (33b), in particular haloC\n5-8\nalkenyl, to form the corresponding protected amines (33c). Deprotection of (33c) affords (5b), which are building blocks P3. Deprotection will depend on the functional group R, thus if R is \nt\n-butoxy, deprotection of the corresponding Boc-protected amine can be accomplished with an acidic treatment, e.g. trifluoroacetic acid. Alternatively, when R is for instance trifluoromethyl, removal of the R group is accomplished with a base, e.g. sodium hydroxide.\n\n\n \n \n \n \nThe following scheme illustrates yet another method for preparing a P3 building block, namely a Gabriel synthesis of primary C\n5-8\nalkenylamines, which can be carried out by the treatment of a phthalimide (34a) with a base, such as NaOH or KOH, and with (33b), which is as specified above, followed by hydrolysis of the intermediate N-alkenyl imide to generate a primary C\n5-8\nalkenylamine (5b-1).\n\n \n \n \n\n\n \n \n \n \nIn the above scheme, n is as defined above.\n\n\n \n \n \n \nCompounds of formula (I) may be converted into each other following art-known functional group transformation reactions. For example, amino groups may be N-alkylated, nitro groups reduced to amino groups, a halo atom may be exchanged for another halo.\n\n\n \n \n \n \nThe compounds of formula (I) may be converted to the corresponding \nN\n-oxide forms following art-known procedures for converting a trivalent nitrogen into its \nN\n-oxide form. Said \nN\n-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzene-carboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. \ntert\n-butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.\n\n\n \n \n \n \nPure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.\n\n\n \n \n \n \nThe compounds of formula (I) may be obtained as racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I), which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound may be synthesized by stereospecific methods of preparation. These methods may advantageously employ enantiomerically pure starting materials.\n\n\n \n \n \n \nIn a further aspect, the present invention concerns a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as specified herein, or a compound of any of the subgroups of compounds of formula (I) as specified herein, and a pharmaceutically acceptable carrier. A therapeutically effective amount in this context is an amount sufficient to prophylactically act against, to stabilize or to reduce viral infection, and in particular HCV viral infection, in infected subjects or subjects being at risk of being infected. In still a further aspect, this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound of formula (I), as specified herein, or of a compound of any of the subgroups of compounds of formula (I) as specified herein.\n\n\n \n \n \n \nTherefore, the compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form or metal complex, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.\n\n\n \n \n \n \nThe compounds of the present invention may also be administered via oral inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder, a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via oral inhalation or insufflation are suitable for the administration of the present compounds.\n\n\n \n \n \n \nThus, the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier. Preferably, the compounds of the present invention are administered via inhalation of a solution in nebulized or aerosolized doses.\n\n\n \n \n \n \nIt is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.\n\n\n \n \n \n \nThe compounds of formula (I) show antiviral properties. Viral infections and their associated diseases treatable using the compounds and methods of the present invention include those infections brought on by HCV and other pathogenic flaviviruses such as Yellow fever, Dengue fever (types 1-4), St. Louis encephalitis, Japanese encephalitis, Murray valley encephalitis, West Nile virus and Kunjin virus. The diseases associated with HCV include progressive liver fibrosis, inflammation and necrosis leading to cirrhosis, end-stage liver disease, and HCC; and for the other pathogenic flaviviruses the diseases include yellow fever, dengue fever, hemorrhagic fever and encephalitis. A number of the compounds of this invention moreover are active against mutated strains of HCV. Additionally, many of the compounds of this invention show a favorable pharmacokinetic profile and have attractive properties in terms ofbioavailabilty, including an acceptable half-life, AUC (area under the curve) and peak values and lacking unfavorable phenomena such as insufficient quick onset and tissue retention.\n\n\n \n \n \n \nThe \nin vitro\n antiviral activity against HCV of the compounds of formula (I) was tested in a cellular HCV replicon system based on \nLohmann et al. (1999) Science 285:110-113\n, with the further modifications described by \nKrieger et al. (2001) Journal of Virology 75: 4614-4624\n, which is further exemplified in the examples section. This model, while not a complete infection model for HCV, is widely accepted as the most robust and efficient model of autonomous HCV RNA replication currently available. Compounds exhibiting anti-HCV activity in this cellular model are considered as candidates for further development in the treatment of HCV infections in mammals. It will be appreciated that it is important to distinguish between compounds that specifically interfere with HCV functions from those that exert cytotoxic or cytostatic effects in the HCV replicon model, and as a consequence cause a decrease in HCV RNA or linked reporter enzyme concentration. Assays are known in the field for the evaluation of cellular cytotoxicity based for example on the activity of mitochondrial enzymes using fluorogenic redox dyes such as resazurin. Furthermore, cellular counter screens exist for the evaluation of non-selective inhibition of linked reporter gene activity, such as firefly luciferase. Appropriate cell types can be equipped by stable transfection with a luciferase reporter gene whose expression is dependent on a constitutively active gene promoter, and such cells can be used as a counter-screen to eliminate non-selective inhibitors.\n\n\n \n \n \n \nDue to their antiviral properties, particularly their anti-HCV properties, the compounds of formula (I) or any subgroup thereof, their prodrugs, \nN\n-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms, are useful in the treatment of individuals experiencing a viral infection, particularly a HCV infection, and for the prophylaxis of these infections. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with viruses, in particular flaviviruses such as HCV.\n\n\n \n \n \n \nThe compounds of the present invention or any subgroup thereof may therefore be used as medicines. Said use as a medicine or method of treatment comprises the systemic administration to viral infected subjects or to subjects susceptible to viral infections of an amount effective to combat the conditions associated with the viral infection, in particular the HCV infection.\n\n\n \n \n \n \nThe present invention also relates to the use of the present compounds or any subgroup thereof in the manufacture of a medicament for the treatment or the prevention of viral infections, particularly HCV infection.\n\n\n \n \n \n \nThe present disclosure furthermore relates to a method of treating a warm-blooded animal infected by a virus, or being at risk of infection by a virus, in particular by HCV, said method comprising the administration of an anti-virally effective amount of a compound of formula (I), as specified herein, or of a compound of any of the subgroups of compounds of formula (I), as specified herein.\n\n\n \n \n \n \nAlso, the combination of previously known anti-HCV compound, such as, for instance, interferon-α (IFN-α), pegylated interferon-α and/or ribavirin, and a compound of formula (I) can be used as a medicine in a combination therapy. The term \"combination therapy\" relates to a product containing mandatory (a) a compound of formula (I), and (b) optionally another anti-HCV compound, as a combined preparation for simultaneous, separate or sequential use in treatment of HCV infections, in particular, in the treatment of infections with HCV.\n\n\n \n \n \n \nAnti-HCV compounds encompass agents selected from an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, and immunomodulatory agent, an antiviral agent, and combinations thereof.\n\n\n \n \n \n \nHCV polymerase inhibitors include, but are not limited to, NM283 (valopicitabine), R803, JTK-109, JTK-003, HCV-371, HCV-086, HCV-796 and R-1479.\n\n\n \n \n \n \nInhibitors of HCV proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors) include, but are not limited to, the compounds of \n \nWO02/18369\n \n (see, e.g., page 273, lines 9-22 and page 274, line 4 to page 276, line 11); BILN-2061, VX-950, GS-9132 (ACH-806), SCH-503034, and SCH-6. Further agents that can be used are those disclosed in \n \nWO98/17679\n \n, \n \nWO00/056331\n \n (Vertex); \n \nWO 98/22496\n \n (Roche); \n \nWO 99/07734\n \n, (Boehringer Ingelheim ), \n \nWO 2005/073216\n \n, \n \nWO 2005073195\n \n (Medivir) and structurally similar agents.\n\n\n \n \n \n \nInhibitors of other targets in the HCV life cycle, including NS3 helicase; metallo-protease inhibitors; antisense oligonucleotide inhibitors, such as ISIS-14803, AVI-4065 and the like; siRNA's such as SIRPLEX-140-N and the like; vector-encoded short hairpin RNA (shRNA); DNAzymes; HCV specific ribozymes such as heptazyme, RPI.13919 and the like; entry inhibitors such as HepeX-C, HuMax-HepC and the like; alpha glucosidase inhibitors such as celgosivir, UT-231B and the like; KPE-02003002; and BIVN 401.\n\n\n \n \n \n \nImmunomodulatory agents include, but are not limited to; natural and recombinant interferon isoform compounds, including α-interferon, β-interferon, γ-interferon, ω-interferon and the like, such as Intron A®, Roferon-A®, Canferon-A300®, Advaferon®, Infergen®, Humoferon®, Sumiferon MP®, Alfaferone®, IFN-beta®, Feron® and the like; polyethylene glycol derivatized (pegylated) interferon compounds, such as PEG interferon-α-2a (Pegasys®), PEG interferon-α-2b (PEG-Intron®), pegylated IFN-α-conl and the like; long acting formulations and derivatizations of interferon compounds such as the albumin-fused interferon albuferon α and the like; compounds that stimulate the synthesis of interferon in cells, such as resiquimod and the like; interleukins; compounds that enhance the development of type 1 helper T cell response, such as SCV-07 and the like; TOLL-like receptor agonists such as CpG-10101 (actilon), isatoribine and the like; thymosin α-1; ANA-245; ANA-246; histamine dihydrochloride; propagermanium; tetrachlorodecaoxide; ampligen; IMP-321; KRN-7000; antibodies, such as civacir, XTL-6865 and the like; and prophylactic and therapeutic vaccines such as InnoVac C, HCV E1E2/MF59 and the like.\n\n\n \n \n \n \nOther antiviral agents include, but are not limited to, ribavirin, amantadine, viramidine, nitazoxanide; telbivudine; NOV-205; taribavirin; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., compounds of \n \nUS5,807,876\n \n, \n \nUS6,498,178\n \n, \n \nUS6,344,465\n \n, \n \nUS6,054,472\n \n, \n \nWO97/40028\n \n, \n \nWO98/40381\n \n, \n \nWO00/56331\n \n, and mycophenolic acid and derivatives thereof, and including, but not limited to VX-950, merimepodib (VX-497), VX-148, and/or VX-944); or combinations of any of the above.\n\n\n \n \n \n \nThus, to combat or treat HCV infections, the compounds of formula (I) may be co-administered in combination with for instance, interferon-α (IFN-α), pegylated interferon-α and/or ribavirin, as well as therapeutics based on antibodies targeted against HCV epitopes, small interfering RNA (Si RNA), ribozymes, DNAzymes, antisense RNA, small molecule antagonists of for instance NS3 protease, NS3 helicase and NS5B polymerase.\n\n\n \n \n \n \nAccordingly, the present invention relates to the use of a compound of formula (I) or any subgroup thereof as defined above for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV viruses, wherein said medicament is used in a combination therapy, said combination therapy preferably comprising a compound of formula (I) and another HCV inhibitory compound, e.g. (pegylated) IFN-α and/or ribavirin.\n\n\n \n \n \n \nIn still another aspect there are provided combinations of a compound of formula (I) as specified herein and an anti-HIV compound. The latter preferably are those HIV inhibitors that have a positive effect on drug metabolism and/or pharmacokinetics that improve bioavailabilty. An example of such an HIV inhibitor is ritonavir.\n\n\n \n \n \n \nAs such, the present invention further provides a combination comprising (a) an HCV NS3/4a protease inhibitor of formula (I) or a pharmaceutically acceptable salt thereof; and (b) ritonavir or a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nThe compound ritonavir, and pharmaceutically acceptable salts thereof, and methods for its preparation are described in \n \nWO 94/14436\n \n. For preferred dosage forms of ritonavir, see \n \nUS 6,037\n \n, \n \n157\n \n, and the documents cited therein: \n \nUS 5,484\n \n, \n \n801\n \n, \n \nUS 08/402,690\n \n, and \n \nWO 95/07696\n \n and \n \nWO 95/09614\n \n. Ritonavir has the following formula:\n\n \n \n \n\n\n \n \n \n \nIn a further embodiment, the combination comprising (a) an HCV NS3/4a protease inhibitor of formula (I) or a pharmaceutically acceptable salt thereof; and (b) ritonavir or a pharmaceutically acceptable salt thereof; further comprises an additional anti-HCV compound selected from the compounds as described herein.\n\n\n \n \n \n \nIn one embodiment of the present invention there is provided a process for preparing a combination as described herein, comprising the step of combining an HCV NS3/4a protease inhibitor of formula (I) or a pharmaceutically acceptable salt thereof, and ritonavir or a pharmaceutically acceptable salt thereof. An alternative embodiment of this invention provides a process wherein the combination comprises one or more additional agent as described herein.\n\n\n \n \n \n \nThe combinations of the present invention may be used as medicaments. Said use as a medicine or method of treatment comprises the systemic administration to HCV-infected subjects of an amount effective to combat the conditions associated with HCV and other pathogenic flavi- and pestiviruses. Consequently, the combinations of the present invention can be used in the manufacture of a medicament useful for treating, preventing or combating infection or disease associated with HCV infection in a mammal, in particular for treating conditions associated with HCV and other pathogenic flavi- and pestiviruses.\n\nIn one embodiment of the present invention there is provided a pharmaceutical composition comprising a combination according to any one of the embodiments described herein and a pharmaceutically acceptable excipient. In particular, the present invention provides a pharmaceutical composition comprising (a) a therapeutically effective amount of an HCV NS3/4a protease inhibitor of the formula (I) or a pharmaceutically acceptable salt thereof, (b) a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof, and (c) a pharmaceutically acceptable excipient. Optionally, the pharmaceutical composition further comprises an additional agent selected from an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, and immunomodulatory agent, an antiviral agent, and combinations thereof.\n\n\n \n \n \n \nThe compositions may be formulated into suitable pharmaceutical dosage forms such as the dosage forms described above. Each of the active ingredients may be formulated separately and the formulations may be co-administered or one formulation containing both and if desired further active ingredients may be provided.\n\n\n \n \n \n \nAs used herein, the term \"composition\" is intended to encompass a product comprising the specified ingredients, as well as any product which results, directly or indirectly, from the combination of the specified ingredients.\n\n\n \n \n \n \nIn one embodiment the combinations provided herein may also be formulated as a combined preparation for simultaneous, separate or sequential use in HIV therapy. In such a case, the compound of general formula (I) or any subgroup thereof, is formulated in a pharmaceutical composition containing other pharmaceutically acceptable excipients, and ritonavir is formulated separately in a pharmaceutical composition containing other pharmaceutically acceptable excipients. Conveniently, these two separate pharmaceutical compositions can be part of a kit for simultaneous, separate or sequential use.\n\n\n \n \n \n \nThus, the individual components of the combination of the present invention can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The present invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term \"administering\" is to be interpreted accordingly. In a preferred embodiment, the separate dosage forms are administered about simultaneously.\n\n\n \n \n \n \nIn one embodiment, the combination of the present invention contains an amount of ritonavir, or a pharmaceutically acceptable salt thereof, which is sufficient to clinically improve the bioavailability of the HCV NS3/4a protease inhibitor of formula (I) relative to the bioavailability when said HCV NS3/4a protease inhibitor of formula (I) is administered alone.\n\n\n \n \n \n \nIn another embodiment, the combination of the present invention contains an amount of ritonavir, or a pharmaceutically acceptable salt thereof, which is sufficient to increase at least one of the pharmacokinetic variables of the HCV NS3/4a protease inhibitor of formula (I) selected from t\n1/2\n, C\nmin\n, C\nmax\n, C\nss\n, AUC at 12 hours, or AUC at 24 hours, relative to said at least one pharmacokinetic variable when the HCV NS3/4a protease inhibitor of formula (I) is administered alone.\n\n\n \n \n \n \nA further embodiment of the disclosure relates to a method for improving the bioavailability of a HCV NS3/4a protease inhibitor comprising administering to an individual in need of such improvement a combination as defined herein, comprising a therapeutically effective amount of each component of said combination.\n\n\n \n \n \n \nIn a further embodiment, the invention relates to the use of ritonavir or a pharmaceutically acceptable salt thereof, as an improver of at least one of the pharmacokinetic variables of a HCV NS3/4a protease inhibitor of formula (I) selected from t\n1/2\n, C\nmin\n, C\nmax\n, C\nss\n, AUC at 12 hours, or AUC at 24 hours; with the proviso that said use is not practised in the human or animal body.\n\n\n \n \n \n \nThe term \"individual\" as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.\n\n\n \n \n \n \nBioavailability is defined as the fraction of administered dose reaching systemic circulation. t\n1/2\n represents the half life or time taken for the plasma concentration to fall to half its original value. C\nss\n is the steady state concentration, i.e. the concentration at which the rate of input of drug equals the rate of elimination. C\nmin\n is defined as the lowest (minimum) concentration measured during the dosing interval. C\nmax\n, represents the highest (maximum) concentration measured during the dosing interval. AUC is defined as the area under the plasma concentration-time curve for a defined period of time.\n\n\n \n \n \n \nThe combinations of this invention can be administered to humans in dosage ranges specific for each component comprised in said combinations. The components comprised in said combinations can be administered together or separately. The NS3/4a protease inhibitors of formula (I) or any subgroup thereof, and ritonavir or a pharmaceutically acceptable salt or ester thereof, may have dosage levels of the order of 0.02 to 5.0 grams-per-day.\n\n\n \n \n \n \nWhen the HCV NS3/4a protease inhibitor of formula (I) and ritonavir are administered in combination, the weight ratio of the HCV NS3/4a protease inhibitor of formula (I) \nto\n ritonavir is suitably in the range of from about 40:1 to about 1:15, or from about 30:1 1 to about 1:15, or from about 15: 1 to about 1: 15, typically from about 10: 1 to about 1:10, and more typically from about 8:1 to about 1:8. Also useful are weight ratios of the HCV NS3/4a protease inhibitors of formula (I) to ritonavir ranging from about 6:1 to about 1:6, or from about 4:1 to about 1:4, or from about 3:1 to about 1:3, or from about 2:1 to about 1:2, or from about 1.5:1 to about 1:1.5. In one aspect, the amount by weight of the HCV NS3/4a protease inhibitors of formula (I) is equal to or greater than that of ritonavir, wherein the weight ratio of the HCV NS3/4a protease inhibitor of formula (I) to ritonavir is suitably in the range of from about 1: 1 to about 15: 1, typically from about 1: 1 to about 10: 1, and more typically from about 1: 1 to about 8: 1. Also useful are weight ratios of the HCV NS3/4a protease inhibitor of formula (I) \nto\n ritonavir ranging from about 1: 1 to about 6: 1, or from about 1: 1 to about 5: 1, or from about 1: 1 to about 4:1, or from about 3:2 to about 3:1, or from about 1:1 to about 2:1 or from about 1:1 to about 1.5:1.\n\n\n \n \n \n \nThe term \"therapeutically effective amount\" as used herein means that amount of active compound or component or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought, in the light of the present invention, by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated. Since the instant invention refers to combinations comprising two or more agents, the \"therapeutically effective amount\" is that amount of the agents taken together so that the combined effect elicits the desired biological or medicinal response. For example, the therapeutically effective amount of a composition comprising (a) the compound of formula (I) and (b) ritonavir, would be the amount of the compound of formula (I) and the amount of ritonavir that when taken together have a combined effect that is therapeutically effective.\n\n\n \n \n \n \nIn general it is contemplated that an antiviral effective daily amount would be from 0.01 mg/kg to 500 mg/kg body weight, more preferably from 0.1 mg/kg to 50 mg/kg body weight. It may be appropriate to administer the required dose as one, two, three, four or more (sub-)doses at appropriate intervals throughout the day. Said (sub-)doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.\n\n\n \n \n \n \nThe exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.\n\n\n \n \n \n \nAccording to one embodiment, the HCV NS3/4a protease inhibitor of formula (I) and ritonavir may be co-administered once or twice a day, preferably orally, wherein the amount of the compounds of formula (I) per dose is from about 1 to about 2500 mg, and the amount of ritonavir per dose is from 1 to about 2500 mg. In another embodiment, the amounts per dose for once or twice daily co-administration are from about 50 to about 1500 mg of the compound of formula (I) and from about 50 to about 1500 mg of ritonavir. In still another embodiment, the amounts per dose for once or twice daily co-administration are from about 100 to about 1000 mg of the compound of formula (I) and from about 100 to about 800 mg of ritonavir. In yet another embodiment, the amounts per dose for once or twice daily co-administration are from about 150 to about 800 mg of the compound of formula (I) and from about 100 to about 600 mg of ritonavir. In yet another embodiment, the amounts per dose for once or twice daily co-administration are from about 200 to about 600 mg of the compound of formula (I) and from about 100 to about 400 mg of ritonavir. In yet another embodiment, the amounts per dose for once or twice daily co-administration are from about 200 to about 600 mg of the compound of formula (I) and from about 20 to about 300 mg of ritonavir. In yet another embodiment, the amounts per dose for once or twice daily co-administration are from about 100 to about 400 mg of the compound of formula (I) and from about 40 to about 100 mg of ritonavir.\n\n\n \n \n \n \nExemplary combinations of the compound of formula (I) (mg)/ritonavir (mg) for once or twice daily dosage include 50/100, 100/100, 150/100, 200/100, 250/100, 300/100, 350/100, 400/100, 450/100, 50/133, 100/133, 150/133, 200/133, 250/133, 300/133, 50/150, 100/150, 150/150, 200/150, 250/150, 50/200, 100/200, 150/200, 200/200, 250/200, 300/200, 50/300, 80/300, 150/300, 200/300, 250/300, 300/300, 200/600, 400/600, 600/600, 800/600, 1000/600, 200/666, 400/666, 600/666, 800/666, 1000/666, 1200/666, 200/800, 400/800, 600/800, 800/800, 1000/800, 1200/800, 200/1200, 400/1200, 600/1200, 800/1200, 1000/1200, and 1200/1200. Other exemplary combinations of the compound of formula (I) (mg)/ritonavir (mg) for once or twice daily dosage include 1200/400, 800/400, 600/400, 400/200, 600/200, 600/100, 500/100, 400/50, 300/50, and 200/50.\n\n\n \n \n \n \nIn one embodiment of the present disclosure there is provided an article of manufacture comprising a composition effective to treat an HCV infection or to inhibit the NS3 protease of HCV; and packaging material comprising a label which indicates that the composition can be used to treat infection by the hepatitis C virus; wherein the composition comprises a compound of the formula (I) or any subgroup thereof, or the combination as described herein.\n\n\n \n \n \n \nAnother embodiment of the present disclosure concerns a kit or container comprising a compound of the formula (I) or any subgroup thereof, or a combination according to the invention combining an HCV NS3/4a protease inhibitor of formula (I) or a pharmaceutically acceptable salt thereof, and ritonavir or a pharmaceutically acceptable salt thereof, in an amount effective for use as a standard or reagent in a test or assay for determining the ability of potential pharmaceuticals to inhibit HCV NS3/4a protease, HCV growth, or both. This aspect of the invention may find its use in pharmaceutical research programs.\n\n\n \n \n \n \nThe compounds and combinations of the present invention can be used in high-throughput target-analyte assays such as those for measuring the efficacy of said combination in HCV treatment.\n\n\n \n\n\n\n\nExamples\n\n\n\n\n\n\n \n \n \nThe following examples are intended to illustrate the present invention and not to limit it thereto.\n\n\n \n \n \n \nGeneral: LC/MS analyses were performed on a Waters Alliance 2795 HT attached to a Micromass ZMD mass spectrometer using electrospray ionisation in positive mode. \nEluent:\n A: water, 0.1% TFA, B: acetonitrile, 0.1% TFA. \nDetection:\n UV (diode array: 210-300 nm). \nGradients:\n Method A: 20 to 70% B in A (1.5 mL min\n-1\n) over 5 min. Method B: 30 to 80% B in A (1.5 mL min\n-1\n) over 5 min. Method C: 40 to 80% B in A (1.5 mL min\n-1\n) over 5 min. Method D: 50 to 90% B in A (1.5 mL min\n-1\n) over 5 min. Method E: 20 to 70% B in A (0.9 mL min\n-1\n) over 2.5 min. Method F: 30 to 80% B in A (0.9 mL min\n-1\n) over 2.5 min. Method G: 40 to 80% B in A (0.9 mL min\n-1\n) over 2.5 min. Method H: 50 to 90% B in A (0.9 mL min\n-1\n) over 2.5 min. \nColumn:\n Methods A-D: Phenomonex, Synergi MAX RP-80A column (5.0 cm, 4.6 mm φ, 4 µm). Methods E-H: Phenomonex, Synergi MAX RP-80A column (3.0 cm, 3.0 mm φ, 4 µm).\n\n\n \n \nExample 1\n: Synthesis of 1-[(3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carbonyl)-amino]-2-vinyl-cyclopropane carboxylic acid ethyl ester \n(3)\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of \n1\n (857 mg, 5.5 mmol), in DMF (14 mL) and DCM (25 mL) at room temperature, was added \n2\n (1.15 g, 6.0 mmol), HATU (2.29 g, 6.0 mmol) and DIPEA (3.82 mL, 22 mmol). The reaction was stirred under N\n2\n-atmosphere at ambient temperature for 1 h. LC/MS analysis showed complete conversion and the reaction mixture was concentrated \nin vacuo.\n The residue was re-dissolved in DCM (100 mL) and 0.1 M HCl (aq) and the phases separated. The organic phase was washed with NaHCO\n3\n (aq) and brine, dried (MgSO\n4\n) and filtered. Removal of the solvent \nin vacuo\n afforded the target compound \n3\n (1.6 g, 99%). LC/MS (Method A): t\nR\n=2.46 min, >95%, m/z (ESI\n+\n) = 294(MH\n+\n)\n\n\n \n \nExample 2\n: Synthesis of 2-(1-Ethoxycarbonyl-2-vinylcyclopropylcarbamoyl)-4-hydroxy-cyclopentane carboxylic acid diisopropylethylamine salt \n(4)\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nTo a solution of \n3\n (800 mg, 2.73 mmol) in water (15 mL) in a 20 mL microwave reaction vessel was added DIPEA (1.2 mL, 6.8 mmol) and a stir bar. The reaction vessel was sealed and the immiscible slurry was shaken vigorously before insertion in the microwave oven cavity. After 1 min of pre-stirring, the reaction was irradiated for 40 min to a set temperature of 100 °C. After cooling to 40 °C, the transparent solution was concentrated \nin vacuo,\n and the residual brown oil co-evaporated 3 times with MeCN to remove any residual water. The crude product 4, in the form of a DIPEA salt, was immediately taken forward to the next step. LC/MS (Method A): t\nR\n=1.29 min, >95%, m/z (ESI\n+\n)= 312(MH\n+\n).\n\n\n \n \nExample 3\n: Synthesis of 1-{[2-(Hex-5-enylmethylcarbamoyl)-4-hydroxycyclopentane carbonyl]amino}-2-vinylcyclopropane carboxylic acid ethyl ester (6)\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe crude compound \n4\n (5.5 mmol) was dissolved in DCM (50 mL) and DMF (14 mL) followed by addition of HATU (2.09 g, 5.5 mmol), \n5\n (678 mg, 6.0 mmol) and DIPEA (3.08 mL, 17.5 mmol) at room temperature. The reaction was stirred at ambient temperature for 1 h. LC/MS analysis showed complete conversion and the reaction mixture was concentrated \nin vacuo.\n The residue was re-dissolved in EtOAc (100 mL) and the organic phase washed with 0.1 M HCl (aq), K\n2\nCO\n3\n (aq) and brine, dried (MgSO\n4\n) and filtered. Evaporation of the solvent \nin vacuo\n gave an oil which was purified by flash chromatography (Silica, EtOAc:MeOH) to afford the target compound 6 (1.65 g, 74%). TLC (Silica): MeOH:EtOAc 5:95, R\nf\n=0.5; LC/MS (Method A): t\nR\n=3.44 min, >95%, m/z (ESI\n+\n)= 407(MH\n+\n).\n\n\n \n \nExample 4\n: Synthesis of 1-{[2-(Hex-5-enylmethylcarbamoyl)-4-hydroxycyclopentane-carbonyl]amino}-2-vinylcyclopropanecarboxylic acid (7).\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nCompound \n6\n (493 mg, 1.21 mmol) was dissolved in DMF (1 mL) and transferred to a 20 mL microwave reaction vessel. Then, aqueous LiOH (2 M, 10.5 mL) and a stirbar were added. The reaction vessel was sealed and the immiscible slurry was shaken vigorously before insertion in the microwave cavity. The reaction was irradiated for 30 min to 130 °C. The reaction mixture was cooled to 40 °C and the clear solution acidified to pH 2 with aqueous HCl (1 M, 24 mL) and extracted 3 times with EtOAc (20 mL). The pooled organic layers were washed with brine, dried (MgSO\n4\n) and filtered. The solvent was evaporated \nin vacuo\n to afford compound 7 (410 mg, 90 %). LC/MS (Method A): t\nR\n= 2.46 min, >95%, m/z (ESI\n+\n)= 379(MH\n+\n).\n\n\n \n \nExample 5\n: Synthesis of 4-Hydroxy-cyclopentane-1,2-dicarboxylic acid 1-[(1-cyclopropanesulfonylamino carbonyl-2-vinyl-cyclopropyl)-amide] 2-(hex-5-enylmethyl-amide) \n(8).\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe crude acid 7 (410 mg, 1.09 mmol) was dissolved in DMF (1.5 mL) and DCM (4.5 mL) followed by addition of EDAC (417 mg, 2.18 mmol) at room temperature. The mixture was allowed to incubate with stirring at room temperature. After 10 min, DMAP (133 mg, 1.09 mmol) was added followed by another 20 min incubation at room temperature. Subsequently, a pre-mixed solution of cyclopropanesulfonic acid amide (527 mg, 4.36 mmol) and DBU (663 mg, 4.36 mmol) in DMF (2 mL) and DCM (2 mL) was added followed by heating in the microwave oven to 100°C for 30 min. The resulting red solution was concentrated \nin vacuo\n and re-dissolved in EtOAc (20 mL). The organic phase was washed with 1 M HCl (aq) (3x 10 mL) and brine (10 mL), dried (MgSO\n4\n) and filtered. The solvent was evaporated \nin vacuo\n to yield the crude sulfonamide which was further purified by chromatography (Silica, EtOAc:MeOH, 97.5:2.5) to afford the target compound \n8\n (403 mg, 77%); LC/MS (Method A): t\nR\n= 3.31 min, >95%, m/z (ESI\n+\n)= 482(MH\n+\n).\n\n\n \n \nExample 6-1\n: Synthesis of 2,3-Dihydroindole-1-carboxylic acid 3-(1-cyclopropane-sulfonylaminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethyl-carbamoyl)cyclopentyl ester (11).\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nCompound \n8\n (19.4 mg, 40 µmol) was dissolved in DCM (1.8 mL) followed by addition of solid NaHCO\n3\n (14 mg, 160 µmol) and a stirbar. To this slurry was then added phosgene in toluene (1.93 M, 430 µl, 0.8 mmol) and the mixture was stirred vigorously for 2 h to afford the chloroformate \n9.\n LC/MS (Method G): t\nR\n= 2.65 min, >95%, m/z (ESI\n+\n)= 544(MH\n+\n). The solvent was evaporated \nin vacuo\n and the residue was co-evaporated 3 times with DCM to remove any residual phosgene.\n\nThe afforded chloroformate \n9\n was subsequently re-dissolved in DCM (1 mL) and 2,3 dihydroindole (68 µmol) was added. The mixture was allowed to stir at ambient temperature for 2 h after which time LC/MS showed complete conversion. Then, DCM (1 mL) was added to the mixture and the solution was washed 2 times with 1 M HCl (aq), NaHCO\n3\n (aq) and brine. The organic phase was dried (MgSO\n4\n) and filtered. Evaporation of the solvent \nin vacuo\n gave a crude which was further purified by preparative LC/MS to afford compound \n10:\n LC/MS (Method H): t\nR\n= 1.58 min, >95%, m/z (ESI\n+\n)= 627(MH\n+\n).\n\n\n \n \nExample 6-2\n: 3,4-Dihydro-2\nH\n-quinoline-1-carboxylic acid 3-(1-cyclopropanesulfonyl aminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethylcarbamoyl) cyclopentyl ester \n(11).\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was synthesized from 1,2,3,4-tetrahydroquinoline according to the procedure described in Example 6-1. LC/MS (Method H): t\nR\n= 1.74 min, >95%, m/z (ESI\n+\n)= 641(MH\n+\n).\n\n\n \n \nExample 6-3\n: 2,3-Dihydrobenzo[1,4]oxazine-4-carboxylic acid 3-(1-cyclopropane sulfonylaminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethylcarbamoy1) cyclopentyl ester \n(12).\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was synthesized from 3,4-dihydro-2H-benzo[1,4]oxazine according to the procedure described in Example 6-1. LC/MS (Method H): t\nR\n= 1.56 min, >95%, m/z (ESI\n+\n)= 643(MH\n+\n).\n\n\n \n \nExample 6-4\n: 1,3-Dihydroisoindole-2-carboxylic acid 3-(1-cyclopropanesulfonyl aminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethylcarbamoyl) cyclopentyl ester \n(13)\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was synthesized from 2,3-dihydro-1H-isoindole according to the procedure described in Example 6-1. LC/MS (Method H): t\nR\n= 1.37 min, >95%, m/z (ESI\n+\n)= 627(MH\n+\n).\n\n\n \n \nExample 7\n: 3,4-Dihydro-1\nH\n-isoquinoline-2-carboxylic acid 3-(1-cyclopropane sulfonylaminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethyl carbamoyl)cyclopentyl ester \n(16).\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \np\n-Nitrophenyl chloroformate (25.9 mg, 0.129 mmol) was dissolved in MeCN (1 mL). To this solution was added solid NaHCO\n3\n (15.7 mg, 0.19 mmol) and the suspension was cooled in an ice/water bath. To the cooled solution was then added a solution of 1,2,3,4-tetrahydro-isoquinoline (0.123 mmol) in MeCN (0.5 mL) and the reaction was allowed to incubate at ambient temperature for 2 h. LC/MS analysis showed complete conversion to compound \n15.\n This solution was then added to a mixture of \n8\n (49.2 mg, 102 µmol) and NaH (60 % in oil) (4.5 mg, 112 µmol) followed by heating of the reaction to 50 °C for 1 h. The reaction was quenched with NH\n4\nCl (aq) (5 mL) and EtOAc (5 mL) was added. The organic layer was washed with 1 M HCl (aq) and brine, dried (MgSO\n4\n) and filtered. Evaporation of the solvent gave an oil which was further purified using preparative LC/MS to afford the target product \n16:\n LC/MS (Method X): t\nR\n= 5.13 min, >90%, m/z (ESI\n+\n)= 641 (MH\n+\n).\n\n\n \n \nExample 8-1\n: 2,3-Dihydroindole-1-carboxylic acid 4-cyclopropanesulfonylamino carbonyl-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0\n4,6\n]octadec-7-en-17-yl ester, \n(17)\n.\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nCompound \n10\n (14.6 µmol) was dissolved in DCE (dried over mol sieves, N\n2\n-gassed) (10 mL) in a 20 mL microwave reaction vessel with a stir bar. To this solution was added Hoveyda-Grubb's 2\nnd\n generation catalyst (2.3 mg, 3.6 µmol) and the reaction vessel was purged with N\n2\n(g) and sealed. The reaction was irradiated for 15 min with a set temperature of 150°C. The solvent was removed \nin vacuo\n and the residue purified by flash chromatography (Silica; DCM, then 10% MeOH in DCM). The product was subsequently purified by preparative LC/MS to afford the target compound 17: LC/MS (Method H): t\nR\n= 1.13 min, >95%, m/z (ESI\n+\n)= 599(MH\n+\n).\n\n\n \n \nExample 8-2\n: 3,4-Dihydro-1\nH\n-isoquinoline-2-carboxylic acid 4-cyclopropanesulfonyl amino carbonyl-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0\n4,6\n]octadec-7-en-17-yl ester \n(18)\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was prepared from 3,4-Dihydro-1\nH\n-isoquinoline-2-carboxylic acid 3-(1-cyclopropane sulfonylarninocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethyl carbamoyl)cyclopentyl ester \n(16)\n following the procedure described in Example 8-1. LC/MS (Method A): t\nR\n= 4.51 min, >95%, m/z (ESI\n+\n)= 613(MH\n+\n).\n\n\n \n \nExample 8-3\n: 2,3-Dihydrobenzo[1,4]oxazine-4-carboxylic acid 4-cyclopropane sulfonylamino carbonyl-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0\n4,6\n]octadec-7-en-17-yl ester \n(19)\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was prepared from 2,3-Dihydrobenzo[1,4]oxazine-4-carboxylic acid 3-(1-cyclopropane sulfonylaminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethyl carbamoyl) cyclopentyl ester \n(12)\n following the procedure described in Example 8-1: LC/MS (Method H): t\nR\n= 1.11 min, >95%, m/z (ESI\n+\n) = 615(MH\n+\n).\n\n\n \n \nExample 8-4\n: 1,3-Dihydro-isoindole-2-carboxylic acid 4-cyclopropanesulfonylamino carbonyl-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0\n4,6\n]octadec-7-en-17-yl ester, \n(20).\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was prepared from 1,3-Dihydroisoindole-2-carboxylic acid 3-(1-cyclopropanesulfonyl aminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethyl carbamoyl) cyclopentyl ester \n(13)\n following the procedure described in Example 8-1: LC/MS (Method F): t\nR\n= 2.33 min, >95%, m/z (ESI\n+\n)= 599(MH\n+\n).\n\n\n \n \nExample 8-5\n: 3,4-Dihydro-2\nH\n-quinoline-1-carboxylic acid 4-cyclopropane sulfonyl-aminocarbonyl-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0\n4,6\n]octadec-7-en-17-yl ester, \n(21):\n \n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThe title compound was prepared from 3,4-Dihydro-2\nH\n-quinoline-1-carboxylic acid 3-(1-cyclopropanesulfonyl aminocarbonyl-2-vinylcyclopropylcarbamoyl)-4-(hex-5-enylmethyl carbamoyl) cyclopentyl ester \n(11)\n following the procedure described in Example 8-1: LC/MS (Method H): t\nR\n= 1.25 min, >95%, m/z (ESI\n+\n)= 613(MH\n+\n).\n\n\n \n\n\nExample 9\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n2-(1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester (22)\n\n\n\n\n \n \n \nBoc-protected 4-hydroxy proline (4 g, 17.3 mmol), HATU (6.9 g, 18.2 mmol) and 1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester prepared as described in \n \nWO03/099274\n \n, (3.5 g, 18.3 mmol) were dissolved in DMF (60 ml) and cooled to 0° on an ice-bath. Diisopropylethyl amine (DIPEA) (6ml) was added. The ice-bath was removed and the mixture was left at ambient temperature over-night. Dichloromethane (∼80 ml) was then added and the organic phase was washed with aqueous sodium hydrogen carbonate, citric acid, water, brine and dried over sodium sulphate. Purification by flash chromatography (ether → 7% methanol in ether) gave pure title compound (6.13 g, 96%)\n\n\n \n\n\nExample 10\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n2-(1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(4-nitro-benzoyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester (23)\n\n\n\n\n \n \n \nCompound 22 (from example 9) (11.8 g, 32.0 mmol) and pyridine (27 ml, 305 mmol) was dissolved in DCM (200 ml) and cooled to 0°C, 4-nitrobenzoyl chloride (6.6 g, 35.6 mmol) was added and the solution was stirred at room temperature overnight. The reaction mixture was washed with NaHCO3 (aq), aqueous citric acid and brine, dried over MgS04 and evaporated on silica. The crude product was purified by column chromatography on silica (EtOAc/n-Heptane: 50/50) to give 11.84 g, 72 % of the title compound \n5.\n \n\n\n \n\n\nExample 11\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n4-Nitro-benzoic acid 5-(1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-pyrrolidin-3-yl ester (24)\n\n\n\n\n \n \n \nCompound 23 (11.84 g, 22.9 mmol) was deprotected in TFA (30 ml) dissolved in DCM (100 ml) and then worked up by methods known in the chemical art to give the title compound (9.37 g, 98 %).\n\n\n \n\n\nExample 12\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n4-Nitro-benzoic acid 5-(1-ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-1-[hept-6-enyl-(4-methoxy-benzyl)-carbamoyl]-pyrrolidin-3-yl ester (25)\n\n\n\n\n \n \n \nCompound 24 (4.68 g, 11.2 mmol) was dissolved in THF (100 ml), NaHCO\n3\n (s) (appr. 5 ml) was added followed by phosgene-solution (20 % in toluene, 11.6 ml, 22.5 mmol). The reaction mixture was stirred vigorously for 1h and then filtrated, evaporated and redissolved in DCM (100ml). NaHCO\n3\n (s) (appr. 5 ml) was added followed by hept-6-enyl-(4-methoxy-benzyl)-amin (3.92 g, 16.8 mmol). The reaction mixture was stirred at room temperature overnight, filtrated and evaporated on silica. The crude product was purified by column chromatography on silica (EtOAc/ n-Heptane: 25/75) to give the title compound (6.9 g, 91 %).\n\n\n \n\n\nExample 13\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n14-(4-Methoxy-benzyl)-18-(4-nitro-benzoyloxy)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carboxylic acid ethyl ester (26)\n\n\n\n\n \n \n \nCompound 25 (406 mg, 0.6 mmol) was dissolved in DCE (250 ml) and degassed. Hoveyda-Grubbs Catalyst 2\nnd\n generation (26 mg, 0.042 mmol) was added and the solution was heated to reflux. After 3 h the solution was evaporated and used direct in the next step.\n\n\n \n\n\nExample 14\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n18-Hydroxy-14-(4-methox-benzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]-nonadec-7-ene-4-carboxylic acid ethyl ester (27)\n\n\n\n\n \n \n \nCrude compound 26 (445 mg) was dissoved in THF (20 ml), MeOH (10 ml) and water (10 ml). After cooling to 0°C 1M LiOH (2 ml) was added. After 1.5 h the hydrolysis was completed and HOAc (1ml) was added and the solution was evaporated to appr 10 ml. Water was added and the mixture was extracted with DCM ( 2 x 30 ml). The pooled organic phase was washed with NaHCO\n3\n (aq), water, brine and dried over MgSO4. The crude product was purified by column chromatography on silica (DCM/ MeOH: 100/0 - 80/20) to give the title compound (201 mg, 67 %).\n\n\n \n\n\nExample 15\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n18-Ethoxymethoxy-14-(4-methoxy-benzyl)-2,15-dioxo-3,14,16-triaza-tricyclo-[14.3.0.0*4,6*]nonadec-7-ene-4-carboxylic acid ethyl ester (28)\n\n\n\n\n \n \n \nTo a stirred solution of the alcohol 27 (1.35 g, 2.70 mmol, 75 % purity) and N-ethyldiisopropylamine (1.42 ml, 8.1 mmol) in dichloromethane (15 ml) at 0 °C was added chloromethyl ethyl ether (0.5 ml, 5.4 mmol). After stirring at rt on the reaction mixture was cooled to 0 °C and more N-ethyldiisopropylamine (1 ml, 5.7 mmol) and chloromethyl ethyl ether (0.3 ml, 3.2 mmol) was added, then stirred additional 16 h at rt. The reaction mixture was then directly applied on a silicagel column and eluted using stepwise gradient elution (ethyl acetate in hexane 50-80 %). Concentration of the appropriate fractions gave the title compound as a slight brown syrup which crystallized upon standing (0.8 g, 53%). LR-MS: Calcd for C\n30\nH\n44\nN\n3\nO\n7\n: 558. Found: 558 [M+H].\n\n\n \n\n\nExample 16\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n18-Ethoxymethoxy-14-(4-methoxy-benzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carboxylic acid (29)\n\n\n\n\n \n \n \nA solution of the ester 28 (0.775 g, 1.39 mmol) in 1:1:1 THF-Methanol-aq. 1M LiOH (36 ml) was stirred at rt for 3.5 h after which TLC (95:5 and 9:1 dichloromethane-methanol) and LC-MS indicated complete conversion into the carboxylic acid. The reaction mixture was then concentrated into approximately 1/3 of the volume, then diluted with water (10 ml) and acidified to approx. pH 4 using aq. 10 % citric acid (60 ml) upon which a precipitate formed. The mixture was washed with ethyl acetate (3 x 25 ml) and the combined organic layers were washed with brine (2 x 50 ml), then dried (Na\n2\nSO\n4\n), filtered and concentrated. The residue was concentrated from toluene (3 x 10 ml) which gave the crude title compound as an off-white foam (0.75 g, quantitative). LR-MS: Calcd for C\n28\nH\n40\nN\n3\nO\n7\n: 530. Found: 530 [M-H].\n\n\n \n\n\nExample 17\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\nCompound 30\n\n\n\n\n \n \n \nTo a solution of the carboxylic acid 29 (approx. 1.39 mmol) in dichloromethane (10 ml) at rt was added N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide x HCl (0.32 g, 1.67 mmol), then stirred overnight after which LC-MS indicated complete conversion of the acid into the product. The reaction mixture was then diluted with dichloromethane (10 ml), washed with water (3 x 10 ml), then dried (Na\n2\nSO\n4\n) filtered and concentrated into a colorless solid (crude yield: 0.7 g) which was used immediately in the next step. LR-MS: Calcd for C\n28\nH\n38\nN\n3\nO\n6\n: 512. Found: 512 [M+H].\n\n\n \n\n\nExample 18\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\nCyclopropanesulfonic acid [18-ethoxymethoxy-14-(4-methoxy-benzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl]-amide (31)\n\n\n\n\n \n \n \nTo a stirred solution of the crude oxazolinone 30 (0.328 g, 0.64 mmol) in dichloromethane (4 ml) was added cyclopropylsulfonamide (0.117 g, 0.96 mmol) and 1,8-diazabicyclo[5.4.0]-undec-7-ene (0.19 ml, 1.3 mmol), then stirred at rt overnight. The reaction mixture was monitored by LC-MS then diluted with dichloromethane (20 ml), washed successively with aq. 10 % citric acid (3 x 15 ml) and brine (1 x 15 ml), then dried (Na\n2\nSO\n4\n), filtered and concentrated into an off-white foam. Column chromatography of the residue using stepwise gradient elution (ethyl acetate in toluene 60-100 %) followed by concentration and drying of the appropriate fractions gave the title compound as a colorless foam (0.27 g, 66 % over 3 steps).\n\nNMR data (500 MHz, DMSO-d\n6\n): \n1\nH, 0.9-1.6 (m, 14H), 1.80 (m, 1H), 1.90 (m, 1H), 2.0-2.2 (m, 3H), 2.25 (m, 1H), 2.95 (m, 1H), 3.05 (m, 1H), 3.3-3.4 (m, 2H), 3.50 (q, 2H), 3.7-3.8 (m, 4H), 3.97 (d, 1H), 4.3-4.4 (m, 2H), 4.55 (d, 1H), 4.63 (m, 2H), 5.12 (m, 1 H), 5.70 (m, 1H), 6.88 (d, 2H), 7.19 (d, 2H), 8.12 (s, 1H). LR-MS: Calcd for C\n31\nH\n45\nN\n4\nO\n8\nS: 633. Found: 633 [M+H].\n\n\n \n\n\nExample 19\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\nCyclopropanesulfonic acid (18-hydroxy-2,15-dioxo-3,14,16-triaza-tricyclo-[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl)-amide (32)\n\n\n\n\n \n \n \nA solution of the acetal 31 (0.038 g, 0.06 mmol) in 1:1:1 THF-methanol-2 M aq. hydrochloric acid (1.5 ml) was stirred at rt for 30 min, then additional conc. hydrochloric acid (0.1 ml) was added and then stirred at rt overnight. The reaction mixture was then neutralized using aq. saturated sodium hydrogen carbonate, then concentrated onto silica. Flash chromatography of the residue using 9:1 ethyl acetate-methanol gave a colorless foam (0.020 g, 73 %). LR-MS: Calcd for C\n20\nH\n29\nN\n4\nO\n6\nS: 453. Found: 453 [M-H].\n\n\n \n\n\nExample 20-1\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n1,3-Dihydro-isoindole-2-carboxylic acid 4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-en-18-yl ester (33)\n\n\n\n\n \n \n \nAlcohol 32 (25 mg, 55 umol) was dissolved in dry DCM (2 mL). To this solution was added solid NaHCO\n3\n (14 mg, 165 umol) and phosgene (1.9 M in toluene, 868 µL, 1.65 mmol). The mixture was stirred for 48 h to afford the intermediate chloroformate. LC/MS (Method F): t\nR\n= 2.32 min, m/z (ESI\n+\n)= 516 (MH\n+\n). The solvent was removed \nin vacuo\n and the residue was co-evaporated with DCM to remove any residual phosgene. The afforded chloroformate was subsequently re-dissolved in dry DCE (2 ml) and isoindoline (83 µmol) was added followed by solid K\n2\nCO\n3\n (110 µmol) and powdered 4Å mol.sieves (1 spatula). The mixture was heated to 100 °C for 45 min, after which time LC/MS analysis showed no remaining chloroformate. The reaction was filtered and the filtrate concentrated \nin vacuo\n to afford a crude which was purified by preparative LC/MS to yield the title compound. LC/MS (Method H): t\nR\n= 1.55 min, >95%, m/z (ESI\n+\n)= 600 (MH\n+\n).\n\n\n \n\n\nExample 20-2\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n2,3-Dihydro-indole-1-carboxylic acid 4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-en-18-yl ester (34)\n\n\n\n\n \n \n \nThe title compound was prepared according to the procedure described in Example 20-1, except that indoline was used instead of isoindoline. LC/MS (Method H): t\nR\n= 1.68 min, 95%, m/z (ESI\n+\n)= 600 (MH\n+\n).\n\n\n \n\n\nExample 20-3\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n3,4-Dihydro-1H-isoquinoline-2-carboxylic acid 4-cyclopropanesulfonylamino carbonyl-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-en-18-yl ester (35)\n\n\n\n\n \n \n \nThe title compound was prepared according to the procedure described in Example 20-1, except that 1,2,3,4-tetrahydro-isoquinoline was used instead of isoindoline. LC/MS (Method H): t\nR\n= 1.60 min, 95%, m/z (ESI\n+\n)= 614 (MH\n+\n).\n\n\n \n\n\nExample 20-4\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n3,4-Dihydro-2H-quinoline-1-carboxylic acid 4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-3,14,16-triaza-a-tricyclo[14.3.0.0*4,6*]nonadec-7-en-18-yl ester (36)\n\n\n\n\n \n \n \nThe title compound was prepared according to the procedure described in Example 20-1, except that 1,2,3,4-tetrahydro-quinoline was used instead of isoindoline. LC/MS (Method H): t\nR\n= 1.77 min, 95%, m/z (ESI\n+\n)= 614 (MH\n+\n).\n\n\n \n\n\nExample 20-5\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n5-Methyl-2,3-dihydro-indole-1-carboxylic acid 4-cyclopropanesulfonylamino-carbonyl-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-en-18-yl ester (37)\n\n\n\n\n \n \n \nThe title compound was prepared according to the procedure described in Example 20-1, except that 5-methyl-2,3-dihydro-1H-indole was used instead of isoindoline. LC/MS (Method H): t\nR\n= 1.91 min, 95%, m/z (ESI\n+\n)= 614 (MH\n+\n).\n\n\n \n\n\nExample 20-6\n\n\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n\n\n5-Dimethylsulfamoyl-2,3-dihydro-indole-1-carboxylic acid 4-cyclopropanesulfonyl aminocarbonyl-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-en-18-yl ester (38)\n\n\n\n\n \n \n \nThe title compound was prepared according to the procedure described in Example 20-1, except that 2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide was used instead of isoindoline. LC/MS (Method H): t\nR\n= 1.53 min, 95%, m/z (ESI\n+\n)= 707 (MH\n+\n).\n\n\n \n\n\nExample 21: Synthesis of crystalline cyclopentane\n\n\n\n\nSynthesis of 3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid \ntert\n-butyl ester (40)\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \nDMAP (14 mg, 0.115 mmol) and Boc\n2\nO (252 mg, 1.44 mmol) was added to a stirred solution of \n39\n (180 mg, 1.15 mmol) in 2 mL CH\n2\nCl\n2\n under inert argon atmosphere at 0°C. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated and the crude product was purified by flash column chromatography (toluene/ethyl acetate gradient 15:1, 9:1, 6:1, 4:1, 2:1) which gave the title compound (124 mg, 51%) as white crystals.\n\n\n1\nH-NMR (300 MHz, CD\n3\nOD) δ 1.45 (s, 9H), 1.90 (d, \nJ\n = 11.0 Hz, 1H), 2.10-2.19 (m, 3H), 2.76-2.83 (m, 1H), 3.10 (s, 1H), 4.99 (s, 1H); \n13\nC-NMR (75.5 MHz, CD\n3\nOD) δ 27.1, 33.0, 37.7, 40.8, 46.1, 81.1, 81.6, 172.0, 177.7.\n\n\n \n \n \n \nAlternative method for the preparation of compound 40\n\n \n \n \n\n\n \n \n \n \nCompound \n39\n (13.9 g, 89 mmol) was dissolved in dichloromethane (200 ml) and then cooled to approximately -10°C under nitrogen. Isobutylene was then bubbled into the solution until the total volume had increased to approximately 250 mL which gave a turbid solution. BF\n3\n.Et\n2\nO (5.6 ml, 44.5 mmol, 0.5 eq.) was added and the reaction mixture was kept at approximately -10°C under nitrogen. After 10 min, a clear solution was obtained. The reaction was monitored by TLC (EtOAc-Toluene 3:2 acidified with a few drops of acetic acid and hexane-EtOAc 4:1, staining with basic permanganate solution). At 70 min only traces of compound \n39\n remained and aq. saturated NaHCO\n3\n (200 ml) was added to the reaction mixture, which was then stirred vigorously for 10 min. The organic layer was washed with saturated NaHCO\n3\n (3 x 200 ml) and brine (1 x 150 ml), then dried with sodium sulfite, filtered and the residue was evaporated to an oily residue. Upon addition of hexane to the residue, the product precipitated. Addition of more hexane and heating to reflux gave a clear solution from which the product crystallized. The crystals were collected by filtration and were washed with hexane (rt), then air-dried for 72 h giving colourless needles (12.45 g, 58.7 mmol, 66%).\n\n\n \n\n\nExample 22: Activity of compounds of formula (I)\n\n\n\n\nReplicon assay\n\n\n \n \n \nThe compounds of formula (I) were examined for activity in the inhibition of HCV RNA replication in a cellular assay. The assay demonstrated that the compounds of formula (I) exhibited activity against HCV replicons functional in a cell culture. The cellular assay was based on a bicistronic expression construct, as described by \nLohmann et al. (1999) Science vol. 285 pp. 110-113\n with modifications described by \nKrieger et al. (2001) Journal of Virology 75: 4614-4624\n, in a multi-target screening strategy. In essence, the method was as follows.\n\nThe assay utilized the stably transfected cell line Huh-7 luc/neo (hereafter referred to as Huh-Luc). This cell line harbors an RNA encoding a bicistronic expression construct comprising the wild type NS3-NS5B regions of HCV type 1b translated from an Internal Ribosome Entry Site (IRES) from encephalomyocarditis virus (EMCV), preceded by a reporter portion (FfL-luciferase), and a selectable marker portion (neo\nR\n, neomycine phosphotransferase). The construct is bordered by 5' and 3' NTRs (non-translated regions) from HCV type 1b. Continued culture of the replicon cells in the presence of G418 (neo\nR\n) is dependent on the replication of the HCV RNA. The stably transfected replicon cells that express HCV RNA, which replicates autonomously and to high levels, encoding \ninter alia\n luciferase, are used for screening the antiviral compounds.\n\n\n \n \n \n \nThe replicon cells were plated in 384 well plates in the presence of the test and control compounds which were added in various concentrations. Following an incubation of three days, HCV replication was measured by assaying luciferase activity (using standard luciferase assay substrates and reagents and a Perkin Elmer ViewLux\nTm\n ultraHTS microplate imager). Replicon cells in the control cultures have high luciferase expression in the absence of any inhibitor. The inhibitory activity of the compound on luciferase activity was monitored on the Huh-Luc cells, enabling a dose-response curve for each test compound. EC50 values were then calculated, which value represents the amount of the compound required to decrease by 50% the level of detected luciferase activity, or more specifically, the ability of the genetically linked HCV replicon RNA to replicate.\n\n\n \nInhibition assay\n\n\n \n \n \nThe aim of this \nin vitro\n assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay provides an indication of how effective compounds of the present invention would be in inhibiting HCV NS3/4A proteolytic activity.\n\n\n \n \n \n \nThe inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in \nPoliakov, 2002 Prot Expression & Purification 25 363 371\n. Briefly, the hydrolysis of a depsipeptide substrate, Ac-DED(Edans)EEAbuy[COO]ASK(Dabcyl)-NH\n2\n (AnaSpec, San José, USA), was measured spectrofluorometrically in the presence of a peptide cofactor, KKGSVVIVGRIVLSGK (Åke Engström, Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden). [\nLandro, 1997 #Biochem 36 9340-9348\n]. The enzyme (1 nM) was incubated in 50 mM HEPES, pH 7.5, 10 mM DTT, 40% glycerol, 0.1% n-octyl-D-glucoside, with 25 µM NS4A cofactor and inhibitor at 30 °C for 10 min, whereupon the reaction was initiated by addition of 0.5 µM substrate. Inhibitors were dissolved in DMSO, sonicated for 30 sec. and vortexed. The solutions were stored at - 20°C between measurements.\n\n\n \n \n \n \nThe final concentration of DMSO in the assay sample was adjusted to 3.3%. The rate of hydrolysis was corrected for inner filter effects according to published procedures. [\nLiu, 1999 Analytical Biochemistry 267 331-335\n]. Ki values were estimated by nonlinear regression analysis (GraFit, Erithacus Software, Staines, MX, UK), using a model for competitive inhibition and a fixed value for Km (0.15 µM). A minimum of two replicates was performed for all measurements.\n\n\n \n \n \n \nThe following Table 1 lists compounds that were prepared according to any one of the above examples. The activities of the compounds tested are also depicted in Table 1.\n\n \n \n\n\n \n \n \n \n \nCompound nr.\n \n \n \n \n \n \nn\n \nEC\n50\n(µM) Replicon assay\n \nKi (nM) Enzymatic assay\n \n \n \n \n1\n \n \n \n \n \n \n4\n \n0.809\n \n5.1\n \n \n \n2\n \n \n \n \n \n \n4\n \n3.369\n \n14.7\n \n \n \n3\n \n \n \n \n \n \n4\n \n>10\n \n62\n \n \n \n5\n \n \n \n \n \n \n4\n \n>10\n \n12\n \n \n \n6\n \n \n \n \n \n \n4\n \n>10\n \n24"
  },
  {
    "id": "WO2011001089A1",
    "text": "Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics AbstractThe present invention relates to novel benzenesulfonamide compounds having a structure of formula (I), as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary medicine, as well as to the use thereof in cosmetic compositions. Claims\n\n\n\n\n\n\n \nRevendications \n claims\n\n\n\n\n\n\n\n\n \n1. Composé de formule générale (I) suivante : \n1. Compound of general formula (I) below:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \ndans laquelle \nin which\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical - C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nR \n1\n is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl a radical - C (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;\n\n\n\n\n\n\n \n R\n3\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical cycloalkyle, un radical cycloalkyle substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical or a radical. heterocyclic, a substituted heterocyclic radical, a cycloalkyl radical, a substituted cycloalkyl radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2 ou 3 ; \nn can take the values of 0, 1, 2 or 3;\n\n\n\n\n\n\n \nainsi que les sels d'addition des composés de formule générale (I) avec un acide pharmaceutiquement acceptable, les sels d'addition des composés de formule générale (I) avec une base pharmaceutiquement acceptable et les énantiomères des composés de formule générale (I). \nas well as the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable acid, the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable base and the enantiomers of the compounds of general formula (I) .\n\n\n\n\n\n\n\n\n\n\n \n2. Sel d'addition avec un acide pharmaceutiquement acceptable d'un composé selon la revendication 1 caractérisé en ce que l'acide pharmaceutiquement acceptable est choisi dans la liste constituée par l'acide chlorhydrique, l'acide bromhydrique, l'acide sulfurique, l'acide nitrique, l'acide phosphorique, l'acide acétique, l'acide trifluoroacétique, l'acide trichloroacétique, l'acide propionique, l'acide glycolique, l'acide pyruvique, l'acide succinique, l'acide benzoïque, l'acide cinnamique, l'acide mandélique, l'acide methanesulfonique, l'acide para-toluène sulfonique, l'acide salicylique, l'acide picrique, l'acide citrique, l'acide oxalique, l'acide tartrique, l'acide malonique, l'acide maléique, l'acide camphorsulfonique et l'acide fumarique.  \n2. Pharmaceutically acceptable acid addition salt of a compound according to claim 1, characterized in that the pharmaceutically acceptable acid is chosen from the list consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, pyruvic acid, succinic acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, para-toluene sulfonic acid, salicylic acid, picric acid, citric acid, oxalic acid, tartaric acid, malonic acid, maleic acid, camphorsulfonic acid and fumaric acid. \n\n\n\n\n\n\n\n\n\n\n \n3. Sel d'addition avec une base pharmaceutiquement acceptable d'un composé selon la revendication\n3. Addition salt with a pharmaceutically acceptable base of a compound according to claim\n\n\n\n\n\n\n \n1 caractérisé en ce que la base pharmaceutiquement acceptable est choisie dans la liste constituée par l'hydroxyde de potassium, l'hydroxyde de sodium, l'hydroxyde de lithium, l'hydroxyde de calcium, la methylamine, l'ethylamine, l'éthanolamine, la propylamine, l'isopropylamine, les 4 isomères de la butylamine, la diméthylamine, diethylamine, la diethanolamine, la dipropylamine, la diisopropylamine, la di n-butylamine, la pyrrolidine, la piperidine, la morpholine, la diethanol phenylamine, la trimethylamine, la triethylamine, la tripropylamine, la quinuclidine, la pyridine, la quinoline, l'isoquinoline, la lysine, l'arginine et l'ornithine. \n1 characterized in that the pharmaceutically acceptable base is selected from the list consisting of potassium hydroxide, sodium hydroxide, lithium hydroxide, calcium hydroxide, methylamine, ethylamine, ethanolamine , propylamine, isopropylamine, the 4 isomers of butylamine, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, diethanol phenylamine, trimethylamine , triethylamine, tripropylamine, quinuclidine, pyridine, quinoline, isoquinoline, lysine, arginine and ornithine.\n\n\n\n\n\n\n\n\n\n\n \n4. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n4. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical -\nR \n1\n is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl , a radical -\n\n\n\n\n\n\n \nC(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nC (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \n R\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2; \nn can take the values of 0, 1, 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n5. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n5. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents a hydrogen, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aralkyl radical, a substituted aralkyl radical or a -C (O) - radical; R \n4\n , a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ;  n peut prendre les valeurs de 1 ou 2; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;  n can take the values of 1 or 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquennent acceptable, leurs sels d'addition avec une base pharmaceutiquennent acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n6. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n6. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ; \nR \n2\n is a hydrogen atom;\n\n\n\n\n\n\n \nR\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n7. Composé selon l'une des revendications 1 à 3 caractérisé en ce \n7. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \nR\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ; \nR \n2\n is a hydrogen atom;\n\n\n\n\n\n\n \n R\n3\n est un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is a heterocyclic radical, a substituted heterocyclic radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n8. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n8. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ; \nR \n2\n is a hydrogen atom;\n\n\n\n\n\n\n \n R\n3\n est un radical hétéroaryle, un radical hétéroaryle substitué, \nR \n3\n is a heteroaryl radical, a substituted heteroaryl radical,\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ;  ainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nn takes the value of 1;  as well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n9. Composé selon l'une des revendications 1 à 8 choisi dans la liste constituée par les composés suivants : \n9. Compound according to one of claims 1 to 8 selected from the list consisting of the following compounds:\n\n\n\n\n\n\n \n 1 ) 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 1) 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 2) (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n 2) (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n3) (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n3) (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 4) (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 4) (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 5) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide \n 5) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 6) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide \n 6) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 7) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide \n 7) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide\n\n\n\n\n\n\n \n8) (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n8) (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 9) (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 9) (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 10) 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1-carboxylate de benzyle \n 10) Benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] ethyl} piperazine-1-carboxylate\n\n\n\n\n\n\n \n 11 ) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)-benzène sulfonylamino]-propionamide \n 11) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzene-sulfonylamino] -propionamide\n\n\n\n\n\n\n \n 12) (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzène sulfonylamino]-propionamide \n 12) (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionamide\n\n\n\n\n\n\n \n13) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-pipérazin-1-yl- propionamide \n13) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide\n\n\n\n\n\n\n \n 14) Chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzène sulfonylamino]-propionamide \n 14) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionamide hydrochloride\n\n\n\n\n\n\n \n 15) Di trifluoro acétate de 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de terbutyle \n 15) 3- {4 - [(S) -2-Hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate di trifluoroacetate tert-butyl\n\n\n\n\n\n\n \n 16) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide \n 16) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 17) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide  18) (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n17) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide  18) (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionannide\n\n\n\n\n\n\n \n 19) (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 19) (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n20) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(4-trifluoronnéthyl- benzyl)-pipérazin-1-yl]-propionannide \n20) (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 21 ) (S)-N-hydroxy-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylamino]-propionannide \n 21) (S) -N-hydroxy-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionannide\n\n\n\n\n\n\n \n 22) (S)-3-[4-(benzo-isoxazol-3-ylnnéthoxy)-benzènesulfonylannino]-N-hydroxy-2-(4-nnéthanesulfonyl- pipérazin-1-yl)-propionannide \n 22) (S) -3- [4- (benzo-isoxazol-3-ylmethoxy) -benzenesulfonylannino] -N-hydroxy-2- (4-nnhanesulfonyl-piperazin-1-yl) -propionicid\n\n\n\n\n\n\n \n 23) (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 23) (S) -N-Hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 24) (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-l]-3-[4-(2-nnéthyl-quinolin-4- ylméthoxy)-benzènesulfonylannino]-propionannide \n 24) (S) -N-hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy)) -benzènesulfonylannino] -propionannide\n\n\n\n\n\n\n \n25) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluoronnéthyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylamino]-propionannide \n25) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino ] -propionannide\n\n\n\n\n\n\n \n 26) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionannide \n 26) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 27) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy -3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylannino]-propionannide \n 27) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylannino ] -propionannide\n\n\n\n\n\n\n \n 28) (S)-2-(4-acétyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 28) (S) -2- (4-Acetyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 29) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-{propyl-[4-(quinolin-4-ylnnéthoxy)- benzènesulfonyl]-annino}-propionannide \n 29) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- {propyl- [4- (quinolin-4-ylmethoxy) -benzenesulfonyl] -annino} -propionanide\n\n\n\n\n\n\n \n30) (S)-2-(4-benzènesulfonyl-pipérazin-1-yl)-N-hydroxy-3-[4-(pyrazolo[1 ,5-a]pyridin-3-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n30) (S) -2- (4-Benzenesulfonyl-piperazin-1-yl) -N-hydroxy-3- [4- (pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 31 ) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(1-nnéthyl-pipéridin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 31) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (1-methyl-piperidin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 32) (S)-2-[4-(4-fluoro-benzoyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(3-nn-tolyl-propoxy)- benzènesulfonylamino]-propionannide \n 32) (S) -2- [4- (4-Fluoro-benzoyl) -piperazin-1-yl] -N-hydroxy-3- [4- (3-nn-tolyl-propoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 33) (S)-N-hydroxy-3-[4-(2-méthyl-naphthalen-1-ylnnéthoxy)-benzènesulfonylannino]-2-(4-propionyl- pipérazin-1-yl)-propionannide \n 33) (S) -N-Hydroxy-3- [4- (2-methyl-naphthalen-1-ylmethoxy) -benzenesulfonylannino] -2- (4-propionyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 34) (S)-N-hydroxy-3-[4-(4-méthyl-pentyloxy)-benzènesulfonylannino]-2-(4-phénylacétyl-pipérazin-1-yl)- propionamide \n 34) (S) -N-hydroxy-3- [4- (4-methylpentyloxy) benzenesulfonylannino] -2- (4-phenylacetylpiperazin-1-yl) propionamide\n\n\n\n\n\n\n \n35) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-pyridin-4-ylnnéthoxy)- benzènesulfonylamino]-propionannide \n35) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 36) (S)-2-(3-acétyl-imidazolidin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 36) (S) -2- (3-Acetyl-imidazolidin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 37) (S)-3-[4-(3,5-diméthyl-benzyloxy)-benzènesulfonylannino]-N-hydroxy-2-innidazolidin-1-yl- propionamide  38) (S)-N-hydroxy-2-(4-nnéthanesulfonyl-[1 ,4]-diazepan-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylamino]-propionannide \n37) (S) -3- [4- (3,5-Dimethyl-benzyloxy) -benzenesulfonylannino] -N-hydroxy-2-innidazolidin-1-yl-propionamide  38) (S) -N-hydroxy-2- (4-nnhanesulfonyl- [1,4] diazepan-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] - propionannide\n\n\n\n\n\n\n \n 39) (S)-2-(4-benzyl-[1 ,4]-diazepan-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 39) (S) -2- (4-Benzyl- [1,4] diazepan-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] - propionannide\n\n\n\n\n\n\n \n40) (S)-2-[1 ,4]-diazocan-1-yl-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]- propionamide. \n40) (S) -2- [1,4] -diazocan-1-yl-N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionamide.\n\n\n\n\n\n\n \n 41 ) (S)-N-hydroxy-3-[4-(2-méthyl-benzofuran-3-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionannide et \n 41) (S) -N-hydroxy-3- [4- (2-methyl-benzofuran-3-ylmethoxy) -benzenesulfonylannino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionannide and\n\n\n\n\n\n\n \n 42) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-isopropyl-1 H-indol-3-ylméthoxy)- benzènesulfonylamino]-propionannide \n 42) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-isopropyl-1H-indol-3-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n\n\n\n\n \n10. Composé selon l'une des revendications 1 à 9 en tant que médicament. \n10. Compound according to one of claims 1 to 9 as a medicament.\n\n\n\n\n\n\n\n\n\n\n \n11. Composé selon l'une des revendications 1 à 9 pour le traitement de pathologies ou de désordres liés à une libération de TNFα. \n11. Compound according to one of claims 1 to 9 for the treatment of pathologies or disorders related to TNFα release.\n\n\n\n\n\n\n\n\n\n\n \n12. Composé selon l'une des revendications 1 à 9 en tant qu'inhibiteur de la production de TNFα. \n12. Compound according to one of claims 1 to 9 as an inhibitor of the production of TNFα.\n\n\n\n\n\n\n\n\n\n\n \n13. Composé selon l'une des revendications 1 à 9 en tant qu'inhibiteurs de l'enzyme TNFα-converting enzyme (TACE). \n13. Compound according to one of claims 1 to 9 as inhibitors of the enzyme TNFα-converting enzyme (TACE).\n\n\n\n\n\n\n\n\n\n\n \n14. Composé selon l'une des revendications 1 à 9 pour le traitement ou l'amélioration des désordres ou pathologies médiés par TACE. \n14. Compound according to one of claims 1 to 9 for the treatment or amelioration of disorders or pathologies mediated by TACE.\n\n\n\n\n\n\n\n\n\n\n \n15. Composé selon l'une des revendications 1 à 9 pour le traitement de maladies ou désordres impliquant une production de TNFα choisies parmi le choc septique, le choc hémodynamique, la malaria, les maladies intestinales inflammatoires (IBD) comme la maladie de Crohn et les colites ulcératives, les maladies osseuses inflammatoires, les infections mycobactériennes, la méningite, les maladies fibrotiques, les maladies cardiaques, l'attaque ischémique, le rejet de greffe, le cancer, l'athérosclérose, l'obésité, les maladies impliquant des phénomènes d'angiogénèse, les maladies auto-immunes, l'ostéoarthrite, l'arthrite rhumatoïde, la spondylarthrite ankylosante, l'arthrite chronique juvénile, la sclérose multiple, le HIV, le diabète melitus non insulino dépendant, les maladies allergiques, l'asthme, la maladie d'obstruction pulmonaire chronique (COPD) et l'inflammation occulaire.  \n15. Compound according to one of claims 1 to 9 for the treatment of diseases or disorders involving TNFα production selected from septic shock, hemodynamic shock, malaria, inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, inflammatory bone diseases, mycobacterial infections, meningitis, fibrotic diseases, heart disease, ischemic attack, transplant rejection, cancer, atherosclerosis, obesity, diseases involving phenomena angiogenesis, autoimmune diseases, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile chronic arthritis, multiple sclerosis, HIV, non-insulin-dependent diabetes mellitus, allergic diseases, asthma , chronic obstructive pulmonary disease (COPD) and eye inflammation. \n\n\n\n\n\n\n\n\n\n\n \n16. Composé selon l'une des revendications 1 à 9 pour le traitement des maladies inflammatoires de la peau, du psoriasis, de la dermatite atopique et du rhumatisme psoriasique. \n16. Compound according to one of claims 1 to 9 for the treatment of inflammatory diseases of the skin, psoriasis, atopic dermatitis and psoriatic arthritis.\n\n\n\n\n\n\n\n\n\n\n \n17. Composé selon l'une des revendications 1 à 9 pour le traitement des pathologies neurologiques à caractère inflammatoire impliquant une production de TNFα choisies parmi la maladie d'Alzheimer, la maladie de Parkinson, les désordres parkinsoniens, la sclérose amyotrophique latérale, les maladies autoimmunes du système nerveux, les maladies autonomiques du système nerveux, les douleurs dorsales, l'œdème cérébral, les désordres cérébrovasculaires, la démence, les maladies autoimmunes de démyelination des fibres nerveuses du système nerveux, les neuropathies diabétiques, l'encéphalite, l'encéphalomyélite, l'épilepsie, le syndrome chronique de fatigue, l'artérite des cellules géantes, le syndrome Guillain-Barre, les maux de tête, la sclérose multiple, la neuralgie, les maladies du système nerveux périphérique, les polyneuropathies, la polyradiculoneuropathie, la radiculopathie, les paralysies respiratoires, les maladies des cordes spinales, le syndrome de Tourette, la vasculite du système nerveux centreux, les maladies d'Huntington et l'attaque cérébrale ; \n17. Compound according to one of claims 1 to 9 for the treatment of inflammatory neurological pathologies involving a production of TNFα selected from Alzheimer's disease, Parkinson's disease, parkinsonian disorders, amyotrophic lateral sclerosis, diseases autoimmune nervous system, autonomic diseases of the nervous system, back pain, cerebral edema, cerebrovascular disorders, dementia, autoimmune diseases of demyelination of nerve fibers of the nervous system, diabetic neuropathies, encephalitis, encephalomyelitis, epilepsy, chronic fatigue syndrome, giant cell arteritis, Guillain-Barre syndrome, headache, multiple sclerosis, neuralgia, diseases of the peripheral nervous system, polyneuropathies, polyradiculoneuropathy, radiculopathy, respiratory paralysis, spinal cord diseases, Tourette, vasculitis of the central nervous system, Huntington's disease and stroke; Description\n\n\n\n\n\n\n \n Nouveaux composés benzène-sulfonamides, leur procédé de synthèse et leur utilisation en médecine ainsi qu'en cosmétique \n New benzenesulphonamide compounds, their synthesis process and their use in medicine and cosmetics\n\n\n\n\n\n\n \n DOMAINE TECHNIQUE \n TECHNICAL AREA\n\n\n\n\n\n\n \nLa présente invention se rapporte à de nouveaux composés benzène-sulfonamides répondant à la formule générale (I) suivante : \nThe present invention relates to novel benzenesulphonamide compounds having the following general formula (I):\n\n\n\n\n\n\n \n \n\n ainsi qu'à leur procédé de synthèse et à leur utilisation dans des compositions pharmaceutiques destinées à un usage en médecine humaine ou vétérinaire. \n \n and their method of synthesis and their use in pharmaceutical compositions for use in human or veterinary medicine.\n\n\n\n\n\n\n \n Les composés de la présente invention agissent comme inhibiteurs de l'enzyme de conversion du TNFα encore appelée TACE. Ils sont de ce fait utiles dans le traitement des maladies pour lesquelles diminuer la production de TNFα est d'un grand intérêt. \n The compounds of the present invention act as inhibitors of the TNFα-converting enzyme also called TACE. They are therefore useful in the treatment of diseases for which the reduction of TNFα production is of great interest.\n\n\n\n\n\n\n \n La présente invention se rapporte également à l'utilisation des composés répondant à la formule générale (I) dans des compositions cosmétiques. \n The present invention also relates to the use of the compounds corresponding to the general formula (I) in cosmetic compositions.\n\n\n\n\n\n\n \nETATANTÉRIEUR DE LA TECHNIQUE \nSTATUS OF THE TECHNIQUE\n\n\n\n\n\n\n \nLes adamalysines (« ADAM » ou A Disintegrin and Metalloproteinase) sont une sous famille des enzymes métalloendopeptidases à zinc. Leur ectodomaine comporte un domaine protéasique dont l'activation dépend du zinc, un domaine disintégrine et un domaine riche en cystéines. A ce jour, au moins 30 ADAMs différentes ont été identifiées dont la première caractérisée a été ADAM17 encore appelée TACE (TNFα converting enzyme) [Gueydan C et al. Med.Sci 1997, 13, 83-88 ; Black R.A et al. Nature 1997, 385 :729-733 ; Moss et al. Nature 1997, 385 :733-736]. L'ARNm de TACE est présent dans de nombreux tissus et plus particulièrement au niveau des monocytes, des macrophages, des lymphocytes T mais aussi au niveau des kératinocytes par exemple. \nAdamalysins (\"ADAM\" or A Disintegrin and Metalloproteinase) are a sub-family of zinc metalloendopeptidase enzymes. Their ectodomain has a protease domain whose activation depends on zinc, a disintegrin domain and a domain rich in cysteines. To date, at least 30 different ADAMs have been identified, the first of which was characterized by ADAM17, also called TACE (TNFα converting enzyme) [Gueydan C et al. Med.Sci 1997, 13, 83-88; Black R.A et al. Nature 1997, 385: 729-733; Moss et al. Nature 1997, 385: 733-736]. TACE mRNA is present in many tissues and more particularly at the level of monocytes, macrophages, T lymphocytes, but also at the level of keratinocytes, for example.\n\n\n\n\n\n\n \n TACE est responsable de la coupure du pro-TNFα, protéine membranaire de 26 kDa, pour conduire à la libération du TNFα soluble, protéine de 17kDa, biologiquement active [Schlondorff et al. Biochem J. 2000, 347, 131-138]. Le TNFα soluble libéré par la cellule est capable d'agir sur des sites très éloignés du site de synthèse. \n\n Le TNFα est impliqué dans un grand nombre de processus biologiques pro-inflammatoires [Aggarwal et al, Eur. Cytokine Netw., 1996, 7 : 93-124]. Plusieurs études pharma∞logiques et cliniques ont montré de façon évidente que bloquer les effets du TNFα avec des anticorps spécifiques ou des biologiques anti-TNFα (Etanercept, Adalimumab, Infliximab) était bénéfique dans le traitement de maladies autoimmunes comme l'arthrite rhumatoide [Feldman et al. Lancet, 1994, 344, 1 105), le diabète mélitus non insulino dépendant [Lohmander L. S et al. Arthritis Rheum, 1993, 36, 1214-1222], la maladie de Crohn's [MacDonald et al. Clin. Exp. Immunol. 1990, 81 , 301]. \nTACE is responsible for the cleavage of pro-TNFα, a 26 kDa membrane protein, to lead to the release of soluble TNFα, a 17kDa protein, that is biologically active [Schlondorff et al. Biochem J. 2000, 347, 131-138]. The soluble TNFα released by the cell is able to act on sites far removed from the synthesis site.  TNFα is involved in a large number of pro-inflammatory biological processes [Aggarwal et al, Eur. Cytokine Netw., 1996, 7: 93-124]. Several pharmacological and clinical studies have clearly shown that blocking the effects of TNFα with specific antibodies or anti-TNFα biologics (Etanercept, Adalimumab, Infliximab) was beneficial in the treatment of autoimmune diseases such as rheumatoid arthritis [Feldman et al. Lancet, 1994, 344, 105), non-insulin dependent diabetes mellitus [Lohmander L. S et al. Arthritis Rheum, 1993, 36, 1214-1222], Crohn's disease [MacDonald et al. Clin. Exp. Immunol. 1990, 81, 301].\n\n\n\n\n\n\n \n Le TNFα joue également un rôle fondamental au cours du phénomène inflammatoire déclenché dans les lésions de psoriasis. Les taux sériques de TNFα sont élevés chez les patients psoriasiques [Mussi A et al. J. Biol. Regul. Homeost Agents, 1997, 11 , 115-118] ; les taux de TNFα sont également élevés dans les plaques même de psoriasis [Bonifati C. et al. Clin. Exp. Dermatol., 1994, 19, 383-387]. Les cellules clés de la physiopathologie du psoriasis sont les kératinocytes, les cellules dendritiques et certains lymphocytes T. L'interaction entre ces familles de cellules conduit à une cascade inflammatoire menant aux lésions caractéristiques du psoriasis avec libération de TNFα [Kupper TS, N. Engl. J. Med, 2003, 349, 1987-1990]. Des études cliniques pour le traitement de psoriasis en plaques modéré à sévère par les anti-TNFα biologiques (Etanercept, Adalimumab, Infliximab) ont démontré leur efficacité à la fois sur les lésions psoriasiques et sur la qualité de vie des patients [Ortonne JP, Annales de dermatologie et de vénéreologie, 2005, 132 (8-9 pt2), 4S6-9 et 2005, 132, 9S01-9S70]. \n TNFα also plays a fundamental role during the inflammatory process triggered in psoriasis lesions. Serum TNFα levels are elevated in psoriatic patients [Mussi A et al. J. Biol. Regul. Homeost Agents, 1997, 11, 115-118]; TNFα levels are also high in the same psoriasis plaques [Bonifati C. et al. Clin. Exp. Dermatol., 1994, 19, 383-387]. The key cells in the pathophysiology of psoriasis are keratinocytes, dendritic cells and certain T lymphocytes. The interaction between these families of cells leads to an inflammatory cascade leading to the characteristic lesions of psoriasis with release of TNFα [Kupper TS, N. Engl . J. Med, 2003, 349, 1987-1990]. Clinical studies for the treatment of moderate to severe plaque psoriasis by anti-TNFα agents (Etanercept, Adalimumab, Infliximab) have been shown to be effective in both psoriatic lesions and patients' quality of life [Ortonne JP, Annales Dermatology and Venereology, 2005, 132 (8-9 pt2), 4S6-9 and 2005, 132, 9S01-9S70].\n\n\n\n\n\n\n \nAinsi, les composés qui inhibent la production de TNFα sont d'un grand intérêt pour le traitement des maladies inflammatoires et des maladies impliquant une libération de TNFα. \nThus, compounds that inhibit the production of TNFα are of great interest for the treatment of inflammatory diseases and diseases involving TNFα release.\n\n\n\n\n\n\n \nEXPOSE DE L'INVENTION \nSUMMARY OF THE INVENTION\n\n\n\n\n\n\n \nNotre invention décrit donc de nouvelles molécules qui inhibent l'enzyme TACE (TNFα converting enzyme) et de ce fait, inhibent la sécrétion de TNFα soluble (forme active du TNFα) par les cellules. Ces nouvelles molécules sont donc des principes actifs potentiels pour le traitement des pathologies faisant intervenir une diminution ou une inhibition de la production de TNFα. \nOur invention therefore describes new molecules that inhibit the enzyme TACE (TNFα converting enzyme) and thereby inhibit the secretion of soluble TNFα (active form of TNFα) by the cells. These new molecules are therefore potential active ingredients for the treatment of pathologies involving a decrease or inhibition of TNFα production.\n\n\n\n\n\n\n \nA titre d'illustration, et de façon non limitative, ces pathologies sont par exemple le choc septique, le choc hémodynamique, la malaria, les maladies intestinales inflammatoires (IBD) comme la maladie de Crohn et les colites ulcératives, les maladies osseuses inflammatoires, les infections mycobactériennes, la méningite, les maladies fibrotiques, les maladies cardiaques, l'attaque ischémique, le rejet de greffe, le cancer, l'athérosclérose, l'obésité, les maladies impliquant des phénomènes d'angiogénèse, les maladies auto-immunes, l'ostéoarthrite, l'arthrite rhumatoïde, la spondylarthrite ankylosante, l'arthrite chronique juvénile, la sclérose multiple, le HIV, le diabète melitus non insulino dépendant, les maladies allergiques, l'asthme, la maladie d'obstruction pulmonaire chronique (COPD), l'inflammation occulaire, les maladies inflammatoires de la peau, le psoriasis, la dermatite atopique et le rhumatisme psoriasique. \n\n Ces molécules sont également des principes actifs potentiels pour le traitement de pathologies neurologiques à caractère inflammatoire pour lesquelles diminuer la production de TNFα serait d'un grand intérêt. Ces pathologies listées ci-après de façon non limitative sont par exemple la maladie d'Alzheimer, la maladie de Parkinson, les désordres parkinsoniens, la sclérose amyotrophique latérale, les maladies autoimmunes du système nerveux, les maladies autonomiques du système nerveux, les douleurs dorsales, l'œdème cérébral, les désordres cérébrovasculaires, la démence, les maladies autoimmunes de démyelination des fibres nerveuses du système nerveux, les neuropathies diabétiques, l'encéphalite, l'encéphalomyélite, l'épilepsie, le syndrome chronique de fatigue, l'artérite des cellules géantes, le syndrome Guillain-Barre, les maux de tête, la sclérose multiple, la neuralgie, les maladies du système nerveux périphérique, les polyneuropathies, la polyradiculoneuropathie, la radiculopathie, les paralysies respiratoires, les maladies des cordes spinales, le syndrome de Tourette, la vasculite du système nerveux centreux, les maladies d'Huntington et l'attaque cérébrale ; \nBy way of illustration, and in a nonlimiting manner, these pathologies are, for example, septic shock, hemodynamic shock, malaria, inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, inflammatory bone diseases, mycobacterial infections, meningitis, fibrotic diseases, heart disease, ischemic attack, transplant rejection, cancer, atherosclerosis, obesity, diseases involving angiogenesis, autoimmune diseases , osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile chronic arthritis, multiple sclerosis, HIV, non-insulin-dependent diabetes mellitus, allergic diseases, asthma, chronic pulmonary obstruction disease ( COPD), eye inflammation, inflammatory skin diseases, psoriasis, atopic dermatitis and psoriatic arthritis.  These molecules are also potential active ingredients for the treatment of inflammatory neurological pathologies for which TNFα production would be of great interest. These pathologies listed hereafter without limitation are for example Alzheimer's disease, Parkinson's disease, parkinsonian disorders, amyotrophic lateral sclerosis, autoimmune diseases of the nervous system, autonomic diseases of the nervous system, back pain. , cerebral edema, cerebrovascular disorders, dementia, autoimmune diseases of demyelinating nerve fibers of the nervous system, diabetic neuropathies, encephalitis, encephalomyelitis, epilepsy, chronic fatigue syndrome, arteritis giant cells, Guillain-Barre syndrome, headaches, multiple sclerosis, neuralgia, diseases of the peripheral nervous system, polyneuropathies, polyradiculoneuropathy, radiculopathy, respiratory paralysis, spinal cord diseases, the syndrome of Tourette, vasculitis of the central nervous system, Huntington's disease and stroke ale;\n\n\n\n\n\n\n \nUne grande variété d'inhibiteurs de TACE est déjà connue comme indiqué ci-dessous. Toutefois, un grand nombre de ces inhibiteurs n'agit pas sélectivement sur l'enzyme TACE par rapport à d'autres enzymes de la famille des ADAMs et/ou de matrix métalloprotéinases (MMPs). \nA wide variety of TACE inhibitors is already known as indicated below. However, many of these inhibitors do not selectively act on the TACE enzyme over other enzymes in the family of ADAMs and / or matrix metalloproteinases (MMPs).\n\n\n\n\n\n\n \nOr, l'inhibition non sélective de ces familles d'enzymes induit des effets secondaires indésirables observés In Vivo. Par exemple, l'inhibition de MMP-1 (collagenase-1 ) a été associée aux problèmes de toxicité musculo-squelettique. \nHowever, the non-selective inhibition of these families of enzymes induces undesirable side effects observed in Vivo. For example, inhibition of MMP-1 (collagenase-1) has been associated with musculoskeletal toxicity problems.\n\n\n\n\n\n\n \n Comme inhibiteur non sélectif, on peut citer également l'Apratastat, inhibiteur connu et testé cliniquement en phase 2 pour le traitement de l'arthrite rhumatoïde (Curr Opin Investig Drugs. 2006 Nov;7(11 ), 1014-1019). Cet inhibiteur n'est pas sélectif de l'enzyme TACE par rapport à certaines MMPs (WO 00/44709 ; page 251 , table 10, exemple 61 ). \n As a non-selective inhibitor, there is also known Apratastat, a known inhibitor and clinically tested in phase 2 for the treatment of rheumatoid arthritis (Curr Opin Investig Drugs, Nov. 2006, 7 (11), 1014-1019). This inhibitor is not selective for the TACE enzyme with respect to certain MMPs (WO 00/44709, page 251, table 10, example 61).\n\n\n\n\n\n\n \nD'autres inhibiteurs de TACE également connus et faisant partie de la même famille que l'Apratastat, à savoir celle de dérivés benzène sulfonamides cycliques, ont été décrits dans WO 00/44709 et WO 97/18194. D'autres brevets (WO 96/00214, WO 97/22587) revendiquent des inhibiteurs de MMPs et/ou TACE pour lesquels la partie benzène sulfonamide est séparée de la fonction acide hydroxamique par un seul atome de carbone. Des publications décrivant ce type d'inhibiteurs de MMPs de façon plus large sont aussi celle de MacPherson et al. J. Med. Chem. 1997,40, 2525 et celle de Tamura et al. J. Med. Chem. 1998, 41 , 640. D'autres exemples d'inhibiteurs de MMPs/TACE pour lesquels la fonction sulfonamide est séparée de l'acide hydroxamique par un enchaînement de deux atomes de carbones formant un cycle sont décrits dans les brevets WO 98/16503, WO 98/16506, WO 98/16514 et WO 98/16520. D'autres exemples d'inhibiteurs de MMPs pour lesquels la fonction sulfonamide est séparée de l'acide hydroxamique par un enchaînement de deux atomes de carbones sont également décrits dans WO 2008/045671. \n\n Or, la demanderesse a maintenant découvert de manière inattendue et surprenante que de nouveaux composés de formule générale (I) présentent une très bonne activité inhibitrice de TACE et en particulier, inhibent l'enzyme TACE de façon sélective par rapport à d'autres ADAMs et MMPs. Ainsi, la présente invention concerne des composés de formule générale (I) suivante : \nOther TACE inhibitors also known and belonging to the same family as Apratastat, namely that of cyclic benzene sulfonamide derivatives, have been described in WO 00/44709 and WO 97/18194. Other patents (WO 96/00214, WO 97/22587) claim inhibitors of MMPs and / or TACE for which the benzene sulfonamide part is separated from the hydroxamic acid function by a single carbon atom. Publications describing this type of MMP inhibitors more broadly are also those of MacPherson et al. J. Med. Chem. 1997, 40, 2525 and that of Tamura et al. J. Med. Chem. 1998, 41, 640. Other examples of MMPs / TACE inhibitors for which the sulfonamide function is separated from the hydroxamic acid by a chain of two carbon atoms forming a ring are described in WO 98/16503, WO 98/16506, WO 98/16514 and WO 98/16520. Other examples of MMP inhibitors for which the sulfonamide function is separated from the hydroxamic acid by a two-carbon chain are also described in WO 2008/045671.  Now, the Applicant has now unexpectedly and surprisingly discovered that new compounds of general formula (I) exhibit a very good TACE inhibitory activity and in particular, selectively inhibit TACE enzyme compared to other ADAMs and MMPs. Thus, the present invention relates to compounds of general formula (I) below:\n\n\n\n\n\n\n \n \n\n dans laquelle : \n \n in which :\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical - C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nR \n1\n is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl a radical - C (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur. \nR \n2\n is a hydrogen atom or a lower alkyl radical.\n\n\n\n\n\n\n \n R\n3\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical cycloalkyle, un radical cycloalkyle substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical or a radical. heterocyclic, a substituted heterocyclic radical, a cycloalkyl radical, a substituted cycloalkyl radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2 ou 3 ; \nn can take the values of 0, 1, 2 or 3;\n\n\n\n\n\n\n \nainsi que les sels d'addition des composés de formule générale (I) avec un acide pharmaceutiquement acceptable, les sels d'addition des composés de formule générale (I) avec une base pharmaceutiquement acceptable et les énantiomères des composés de formule générale (I). \nas well as the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable acid, the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable base and the enantiomers of the compounds of general formula (I) .\n\n\n\n\n\n\n \nParmi les sels d'addition des composés de formule générale (I) avec un acide pharmaceutiquement acceptable, on peut citer de préférence les sels avec un acide organique ou avec un acide inorganique. \nAmong the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable acid, there may be mentioned preferably the salts with an organic acid or with an inorganic acid.\n\n\n\n\n\n\n \n Les acides inorganiques appropriés sont par exemple les acides halohydriques comme l'acide chlorhydrique, l'acide bromhydrique, l'acide sulfurique, l'acide nitrique et l'acide phosphorique. \n\n Les acides organiques appropriés sont par exemple l'acide acétique, l'acide trifluoroacétique, l'acide trichloroacétique, l'acide propionique, l'acide glycolique, l'acide pyruvique, l'acide succinique, l'acide benzoïque, l'acide cinnamique, l'acide mandélique, l'acide methanesulfonique, l'acide para-toluène sulfonique, l'acide salicylique, l'acide picrique, l'acide citrique, l'acide oxalique, l'acide tartrique, l'acide malonique, l'acide maléique, l'acide camphorsulfonique et l'acide fumarique. \nSuitable inorganic acids are, for example, hydrohalic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid.  Examples of suitable organic acids are acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, pyruvic acid, succinic acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, para-toluene sulfonic acid, salicylic acid, picric acid, citric acid, oxalic acid, tartaric acid, malonic acid, maleic acid, camphorsulfonic acid and fumaric acid.\n\n\n\n\n\n\n \nParmi les sels d'addition des composés de formule générale (I) avec une base pharmaceutiquement acceptable, on peut citer de préférence les sels avec une base organique ou avec une base inorganique. \nAmong the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable base, there may be mentioned preferably salts with an organic base or with an inorganic base.\n\n\n\n\n\n\n \nLes bases inorganiques sont par exemple l'hydroxyde de potassium, l'hydroxyde de sodium, l'hydroxyde de lithium ou l'hydroxyde de calcium. \nThe inorganic bases are, for example, potassium hydroxide, sodium hydroxide, lithium hydroxide or calcium hydroxide.\n\n\n\n\n\n\n \n Les bases organiques appropriés comprennent les aminés et les amino-acides. Parmi les aminés, on peut citer par exemple les aminés primaires, secondaires ou tertiaires aliphatiques ou aromatiques comme la methylamine, l'ethylamine, l'éthanolamine, la propylamine, l'isopropylamine, les 4 isomères de la butylamine, la diméthylamine, diethylamine, la diethanolamine, la dipropylamine, la diisopropylamine, la di n-butylamine, la pyrrolidine, la piperidine, la morpholine, la diethanol phenylamine, la trimethylamine, la triethylamine, la tripropylamine, la quinuclidine, la pyridine, la quinoline ou l'isoquinoline. \n Suitable organic bases include amines and amino acids. Among the amines, mention may be made, for example, of primary, secondary or tertiary aliphatic or aromatic amines, such as methylamine, ethylamine, ethanolamine, propylamine, isopropylamine, the 4 isomers of butylamine, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, diethanol phenylamine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline or isoquinoline.\n\n\n\n\n\n\n \n Parmi les amino-acides, on peut citer par exemple la lysine, l'arginine et l'ornithine. \n Amino acids include, for example, lysine, arginine and ornithine.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkyle inférieur une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comprenant de 1 à 4 atomes de carbone. \nAccording to the present invention, the term \"lower alkyl radical\" denotes a saturated hydrocarbon chain, linear or branched, comprising from 1 to 4 carbon atoms.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkyle une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comprenant de 1 à 10 atomes de carbone. \nAccording to the present invention, the alkyl radical denotes a saturated hydrocarbon chain, linear or branched, comprising from 1 to 10 carbon atoms.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkenyle une chaîne hydrocarbonée insaturée, linéaire ou ramifiée comprenant de 2 à 10 atomes de carbone et comprenant une ou plusieurs doubles liaisons. \nAccording to the present invention, the term \"alkenyl radical\" denotes an unsaturated, linear or branched hydrocarbon-based chain comprising from 2 to 10 carbon atoms and comprising one or more double bonds.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkynyle une chaîne hydrocarbonée insaturée, linéaire ou ramifiée comprenant de 2 à 10 atomes de carbone et comprenant une ou plusieurs triples liaisons. Selon la présente invention, on désigne par radical alkyle substitué une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comprenant de 1 à 10 atomes de carbone et substitué par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle, un radical hydroxyle. \nAccording to the present invention, alkynyl radical denotes a linear or branched unsaturated hydrocarbon chain comprising from 2 to 10 carbon atoms and comprising one or more triple bonds. According to the present invention, the term \"substituted alkyl radical\" denotes a linear or branched saturated hydrocarbon-based chain comprising from 1 to 10 carbon atoms and substituted by one or more radicals chosen from a halogen atom, an alkoxyl radical and a hydroxyl radical. .\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkenyle substitué une chaîne hydrocarbonée insaturée, linéaire ou ramifiée, comprenant de 2 à 10 atomes de carbone, comprenant une ou \n\n plusieurs doubles liaisons et substituée par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle et un radical hydroxyle. \nAccording to the present invention, the term \"substituted alkenyl radical\" denotes a linear or branched, unsaturated hydrocarbon-based chain comprising from 2 to 10 carbon atoms, comprising one or more  several double bonds and substituted by one or more radicals selected from a halogen atom, an alkoxyl radical and a hydroxyl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkynyle substitué une chaîne hydrocarbonée insaturée, linéaire ou ramifiée, comprenant de 2 à 10 atomes de carbone, comprenant une ou plusieurs triples liaisons et substituée par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle et un radical hydroxyle. \nAccording to the present invention, the term \"substituted alkynyl radical\" denotes a linear or branched, unsaturated hydrocarbon-based chain comprising from 2 to 10 carbon atoms, comprising one or more triple bonds and substituted by one or more radicals chosen from a halogen atom, an alkoxyl radical and a hydroxyl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par cycloalkyle une chaine hydrocarbonée, saturée, cyclique comprenant de 3 à 7 atomes de carbones. \nAccording to the present invention, cycloalkyl denotes a hydrocarbon chain, saturated, cyclic comprising from 3 to 7 carbon atoms.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par cycloalkyle substitué une chaine hydrocarbonée, saturée, cyclique comprenant de 3 à 7 atomes de carbones et substituée par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle et un radical hydroxyle. \nAccording to the present invention, the term \"substituted cycloalkyl\" denotes a hydrocarbon chain, saturated, cyclic comprising from 3 to 7 carbon atoms and substituted by one or more radicals chosen from a halogen atom, an alkoxyl radical and a hydroxyl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical aryle, un cycle hydrocarboné aromatique ou deux cycles fusionnés hydrocarbonés aromatiques. \nAccording to the present invention, the term aryl radical, an aromatic hydrocarbon ring or two aromatic hydrocarbon fused rings.\n\n\n\n\n\n\n \n Les radicaux aryles préférés sont choisis parmi les radicaux phenyle et naphtyle. Selon la présente invention, on désigne par radical aryle substitué, un cycle ou deux cycles fusionnés hydrocarboné(s) aromatique(s) substitué(s) par un ou plusieurs groupes d'atomes choisis parmi un alkyle, un alkoxyle, un aryle, un halogène, un hydroxyle, un cyano, un trifluorométhyle et un nitro. \n The preferred aryl radicals are chosen from phenyl and naphthyl radicals. According to the present invention, the term \"substituted aryl radical\" denotes a ring or two fused aromatic hydrocarbon rings substituted with one or more groups of atoms chosen from alkyl, alkoxyl, aryl, halogen, hydroxyl, cyano, trifluoromethyl and nitro.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical aralkyle, un alkyle substitué par un aryle. \nAccording to the present invention, the term \"aralkyl radical\" denotes an alkyl substituted with an aryl.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical aralkyle substitué, un alkyle substitué par un aryle substitué. \nAccording to the present invention, the term \"substituted aralkyl radical\" denotes an alkyl substituted by a substituted aryl.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétérocyclique une chaîne hydrocarbonée cyclique ou polycyclique, saturée ou insaturée, comprenant un ou plusieurs hétéroatomes choisis parmi O, S et N. \nAccording to the present invention, the term \"heterocyclic radical\" denotes a cyclic or polycyclic hydrocarbon chain, saturated or unsaturated, comprising one or more heteroatoms chosen from O, S and N.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétérocyclique substitué, un radical hétérocyclique substitué par un ou plusieurs groupes d'atomes choisis parmi un alkyle, un alkoxyle, un halogène, un hydroxyle, un cyano, un trifluorométhyle et un nitro. \nAccording to the present invention, the term \"substituted heterocyclic radical\" denotes a heterocyclic radical substituted with one or more groups of atoms chosen from alkyl, alkoxyl, halogen, hydroxyl, cyano, trifluoromethyl and nitro.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétéroaryle, un radical hétérocyclique aromatique c'est-à-dire une chaîne hydrocarbonée cyclique ou polycyclique, aromatique, comprenant un ou plusieurs hétéroatomes choisis parmi O, S et N. \n\n Selon la présente invention, on désigne par radical hétéroaryle substitué, un radical hétéroaryle substitué par un ou plusieurs groupes d'atomes choisis par exemple parmi un alkyle, un alkoxy, un aryle, un aryle substitué, un halogène, un hydroxy, un cyano, un trifluorométhyle et un nitro. Selon la présente invention, on désigne par radical hétéroaralkyle, un radical alkyle substitué par un radical hétéroaryle. \nAccording to the present invention, the term \"heteroaryl radical\" denotes an aromatic heterocyclic radical, that is to say an aromatic cyclic or polycyclic hydrocarbon chain, comprising one or more heteroatoms chosen from O, S and N.  According to the present invention, the term \"substituted heteroaryl radical\" denotes a heteroaryl radical substituted with one or more groups of atoms selected for example from alkyl, alkoxy, aryl, substituted aryl, halogen, hydroxy, cyano, trifluoromethyl and nitro. According to the present invention, heteroaralkyl radical denotes an alkyl radical substituted by a heteroaryl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétéroaralkyle substitué, un radical hétéroaralkyle substitué par un ou plusieurs groupes d'atomes choisis parmi un alkyle, un alkoxyle, un halogène, un hydroxyle, un cyano, un trifluorométhyle et un nitro. \nAccording to the present invention, the term \"substituted heteroaralkyl radical\" denotes a heteroaralkyl radical substituted with one or more groups of atoms chosen from an alkyl, an alkoxyl, a halogen, a hydroxyl, a cyano, a trifluoromethyl and a nitro.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkoxyle un atome d'oxygène substitué par un radical alkyle. Selon la présente invention, on désigne par atome d'halogène un atome de fluor, de chlore, de brome ou d'iode. \nAccording to the present invention, the term \"alkoxyl radical\" denotes an oxygen atom substituted by an alkyl radical. According to the present invention, the term \"halogen atom\" denotes a fluorine, chlorine, bromine or iodine atom.\n\n\n\n\n\n\n \nParmi les composés de formule générale (I) entrant dans le cadre de la présente invention, on peut notamment citer les composés suivants : \nAmong the compounds of general formula (I) within the scope of the present invention, there may be mentioned in particular the following compounds:\n\n\n\n\n\n\n \n1 ) 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n1) 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 2) (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n 2) (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 3) (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n 3) (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 4) (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 4) (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 5) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide \n 5) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n6) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide \n6) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 7) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide \n 7) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide\n\n\n\n\n\n\n \n 8) (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 8) (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 9) (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 9) (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 10) 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1-carboxylate de benzyle \n\n 11 ) (S)-N-hydroxy-2-(4-nnéthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n10) Benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] ethyl} piperazine-1-carboxylate  11) (S) -N-Hydroxy-2- (4-acethanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzene-sulfonylannino] -propionanide\n\n\n\n\n\n\n \n 12) (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylamino]-propionannide \n 12) (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionanide\n\n\n\n\n\n\n \n13) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-pipérazin-1-yl- propionamide \n13) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2-piperazin-1-yl-propionamide\n\n\n\n\n\n\n \n 14) Chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4- ylméthoxy)-benzène sulfonylannino]-propionannide \n 14) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionanide hydrochloride\n\n\n\n\n\n\n \n 15) Di trifluoro acétate de 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de terbutyle \n 15) 3- {4 - [(S) -2-Hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate di trifluoroacetate tert-butyl\n\n\n\n\n\n\n \n 16) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 16) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 17) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylamino]-propionamide \n 17) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n18) (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n18) (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionannide\n\n\n\n\n\n\n \n 19) (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 19) (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 20) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-trifluorométhyl- benzyl)-pipérazin-1-yl]-propionannide \n 20) (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 21 ) (S)-N-hydroxy-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n 21) (S) -N-hydroxy-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionannide\n\n\n\n\n\n\n \n 22) (S)-3-[4-(benzo-isoxazol-3-ylnnéthoxy)-benzènesulfonylannino]-N-hydroxy-2-(4-nnéthanesulfonyl- pipérazin-1-yl)-propionannide \n 22) (S) -3- [4- (benzo-isoxazol-3-ylmethoxy) -benzenesulfonylannino] -N-hydroxy-2- (4-nnhanesulfonyl-piperazin-1-yl) -propionicid\n\n\n\n\n\n\n \n23) (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n23) (S) -N-Hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 24) (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-l]-3-[4-(2-nnéthyl-quinolin-4- ylméthoxy)-benzènesulfonylannino]-propionannide \n 24) (S) -N-hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy)) -benzènesulfonylannino] -propionannide\n\n\n\n\n\n\n \n 25) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluoronnéthyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylannino]-propionannide \n 25) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylannino ] -propionannide\n\n\n\n\n\n\n \n 26) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionannide \n 26) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 27) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy -3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylamino]-propionamide \n 27) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino ] -propionamide\n\n\n\n\n\n\n \n28) (S)-2-(4-acétyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n28) (S) -2- (4-Acetyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 29) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-{propyl-[4-(quinolin-4-ylnnéthoxy)- benzènesulfonyl]-annino}-propionannide \n 29) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- {propyl- [4- (quinolin-4-ylmethoxy) -benzenesulfonyl] -annino} -propionanide\n\n\n\n\n\n\n \n 30) (S)-2-(4-benzènesulfonyl-pipérazin-1-yl)-N-hydroxy-3-[4-(pyrazolo[1 ,5-a]pyridin-3-ylnnéthoxy)- benzènesulfonylamino]-propionamide \n\n 31 ) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(1-méthyl-pipéridin-4-ylméthoxy)- benzènesulfonylamino]-propionannide \n30) (S) -2- (4-Benzenesulfonyl-piperazin-1-yl) -N-hydroxy-3- [4- (pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] -propionamide  31) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (1-methyl-piperidin-4-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 32) (S)-2-[4-(4-fluoro-benzoyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(3-m-tolyl-propoxy)- benzènesulfonylannino]-propionannide \n 32) (S) -2- [4- (4-Fluoro-benzoyl) -piperazin-1-yl] -N-hydroxy-3- [4- (3-m-tolyl-propoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n33) (S)-N-hydroxy-3-[4-(2-méthyl-naphthalen-1-ylnnéthoxy)-benzènesulfonylannino]-2-(4-propionyl- pipérazin-1-yl)-propionannide \n33) (S) -N-Hydroxy-3- [4- (2-methyl-naphthalen-1-ylmethoxy) -benzenesulfonylannino] -2- (4-propionyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 34) (S)-N-hydroxy-3-[4-(4-méthyl-pentyloxy)-benzènesulfonylannino]-2-(4-phénylacétyl-pipérazin-1-yl)- propionamide \n 34) (S) -N-hydroxy-3- [4- (4-methylpentyloxy) benzenesulfonylannino] -2- (4-phenylacetylpiperazin-1-yl) propionamide\n\n\n\n\n\n\n \n 35) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-pyridin-4-ylnnéthoxy)- benzènesulfonylamino]-propionannide \n 35) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 36) (S)-2-(3-acétyl-imidazolidin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylannino]-propionannide \n 36) (S) -2- (3-Acetyl-imidazolidin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 37) (S)-3-[4-(3,5-diméthyl-benzyloxy)-benzènesulfonylannino]-N-hydroxy-2-innidazolidin-1-yl- propionamide \n 37) (S) -3- [4- (3,5-Dimethyl-benzyloxy) -benzenesulfonylannino] -N-hydroxy-2-innidazolidin-1-yl-propionamide\n\n\n\n\n\n\n \n38) (S)-N-hydroxy-2-(4-méthanesulfonyl-[1 ,4]diazepan-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylannino]-propionannide \n38) (S) -N-Hydroxy-2- (4-methanesulfonyl- [1,4] diazepan-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 39) (S)-2-(4-benzyl-[1 ,4]diazepan-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 39) (S) -2- (4-Benzyl- [1,4] diazepan-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 40) (S)-2-[1 ,4]diazocan-1-yl-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]- propionamide. \n 40) (S) -2- [1,4] diazocan-1-yl-N-hydroxy-3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylannino] propionamide.\n\n\n\n\n\n\n \n 41 ) (S)-N-hydroxy-3-[4-(2-méthyl-benzofuran-3-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionamide \n 41) (S) -N-hydroxy-3- [4- (2-methyl-benzofuran-3-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionamide\n\n\n\n\n\n\n \n 42)(S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-isopropyl-1 H-indol-3-ylméthoxy)- benzènesulfonylamino]-propionamide \n 42) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-isopropyl-1H-indol-3-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \nLes composés de formule générale (I) sont préparés selon le schéma réactionnel de la figure 1 présenté ci-dessous. \n\n\nThe compounds of general formula (I) are prepared according to the reaction scheme of FIG. 1 presented below. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFigure 1 Selon la figure 1 , les composés (3) sont obtenus par réaction entre l'acide aminé (1) H-DAP(Boc)- OMe. HCI ou H-(D)-DAP(Boc)-OMe.HCI et le composé (2) (commercial ou préalablement préparé) en présence d'une base tertiaire organique comme la diisopropyléthylamine ou la triéthylamine à une température comprise entre 6O\n0\nC et 12O\n0\nC. Les composés (4) sont obtenus par déprotection de la fonction aminé des composés (3) selon des méthodes classiques comme par exemple l'utilisation d'une solution d'acide chlorhydrique dans l'isopropanol. \nFigure 1 According to Figure 1, the compounds (3) are obtained by reaction between the amino acid (1) H-DAP (Boc) - OMe. HCl or H- (D) -DAP (Boc) -OMe.HCl and the compound (2) (commercial or previously prepared) in the presence of an organic tertiary base such as diisopropylethylamine or triethylamine at a temperature between 60 \n°\n C. and 12O \n0\n C. The compounds (4) are obtained by deprotection of the amine function of the compounds (3) according to conventional methods such as for example the use of a solution of hydrochloric acid in isopropanol.\n\n\n\n\n\n\n \n Une réaction entre le composé (4) et le chlorure de 4-hydroxy-benzène sulfonyle O-protégé par un groupement benzyle par exemple (P = CH2-Ph) (5) en présence d'une base tertiaire comme par exemple la triéthylamine dans du dichlorométhane conduit au composé (6). Une N-alkylation de la fonction sulfonamide peut alors être réalisée par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de potassium dans un solvant tel que du DMF pour conduire au dérivé (7). Le composé (8) est obtenu par déprotection selon les méthodes connues par l'homme de l'art pour déprotéger une fonction phénol. Le composé (9) est obtenu par alkylation de la fonction phénol du composé (8) par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de césium dans de l'acétone ou par réaction de Mitsunobu avec un \n\n dérivé alcool primaire en présence de triphénylphosphine et de diisopropyl azodicarboxylate par exemple. Par réaction de saponification en présence d'une base comme l'hydroxyde de lithium en présence d'eau et de tétrahydrofuranne par exemple, le composé (10) est obtenu. Dans une dernière étape, le composé (11) est obtenu par couplage entre la O-(tert-butyldimethylsilyl)hydroxylamine par exemple et le dérivé (10) dans des conditions de couplage peptidique classiques, en utilisant par exemple comme agents de couplage le chlorhydrate de 1-(3-diméthylaminopropyl)-3- éthylcarbodiimide, l'hydroxybenzotriazole ou le TBTU, et comme base la triéthylamine ou la diisopropyléthylamine dans un solvant tel que le dichlorométhane ou le diméthylformamide. La déprotection de l'acide hydroxamique silylé intermédiairement formé se fait in situ ou par lavage avec une solution aqueuse légèrement acide pour conduire au composé (11). \nA reaction between the compound (4) and 4-hydroxy-benzenesulphonyl chloride O-protected with a benzyl group for example (P = CH 2 -Ph) (5) in the presence of a tertiary base such as for example triethylamine in dichloromethane leads to the compound (6). N-alkylation of the sulfonamide function can then be carried out by reaction with an alkyl halide in the presence of a base such as, for example, potassium carbonate in a solvent such as DMF to yield the derivative (7). The compound (8) is obtained by deprotection according to the methods known to those skilled in the art for deprotecting a phenol function. The compound (9) is obtained by alkylation of the phenol function of the compound (8) by reaction with an alkyl halide in the presence of a base such as, for example, cesium carbonate in acetone or by reaction of Mitsunobu with a  primary alcohol derivative in the presence of triphenylphosphine and diisopropyl azodicarboxylate for example. By saponification reaction in the presence of a base such as lithium hydroxide in the presence of water and tetrahydrofuran, for example, the compound (10) is obtained. In a final step, the compound (11) is obtained by coupling between O- (tert-butyldimethylsilyl) hydroxylamine for example and the derivative (10) under conventional peptide coupling conditions, using for example as coupling agents the hydrochloride. 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, hydroxybenzotriazole or TBTU, and as base triethylamine or diisopropylethylamine in a solvent such as dichloromethane or dimethylformamide. Deprotection of the silylated hydroxamic acid intermediate formed is carried out in situ or by washing with a slightly acidic aqueous solution to yield the compound (11).\n\n\n\n\n\n\n \nUne autre alternative pour l'obtention du composé (11) est présentée dans la figure 2 ci-dessous. \nAnother alternative for obtaining the compound (11) is shown in Figure 2 below.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Figure 2 \n Figure 2\n\n\n\n\n\n\n \nSelon le schéma de synthèse de la figure 2, le dérivé (3) peut éventuellement être alkylé en présence d'une base telle que l'hydrure de sodium et d'un halogénure d'alkyle dans du diméthylformamide par exemple pour conduire au composé (12) à partir duquel le composé (13) est obtenu selon les méthodes classiques de déprotection des aminés comme par exemple l'utilisation d'une solution d'acide chlorhydrique dans l'isopropanol. \nAccording to the synthesis scheme of FIG. 2, the derivative (3) may optionally be alkylated in the presence of a base such as sodium hydride and an alkyl halide in dimethylformamide, for example to give the compound ( 12) from which the compound (13) is obtained according to the standard amine deprotection methods such as, for example, the use of a solution of hydrochloric acid in isopropanol.\n\n\n\n\n\n\n \n Le composé (14) est préalablement préparé à partir du sel de sodium de l'acide 4-hydroxy benzènesulfonique commercial par alkylation avec un halogénure d'alkyle en présence d'une base telle que l'hydroxyde de sodium par exemple dans un mélange de solvants comme l'isopropanol et l'eau par exemple. Le composé (15) est alors obtenu par réaction du dérivé (14) avec du chlorure d'oxalyle en présence de diméthylformamide dans du dichlorométhane par exemple. \n The compound (14) is prepared beforehand from the sodium salt of commercial 4-hydroxy benzenesulfonic acid by alkylation with an alkyl halide in the presence of a base such as sodium hydroxide for example in a mixture of solvents such as isopropanol and water for example. The compound (15) is then obtained by reaction of the derivative (14) with oxalyl chloride in the presence of dimethylformamide in dichloromethane for example.\n\n\n\n\n\n\n \nLe dérivé (9) est obtenu par réaction entre les composés (13) et (15) en présence d'une base comme la triéthylamine dans du dichlorométhane par exemple, \n\n Une voie de synthèse alternative pour l'obtention du composé (11) est également présentée dans la figure 3 ci-dessous. \nThe derivative (9) is obtained by reaction between the compounds (13) and (15) in the presence of a base such as triethylamine in dichloromethane, for example,  An alternative synthetic route for obtaining the compound (11) is also presented in Figure 3 below.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFigure 3 Selon la figure 3, le composé (17) est obtenu par réaction entre l'acide aminé (1) H-DAP(Boc)- OMe. HCI ou H-(D)-DAP(Boc)-OMe.HCI et le composé (16) (préalablement préparé par réaction de la bis (2-chloroéthyl)amine par exemple et du bromure de benzyle en présence de carbonate de potassium dans l'acétonitrile) en présence d'une base tertiaire organique comme la diisopropyléthylamine à une température de 12O\n0\nC environ. Après déprotection de la fonction aminé, le composé (18) est condensé avec le chlorure de sulfonyle (15) pour conduire au dérivé (19). Une N- alkylation de la fonction sulfonamide peut alors être réalisée par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de potassium dans un solvant tel que du DMF pour conduire au dérivé (20). Selon les conditions classiques d'hydrogénation du composé (20) en présence de palladium sur charbon dans un solvant tel que l'éthanol par exemple, le composé (21) est obtenu. Le composé (9) est obtenu selon les méthodes classiques de synthèse par exemple par réaction du composé (21) avec un chlorure d'acyle, ou un chlorure de sulfonyle en présence de triéthylamine, ou par réaction avec un halogénure d'alkyle en présence d'une base comme l'hydrure \n\n de sodium par exemple. Par réaction de saponification en présence d'une base comme l'hydroxyde de lithium en présence d'eau et de tétrahydrofuranne par exemple, le composé (10) est obtenu. Dans une dernière étape, le composé (11) est obtenu par couplage entre la O-(tert- butyldimethylsilyl)hydroxylamine par exemple et le dérivé (10) dans des conditions de couplage peptidique classiques, en utilisant par exemple comme agents de couplage le chlorhydrate de 1-(3- diméthylaminopropyl)-3-éthylcarbodiimide, l'hydroxybenzotriazole ou le TBTU, et comme base la triéthylamine ou la diisopropyléthylamine dans un solvant tel que le dichlorométhane ou le diméthylformamide. La déprotection de l'acide hydroxamique silylé intermédiairement formé se fait in situ ou par lavage avec une solution aqueuse acide pour conduire au composé (11). \nFigure 3 According to Figure 3, the compound (17) is obtained by reaction between the amino acid (1) H-DAP (Boc) - OMe. HCI or H- (D) -DAP (Boc) -OMe.HCl and the compound (16) (previously prepared by reaction of bis (2-chloroethyl) amine for example and benzyl bromide in the presence of potassium carbonate in acetonitrile) in the presence of an organic tertiary base such as diisopropylethylamine at a temperature of approximately 120 \n°\n C. After deprotection of the amine function, the compound (18) is condensed with the sulfonyl chloride (15) to yield the derivative (19). N-alkylation of the sulfonamide function can then be accomplished by reaction with an alkyl halide in the presence of a base such as, for example, potassium carbonate in a solvent such as DMF to yield the derivative (20). According to the conventional conditions of hydrogenation of the compound (20) in the presence of palladium on carbon in a solvent such as ethanol for example, the compound (21) is obtained. The compound (9) is obtained according to the conventional methods of synthesis, for example by reaction of the compound (21) with an acyl chloride, or a sulfonyl chloride in the presence of triethylamine, or by reaction with an alkyl halide in the presence a base like hydride  sodium for example. By saponification reaction in the presence of a base such as lithium hydroxide in the presence of water and tetrahydrofuran, for example, the compound (10) is obtained. In a last step, the compound (11) is obtained by coupling between O- (tert-butyldimethylsilyl) hydroxylamine for example and the derivative (10) under conventional peptide coupling conditions, using for example as coupling agents the hydrochloride. 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, hydroxybenzotriazole or TBTU, and as base triethylamine or diisopropylethylamine in a solvent such as dichloromethane or dimethylformamide. The deprotection of the silylated hydroxamic acid intermediate formed is carried out in situ or by washing with an acidic aqueous solution to yield the compound (11).\n\n\n\n\n\n\n \nUne voie de synthèse alternative pour les composés avec R1 représentant un radical -(CO)-R\n4\n est décrite dans la figure 4. \nAn alternative synthetic route for compounds with R 1 representing a radical - (CO) -R \n4\n is described in Figure 4.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFigure 4 \nFigure 4\n\n\n\n\n\n\n \nAprès déprotection de la fonction aminé du composé (17) suivant des conditions classiques d'hydrogénation en présence de palladium sur charbon dans un solvant tel que l'éthanol par exemple, le composé (22) est obtenu. Par réaction avec un chlorure d'acyle, R\n4\nCOCI en présence d'une base telle que la triéthylamine, le composé (23) est obtenu. Lorsque R\n2\n représente un radical alkyle inférieur, une N-alkylation du carbamate est alors réalisée par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de potassium dans un solvant tel que du \n\n DMF pour conduire au dérivé (24). Par réaction de saponification en présence d'une base comme l'hydroxyde de lithium en présence d'eau et de tétrahydrofuranne par exemple, le composé (25) est préparé. Un couplage entre le chlorhydrate de O-allylhydroxylamine par exemple et le dérivé (25) permet d'obtenir le composé (26) dans des conditions de couplage peptidique classiques. Pour cela, on utilise par exemple le chlorhydrate de 1-(3-diméthylaminopropyl)-3-éthylcarbodiimide, l'hydroxybenzotriazole ou le TBTU comme agents de couplage, et la triéthylamine ou la diisopropyléthylamine comme base. La réaction s'effectue dans un solvant tel que le dichlorométhane ou le diméthylformamide. Après déprotection de la fonction aminé du composé (26) selon des méthodes classiques, le composé (27) est obtenu. Il est condensé avec le chlorure de sulfonyle (15) pour conduire au composé (28). Dans une dernière étape, le composé (29) est obtenu par déprotection de la fonction hydroxylamine du composé (28) selon des méthodes classiques comme par exemple le traitement par du tétrakis(triphénylphosphine)palladium (0) et du carbonate de potassium dans du méthanol. \nAfter deprotection of the amine function of the compound (17) according to conventional conditions of hydrogenation in the presence of palladium on carbon in a solvent such as ethanol for example, the compound (22) is obtained. By reaction with an acyl chloride, R \n4\n COCI in the presence of a base such as triethylamine, the compound (23) is obtained. When R \n2\n represents a lower alkyl radical, an N-alkylation of the carbamate is then carried out by reaction with an alkyl halide in the presence of a base such as, for example, potassium carbonate in a solvent such as  DMF to lead to the derivative (24). By saponification reaction in the presence of a base such as lithium hydroxide in the presence of water and tetrahydrofuran, for example, the compound (25) is prepared. A coupling between O-allylhydroxylamine hydrochloride for example and the derivative (25) makes it possible to obtain the compound (26) under conventional peptide coupling conditions. For this purpose, for example, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole or TBTU are used as coupling agents, and triethylamine or diisopropylethylamine as the base. The reaction is carried out in a solvent such as dichloromethane or dimethylformamide. After deprotection of the amine function of the compound (26) according to conventional methods, the compound (27) is obtained. It is condensed with sulfonyl chloride (15) to yield compound (28). In a final step, the compound (29) is obtained by deprotection of the hydroxylamine function of the compound (28) according to standard methods, for example treatment with tetrakis (triphenylphosphine) palladium (0) and potassium carbonate in methanol. .\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) préférés sont ceux pour lesquels : R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical - C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nAccording to the present invention, the preferred compounds of general formula (I) are those for which: R \n1\n represents a hydrogen, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical or an alkynyl radical; substituted, an aralkyl radical, a substituted aralkyl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical, a radical - C (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur. \nR \n2\n is a hydrogen atom or a lower alkyl radical.\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2; \nn can take the values of 0, 1, 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) particulièrement préférés sont ceux pour lesquels : \nAccording to the present invention, the compounds of general formula (I) that are particularly preferred are those for which:\n\n\n\n\n\n\n \nR\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents a hydrogen, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aralkyl radical, a substituted aralkyl radical or a -C (O) - radical; R \n4\n , a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \n\n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;  R \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 1 ou 2; \nn can take the values of 1 or 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquennent acceptable, leurs sels d'addition avec une base pharmaceutiquennent acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) plus particulièrement préférés sont ceux pour lesquels : \nAccording to the present invention, the compounds of general formula (I) that are more particularly preferred are those for which:\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène, \nR \n2\n is a hydrogen atom,\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) encore plus particulièrement préférés sont ceux pour lesquels : \nAccording to the present invention, the compounds of general formula (I) still more particularly preferred are those for which:\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène, \nR \n2\n is a hydrogen atom,\n\n\n\n\n\n\n \n R\n3\n est un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is a heterocyclic radical, a substituted heterocyclic radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \n\n Selon la présente invention, les composés de formule générale (I) les plus particulièrement préférés sont ceux pour lesquels : \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.  According to the present invention, the compounds of general formula (I) most particularly preferred are those for which:\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène, \nR \n2\n is a hydrogen atom,\n\n\n\n\n\n\n \n R\n3\n est un radical hétéroaryle, un radical hétéroaryle substitué, \nR \n3\n is a heteroaryl radical, a substituted heteroaryl radical,\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nLes composés selon l'invention présentent une très bonne activité inhibitrice de TACE et en particulier, ils inhibent l'enzyme TACE de façon sélective par rapport à d'autres ADAMs et MMPs. Cette activité inhibitrice de l'enzyme TACE est mesurée dans un test enzymatique et quantifiée par la mesure d'une IC\n50\n (concentration d'inhibiteur nécessaire pour obtenir 50% d'inhibition de l'enzyme TACE), comme décrit dans l'exemple 28. Les composés de la présente invention présentent une IC\n50\n pour TACE inférieure ou égale à 10μM et plus particulièrement inférieure ou égale à 1μM. De façon avantageuse, les composés de la présente invention présentent une IC\n50\n pour TACE inférieure ou égale à 0,5μM. \nThe compounds according to the invention have a very good TACE inhibitory activity and in particular, they inhibit the TACE enzyme selectively compared with other ADAMs and MMPs. This inhibitory activity of the enzyme TACE is measured in an enzymatic test and quantified by the measurement of an IC \n50\n (concentration of inhibitor necessary to obtain 50% inhibition of the TACE enzyme), as described in the example 28. The compounds of the present invention have an IC \n50\n for TACE of less than or equal to 10 μM and more particularly less than or equal to 1 μM. Advantageously, the compounds of the present invention have an IC \n50\n for TACE of less than or equal to 0.5 μM.\n\n\n\n\n\n\n \n De façon avantageuse, ces composés sont également très sélectifs de TACE par rapport aux autres ADAMs et MMPs (test décrit dans l'exemple 29): leur activité inhibitrice est au moins 10 fois plus importante pour TACE que pour d'autres ADAMs et MMPs (c'est-à-dire que la valeur de l'IC\n50\n pour TACE est au moins 10 fois plus petite que celle pour d'autres ADAMs et MMPs), et plus avantageusement au moins 100 fois plus importante. \nAdvantageously, these compounds are also very selective for TACE compared to other ADAMs and MMPs (test described in Example 29): their inhibitory activity is at least 10-fold greater for TACE than for other ADAMs and MMPs ( i.e., the IC \n50 value\n for TACE is at least 10 times smaller than that for other ADAMs and MMPs), and more preferably at least 100 times greater.\n\n\n\n\n\n\n \nTACE (TNFα-Converting Enzyme) catalyse la formation du TNF-alpha soluble à partir de la protéine précurseur (TNFα transmembranaire) liée aux membranes de certaines cellules. Le TNFαest une cytokine pro-inflammatoire qui est connue pour jouer un rôle dans de nombreuses pathologies à caractère inflammatoire. \nTACE (TNFα-Converting Enzyme) catalyzes the formation of soluble TNF-alpha from the precursor protein (transmembrane TNFα) bound to the membranes of certain cells. TNFα is a pro-inflammatory cytokine that is known to play a role in many inflammatory diseases.\n\n\n\n\n\n\n \n L'invention vise donc l'utilisation d'au moins un composé de formule générale (I) tel que défini ci- dessus pour le traitement de pathologies ou de désordres liés à une libération de TNFα. Un inhibiteur de l'enzyme TACE de formule générale (I) diminue la production de TNFα. De ce fait, il est utile pour le traitement de pathologies liées à une libération de TNFα. \n The invention therefore relates to the use of at least one compound of general formula (I) as defined above for the treatment of pathologies or disorders related to TNFα release. An inhibitor of the enzyme TACE of general formula (I) decreases the production of TNFα. Therefore, it is useful for the treatment of pathologies related to TNFα release.\n\n\n\n\n\n\n \nL'invention vise aussi l'utilisation d'au moins un composé de formule générale (I) tel que défini ci- dessus pour la préparation d'une composition pharmaceutique ou cosmétique dans laquelle ledit composé a une activité inhibitrice de l'enzyme TACE. \nThe invention also relates to the use of at least one compound of general formula (I) as defined above for the preparation of a pharmaceutical or cosmetic composition in which said compound has an inhibitory activity of the enzyme TACE.\n\n\n\n\n\n\n \n Elle vise donc l'utilisation d'au moins un composé de formule générale (I) tel que défini ci-dessus pour le traitement de pathologies ou de désordres qui sont améliorés par l'inhibition de l'enzyme TACE. \n\n L'invention concerne également une méthode de traitement thérapeutique (humain ou animal) ou cosmétique, consistant en l'administration ou l'application d'une composition pharmaceutique ou cosmétique comprenant Je44t un composé de formule générale (I) en tant qu'inhibiteur de TACE et de ce fait en tant qu'inhibiteur de la production de TNFα soluble. \nIt therefore aims at the use of at least one compound of general formula (I) as defined above for the treatment of pathologies or disorders which are improved by the inhibition of the enzyme TACE.  The invention also relates to a method of therapeutic treatment (human or animal) or cosmetic, consisting of the administration or the application of a pharmaceutical or cosmetic composition comprising a compound of general formula (I) as inhibitor of TACE and thereby as an inhibitor of the production of soluble TNFα.\n\n\n\n\n\n\n \nAinsi, l'invention concerne l'utilisation d'au moins un composé de formule générale (I) tel que défini ci- dessus pour le traitement de pathologies ou de désordres liés à une production de TNFα. \nThus, the invention relates to the use of at least one compound of general formula (I) as defined above for the treatment of pathologies or disorders related to TNFα production.\n\n\n\n\n\n\n \nL'invention concerne également l'utilisation d'un composé de formule générale (I) tel que défini ci- dessus pour la préparation d'un médicament destiné au traitement de pathologies pour lesquelles diminuer la production de TNFα serait d'un grand intérêt. \nThe invention also relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of pathologies for which the reduction of TNFα production would be of great interest.\n\n\n\n\n\n\n \n En effet, les composés utilisés selon l'invention sont particulièrement appropriés au traitement et à la prévention des désordres / maladies tels que les maladies inflammatoires listées ci-après mais non limitatives comme le choc septique, le choc hémodynamique, la malaria, les maladies intestinales inflammatoires (IBD) comme la maladie de Crohn et les colites ulcératives, les maladies osseuses inflammatoires, les infections mycobactériennes, la méningite, les maladies fibrotiques, les maladies cardiaques, l'athérosclérose, l'obésité, l'attaque ischémique, le rejet de greffe, le cancer, les maladies impliquant des phénomènes d'angiogénèse, les maladies auto-immunes, l'ostéoarthrite, l'arthrite rhumatoïde, la spondylarthrite ankylosante, l'arthrite chronique juvénile, la sclérose multiple, le HIV, le diabète melitus non insulino dépendant, les maladies allergiques, l'asthme, la maladie d'obstruction pulmonaire chronique (COPD), les maladies inflammatoires de la peau, le psoriasis, la dermatite atopique et le rhumatisme psoriasique. \n Indeed, the compounds used according to the invention are particularly suitable for the treatment and prevention of disorders / diseases such as the inflammatory diseases listed below but not limiting such as septic shock, hemodynamic shock, malaria, intestinal diseases Inflammatory diseases (IBD) such as Crohn's disease and ulcerative colitis, inflammatory bone diseases, mycobacterial infections, meningitis, fibrotic diseases, heart disease, atherosclerosis, obesity, ischemic attack, rejection of transplantation, cancer, diseases involving angiogenesis phenomena, autoimmune diseases, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile chronic arthritis, multiple sclerosis, HIV, diabetes melitus non dependent insulin, allergic diseases, asthma, chronic pulmonary obstruction disease (COPD), inflammatory diseases of skin, psoriasis, atopic dermatitis and psoriatic arthritis.\n\n\n\n\n\n\n \n Ces molécules sont également des principes actifs potentiels pour le traitement de pathologies neurologiques à caractère inflammatoire pour lesquelles diminuer la production de TNFα serait d'un grand intérêt. Ces pathologies listées ci-après de façon non limitative sont par exemple la maladie d'Alzheimer, la maladie de Parkinson, les désordres parkinsoniens, la sclérose amyotrophique latérale, les maladies autoimmunes du système nerveux, les maladies autonomiques du système nerveux, les douleurs dorsales, l'œdème cérébral, les désordres cérébrovasculaires, la démence, les maladies autoimmunes de démyelination des fibres nerveuses du système nerveux, les neuropathies diabétiques, l'encéphalite, l'encéphalomyélite, l'épilepsie, le syndrome chronique de fatigue, l'artérite des cellules géantes, le syndrome Guillain-Barre, les maux de tête, la sclérose multiple, la neuralgie, les maladies du système nerveux périphérique, les polyneuropathies, la polyradiculoneuropathie, la radiculopathie, les paralysies respiratoires, les maladies des cordes spinales, le syndrome de Tourette, la vasculite du système nerveux centreux, les maladies d'Huntington et l'attaque cérébrale ; \n These molecules are also potential active ingredients for the treatment of inflammatory neurological pathologies for which TNFα production would be of great interest. These pathologies listed hereafter without limitation are for example Alzheimer's disease, Parkinson's disease, parkinsonian disorders, amyotrophic lateral sclerosis, autoimmune diseases of the nervous system, autonomic diseases of the nervous system, back pain. , cerebral edema, cerebrovascular disorders, dementia, autoimmune diseases of demyelinating nerve fibers of the nervous system, diabetic neuropathies, encephalitis, encephalomyelitis, epilepsy, chronic fatigue syndrome, arteritis giant cells, Guillain-Barre syndrome, headaches, multiple sclerosis, neuralgia, diseases of the peripheral nervous system, polyneuropathies, polyradiculoneuropathy, radiculopathy, respiratory paralysis, spinal cord diseases, the syndrome of Tourette, vasculitis of the central nervous system, Huntington's disease and stroke ale;\n\n\n\n\n\n\n \nL'invention concerne l'utilisation d'un composé de formule générale (I) tel que défini ci-dessus pour la préparation d'un médicament destiné au traitement de pathologies à caractère inflammatoire dans lesquelles le TNFα est impliqué. \n\n L'invention concerne l'utilisation d'un composé de formule générale (I) tel que défini ci-dessus pour la préparation d'un médicament destiné au traitement de maladies inflammatoires de la peau, du psoriasis, de la dermatite atopique ou du rhumatisme psoriasique ; La présente invention a aussi pour objet une composition pharmaceutique destinée notamment au traitement des affections susmentionnées, et qui est caractérisée par le fait qu'elle comprend, dans un support pharmaceutiquement acceptable et compatible avec le mode d'administration retenu pour cette composition, au moins un composé de formule générale (I). Ce composé de formule générale (I) peut également se présenter sous une de ses formes énantiomériques ou sous la forme d'un de ses sels pharmaceutiquement acceptables. \nThe invention relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of inflammatory diseases in which TNFα is involved.  The invention relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of inflammatory skin diseases, psoriasis, atopic dermatitis or rheumatism. psoriatic; The subject of the present invention is also a pharmaceutical composition intended in particular for the treatment of the abovementioned affections, and which is characterized in that it comprises, in a pharmaceutically acceptable carrier and compatible with the mode of administration chosen for this composition, at least a compound of general formula (I). This compound of general formula (I) may also be in one of its enantiomeric forms or in the form of a pharmaceutically acceptable salt thereof.\n\n\n\n\n\n\n \nOn va maintenant donner, à titre d'illustration et sans aucun caractère limitatif, plusieurs exemples de préparation de composés actifs de formule (I) selon l'invention, ainsi que des résultats d'activité biologiques de tels composés. \nSeveral examples of the preparation of active compounds of formula (I) according to the invention, as well as biological activity results for such compounds, will now be given by way of illustration and without any limiting character.\n\n\n\n\n\n\n \nEXEMPLES DE RÉALISATION \nEXAMPLES OF REALIZATION\n\n\n\n\n\n\n \nLes composés de formule générale (I) sont caractérisés par analyse RMN du proton sur un appareil Advanced 400MHz Bruker. \nThe compounds of general formula (I) are characterized by proton NMR analysis on an Advanced 400MHz Bruker apparatus.\n\n\n\n\n\n\n \nExemple 1 : 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide. \nExample 1: 3 - [(4-But-2-ynyloxy-benzenesulfonyl) methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n1-1 : 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-malonate de diméthyle \n1-1: Dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate\n\n\n\n\n\n\n \n19,5g (141 mmoles) de carbonate de potassium puis 19,5ml (134 mmoles) de diméthylbromomalonate sont additionnés à une solution de 25g (134 mmoles) de pipérazine 1- carboxylate de tertbutyle dans 300ml d'acétonitrile. Le milieu réactionnel est agité à température ambiante pendant 24h puis filtré pour éliminer les sels insolubles et concentré sous vide. Le résidu brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 70/30. 41g (97%) de 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-malonate de diméthyle sont obtenus sous forme d'une huile claire . \n19.5 g (141 mmol) of potassium carbonate and 19.5 ml (134 mmol) of dimethylbromomalonate are added to a solution of 25 g (134 mmol) of tertbutyl piperazine-1-carboxylate in 300 ml of acetonitrile. The reaction medium is stirred at ambient temperature for 24 hours and then filtered to remove the insoluble salts and concentrated in vacuo. The crude residue obtained is purified by chromatography on silica gel eluting with a 70/30 heptane / ethyl acetate mixture. 41 g (97%) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate are obtained in the form of a clear oil.\n\n\n\n\n\n\n \n1-2 : 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-ylméthyl)-malonate de diméthyle: \n1-2: Dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2- (1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl) -malonate:\n\n\n\n\n\n\n \n3,5g (87 mmoles) d'hydrure de sodium sont additionnés par portions à une solution de 25g (87 mmoles) de 2-(4-tert-butoxycarbonyl-piperazin-1-yl)-malonate de diméthyle dans 250ml de tétrahydrofuranne refroidie à 2\n0\nC. Le milieu réactionnel est agité à température ambiante pendant 30 minutes puis ramené à 2\n0\nC avant addition goutte à goutte de 21g (87 mmoles) de 2-bromométhyl- isoindole-1 ,3-dione dans 200ml de tétrahydrofuranne. Le milieu réactionnel est agité à température \n\n ambiante pendant 2Oh, traité par addition de 500ml d'eau puis extrait à l'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée et concentrée sous vide. \n3.5 g (87 mmol) of sodium hydride are added in portions to a solution of 25 g (87 mmol) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate in 250 ml of cooled tetrahydrofuran at 20 \n°\n C. The reaction mixture is stirred at ambient temperature for 30 minutes and then brought back to 20 \n°\n C. before adding dropwise 21 g (87 mmol) of 2-bromomethylisoindole-1,3-dione in 200 ml of tetrahydrofuran. The reaction medium is stirred at room temperature  ambient for 2Oh, treated by addition of 500ml of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated in vacuo.\n\n\n\n\n\n\n \nLe produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 70/30. 27,5g (73%) de 2-(4-tert-Butoxycarbonyl-piperazin-1-yl)-2-(1 ,3-dioxo- 1 ,3-dihydro-isoindol-2-ylmethyl)-malonate de diméthyle sont obtenus sous forme d'un solide blanc . \nThe crude product obtained is purified by chromatography on silica gel eluted with a 70/30 heptane / ethyl acetate mixture. 27.5 g (73%) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2- (1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl) -malonate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-3: 2-aminométhyl-2-(4-tert-butoxycarbonyl-piperazin-1-yl)-malonate de diméthyle \nDimethyl 1-3: 2-aminomethyl-2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate\n\n\n\n\n\n\n \n Une solution de 2,9ml (64 mmoles) d'hydrazine hydrate dans 8ml de méthanol est additionnée à une solution de 27,5g (58 mmoles) de 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-(1 ,3-dioxo-1 ,3-dihydro- isoindol-2-ylméthyl)-malonate de diméthyle dans 300ml de méthanol préalablement refroidie à -5\n0\nC. Le milieu réactionnel est agité de -5\n0\nC à température ambiante pendant 3h. Après évaporation et addition de 300ml d'eau, le milieu réactionnel est extrait à l'acétate d'éthyle. Les phases organiques sont lavées avec une solution aqueuse saturée d'hydrogénocarbonate de sodium, séchées sur sulfate de magnésium, filtrées, évaporées. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 8/2 puis augmentation de la polarité jusqu'à un mélange acétate d'éthyle / méthanol 90/10. 10g (50%) de 2-aminométhyl-2-(4-tert-butoxycarbonyl- piperazin-1-yl)-malonate de diméthyle sont ainsi obtenus sous forme d'une huile claire. \nA solution of 2.9 ml (64 mmol) of hydrazine hydrate in 8 ml of methanol is added to a solution of 27.5 g (58 mmol) of 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2- (1,3-dioxo-1,3-dihydroisoindol-2-ylmethyl) dimethyl malonate in 300 ml of methanol previously cooled to -5 \n°\n C. The reaction medium is stirred at -5 \n°\n C. at room temperature for 3 hours. . After evaporation and addition of 300 ml of water, the reaction medium is extracted with ethyl acetate. The organic phases are washed with a saturated aqueous solution of sodium hydrogencarbonate, dried over magnesium sulphate, filtered and evaporated. The residue obtained is purified by chromatography on silica gel eluted with heptane / ethyl acetate mixture 8/2 and then increasing the polarity to a 90/10 ethyl acetate / methanol mixture. 10 g (50%) of dimethyl 2-aminomethyl-2- (4-tert-butoxycarbonylpiperazin-1-yl) -malonate are thus obtained in the form of a clear oil.\n\n\n\n\n\n\n \n1-4: 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-[(4-but-2-ynyloxybenzènesulfonylamino)-méthyl]- malonate de diméthyle \n1-4: Dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2 - [(4-but-2-ynyloxybenzenesulfonylamino) methyl] malonate\n\n\n\n\n\n\n \n 1 ,1 ml (8 mmoles) de triéthylamine puis 1 ,8ml (7 mmoles) de chlorure de 4-but-2-ynyloxy- benzènesulfonyle sont additionnés sur une solution de 2,5g (7 mmoles) de 2-aminométhyl-2-(4-tert- butoxycarbonyl-piperazin-1-yl)-malonate de diméthyle dans 30ml de dichlorométhane. Le milieu réactionnel est agité à température ambiante pendant 2 heures puis concentré sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 70/30. 2,1g (51 %) de 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-[(4-but-2-ynyloxy- benzènesulfonylamino)-méthyl]-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \n 1.1 ml (8 mmol) of triethylamine and then 1.8 ml (7 mmol) of 4-but-2-ynyloxybenzenesulfonyl chloride are added to a solution of 2.5 g (7 mmol) of 2-aminomethyl-2- Dimethyl (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate in 30 ml of dichloromethane. The reaction medium is stirred at room temperature for 2 hours and then concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 70/30 heptane / ethyl acetate mixture. 2.1 g (51%) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2 - [(4-but-2-ynyloxy-benzenesulfonylamino) methyl] dimalonate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-5: 2-[(4-but-2-ynyloxy-benzènesulfonylamino)-méthyl]-2-piperazin-1-yl-malonate de diméthyle 2,8ml d'acide trifluoroacétique sont additionnés sur une solution de 2,1g ( 4 mmoles) de 2-(4-tert- butoxycarbonyl-piperazin-1-yl)-2-[(4-but-2-ynyloxybenzènesulfonylamino)-méthyl]-malonate de diméthyle dilué dans 30ml de dichlorométhane. Après agitation à température ambiante pendant 24h, une solution aqueuse saturée d'hydrogénocarbonate de sodium est additionnée jusqu'à pH=8 et le milieu réactionnel est extrait par du dichlorométhane. Les phases organiques sont rassemblées, lavées à l'eau, séchées sur sulfate de magnésium puis filtrées et évaporées. 1 ,7g (98%) de 2-[(4-but- 2-ynyloxy-benzènesulfonylamino)-méthyl]-2-pipérazin-1-yl-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \nDimethyl 1-5: 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) -methyl] -2-piperazin-1-yl-malonate 2.8 ml of trifluoroacetic acid are added to a solution of 2.1 g ( 4 mmol) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2 - [(4-but-2-ynyloxybenzenesulfonylamino) methyl] dimalonate diluted in 30 ml of dichloromethane. After stirring at room temperature for 24 hours, a saturated aqueous solution of sodium hydrogencarbonate is added until pH = 8 and the reaction medium is extracted with dichloromethane. The organic phases are combined, washed with water, dried over magnesium sulphate and then filtered and evaporated. 1.7 g (98%) of dimethyl 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) methyl] -2-piperazin-1-yl-malonate are obtained as a white solid.\n\n\n\n\n\n\n \n1-6: 2-[(4-but-2-ynyloxy-benzènesulfonylamino)-méthyl]-2-(4-méthanesulfonyl-pipérazin-1-yl)- malonate de diméthyle \n\n 0,6ml (4 mmoles) de triéthylamine puis 0,3ml (4 mmoles) de chlorure de méthanesulfonyle sont additionnés sur une solution de 1 ,6g (4 mmoles) de 2-[(4-but-2-ynyloxy-benzènesulfonylamino)- méthyl]-2-piperazin-1-yl-malonate de diméthyle dilué dans 30ml de dichlorométhane. Le milieu réactionnel est ensuite agité à température ambiante pendant 3h puis évaporé à sec. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange dichlorométhane/méthanol 99/1. 1 ,1g (58%) de 2-[(4-but-2-ynyloxy-benzènesulfonylamino)-méthyl]-2-(4-méthanesulfonyl- piperazin-1-yl)-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \nDimethyl 1-6: 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) methyl] -2- (4-methanesulfonyl-piperazin-1-yl) malonate  0.6 ml (4 mmol) of triethylamine and then 0.3 ml (4 mmol) of methanesulfonyl chloride are added to a solution of 1.6 g (4 mmol) of 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) - dimethyl methyl] -2-piperazin-1-yl-malonate diluted in 30ml of dichloromethane. The reaction medium is then stirred at room temperature for 3 h and then evaporated to dryness. The crude residue is purified by chromatography on silica gel eluted with a 99/1 dichloromethane / methanol mixture. 1.1 g (58%) of dimethyl 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) -methyl] -2- (4-methanesulfonyl-piperazin-1-yl) -malonate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-7: 2-{(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-méthyl}-2-(4-méthanesulfonyl-pipérazin-1-yl) malonate de diméthyle \nDimethyl 1-7: 2 - {(4-but-2-ynyloxy-benzenesulfonyl) methyl-amino] -methyl} -2- (4-methanesulfonyl-piperazin-1-yl) malonate\n\n\n\n\n\n\n \n 120mg (0,9 mmoles) de carbonate de potassium puis 56μl (0,9 mmoles) d'iodure de méthyle sont additionnés à une solution de 400mg ( 0,8 mmoles) de 2-[(4-but-2-ynyloxy-benzènesulfonylamino)- méthyl]-2-(4-méthanesulfonyl-pipérazin-1-yl)-malonate de diméthyle dans 10ml de diméthylformamide. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h puis hydrolyse par addition d'eau et extrait à l'acétate d'éthyle. Les phases organiques sont lavées par de l'eau puis séchées sur sulfate de magnésium, filtrées et concentrées sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 50/50. 410mg (100%) de 2-{[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-méthyl}-2-(4-méthanesulfonyl- pipérazin-1-yl)-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \n 120 mg (0.9 mmol) of potassium carbonate and then 56 μl (0.9 mmol) of methyl iodide are added to a solution of 400 mg (0.8 mmol) of 2 - [(4-but-2-ynyloxy) dimethylformamide (dimethylformamide) benzenesulfonylamino) methyl) -2- (4-methanesulfonyl-piperazin-1-yl) -malonate in 10 ml of dimethylformamide. The reaction medium is then stirred at room temperature for 18 h and then hydrolyzed by adding water and extracted with ethyl acetate. The organic phases are washed with water and then dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 410 mg (100%) of dimethyl 2 - {[(4-but-2-ynyloxy-benzenesulfonyl) methyl-amino] -methyl} -2- (4-methanesulfonyl-piperazin-1-yl) -malonate are obtained under form of a white solid.\n\n\n\n\n\n\n \n1-8: acide 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-piperazin-1-yl)- propanoïque \n1-8: 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid\n\n\n\n\n\n\n \n 1 ,7ml (1 ,7 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M sont additionnés sur une solution de 270mg (0,5 mmoles) de 2-{[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl- amino]-méthyl}-2-(4-méthanesulfonyl-pipérazin-1-yl) malonate de diméthyle dans 7ml de tétrahydrofuranne et 2ml de méthanol. Le milieu réactionnel est agité à 4O\n0\nC pendant 15h puis ramené à pH=6 par l'addition d'une solution aqueuse d'acide chlorohydrique de concentration 1 M. Après évaporation sous vide des solvants, le produit précipite. Le résidu obtenu est repris dans 5ml d'eau et agité pendant 30min jusqu'à précipitation. Le produit est filtré, rincé à l'eau puis séché sous vide. 200mg (87%) d'acide 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl- pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n1.7 ml (1.7 mmol) of a 1M aqueous solution of sodium hydroxide are added to a solution of 270 mg (0.5 mmol) of 2 - {[(4-but-2-ynyloxy) dimethyl benzenesulfonyl) methyl-amino-methyl-2- (4-methanesulfonyl-piperazin-1-yl) malonate in 7 ml of tetrahydrofuran and 2 ml of methanol. The reaction medium is stirred at 40 \n°\n C. for 15 hours and then brought to pH = 6 by the addition of a 1M aqueous solution of hydrochloric acid. After evaporation of the solvents under vacuum, the product precipitates. The residue obtained is taken up in 5 ml of water and stirred for 30 min until precipitation. The product is filtered, rinsed with water and then dried under vacuum. 200 mg (87%) of 3 - [(4-but-2-ynyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-9: 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n1-9: 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n63mg ( 0,5 mmoles) de 1-hydroxybenzotriazole puis 88mg (0,5 mmoles) de chlorhydrate de 1-éthyl-3- (3-diméthylaminopropyl)carbodiimide sont ajoutés à une solution de 200mg (0,4 mmoles) d' acide 3- [(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoïque dans 6ml de diméthylformamide. Le milieu réactionnel est agité 10min à température ambiante puis 68mg (0,5 mmoles) de O-tert-butyldiméthysilylhydroxylamine sont ajoutés . Le milieu réactionnel est ensuite agité à température ambiante pendant 24h, hydrolyse par l'addition de 2ml d'une solution \n\n aqueuse d'acide citrique 5% et agité pendant 30 minutes supplémentaires. Après extraction à l'acétate d'éthyle, la phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange dichlorométhane/méthanol 95/5. 100mg (50%) de 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl- amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 86\n0\nC. \n63 mg (0.5 mmol) of 1-hydroxybenzotriazole and then 88 mg (0.5 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride are added to a solution of 200 mg (0.4 mmol) of acid. 3 - [(4-But-2-ynyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid in 6 ml of dimethylformamide. The reaction medium is stirred for 10 min at room temperature and then 68 mg (0.5 mmol) of O-tert-butyldimethylsilylhydroxylamine are added. The reaction medium is then stirred at ambient temperature for 24 h, hydrolyzed by the addition of 2 ml of a solution  aqueous citric acid 5% and stirred for a further 30 minutes. After extraction with ethyl acetate, the organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. The crude residue is purified by chromatography on silica gel eluted with a 95/5 dichloromethane / methanol mixture. 100mg (50%) of 3 - [(4-but-2-ynyloxy-benzenesulfonyl) -methylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide are obtained in the form of a white solid with a melting point of 86 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 1 ,91 (s, 3H); 2,63-2,68 (m, 2H); 2,72 (s, 3H); 2,72-2,75 (m, 2H); 2,92 (s, 3H); 3,05-3,15 (m, 5H); 3,30-3,38 (m, 2H); 4,93 (s, 2H); 7,24 (d, J=6,8Hz, 2H); 7,79 (d, J=6,8Hz, 2H); 9,06 (s, 1 H); 10.77 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 1.91 (s, 3H); 2.63-2.68 (m, 2H); 2.72 (s, 3H); 2.72-2.75 (m, 2H); 2.92 (s, 3H); 3.05-3.15 (m, 5H); 3.30-3.38 (m, 2H); 4.93 (s, 2H); 7.24 (d, J = 6.8 Hz, 2H); 7.79 (d, J = 6.8 Hz, 2H); 9.06 (s, 1H); 10.77 (s, 1H).\n\n\n\n\n\n\n \nExemple 2: (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propionamide. 2-1: Sel de sodium de l'acide 4-but-2-ynyloxy-benzènesulfonique \nExample 2: (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide. 2-1: Sodium salt of 4-but-2-ynyloxy-benzenesulfonic acid\n\n\n\n\n\n\n \n 50g (370 mmoles) de 1-bromo-but-2-yne sont additionnés sur une solution de 43g (185 mmoles) de sel de sodium de l'acide 4-hydroxy-benzènesulfonique commercial et de 185ml (185 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M dans 800ml d'isopropanol. Le milieu réactionnel est chauffé à 7O\n0\nC pendant 18h. \n50 g (370 mmol) of 1-bromo-but-2-yne are added to a solution of 43 g (185 mmol) of sodium salt of commercial 4-hydroxy-benzenesulphonic acid and 185 ml (185 mmol) of a 1 M aqueous sodium hydroxide solution in 800 ml of isopropanol. The reaction medium is heated at 70 \n°\n C. for 18 h.\n\n\n\n\n\n\n \nAprès évaporation de l'isopropanol, le produit obtenu est filtré, rincé à l'isopropanol et à l'éther diéthylique puis séché sous vide. 46g (100%) du sel de sodium de l'acide 4-but-2-ynyloxy- benzènesulfonique sont obtenus sous forme d'un solide blanc . \nAfter evaporation of the isopropanol, the product obtained is filtered, rinsed with isopropanol and diethyl ether and then dried under vacuum. 46 g (100%) of the sodium salt of 4-but-2-ynyloxybenzenesulfonic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n2.2: Chlorure de 4-but-2-ynyloxy-benzènesulfonyle \n2.2: 4-but-2-ynyloxybenzenesulfonyl chloride\n\n\n\n\n\n\n \n30g (107 mmoles) du sel de sodium de l'acide 4-but-2-ynyloxy-benzènesulfonique dans 120ml de diméthylformamide sont additionnés goutte à goutte à une solution de 28ml (321 mmoles) de chlorure d'oxalyle dans 120ml de dichlorométhane, préalablement refroidie à -1O\n0\nC puis le milieu réactionnel est agité à température ambiante pendant 18h. 800ml de glace sont additionnés et le milieu est extrait à l'acétate d'éthyle. Les phases organiques sont rassemblées, lavées à l'eau, séchées de sulfate de magnésium, filtrées et concentrées sous vide. 22g (84%) de chlorure de 4-but-2-ynyloxy- benzènesulfonyle sous la forme d'un solide beige . \n30 g (107 mmol) of the sodium salt of 4-but-2-ynyloxybenzenesulfonic acid in 120 ml of dimethylformamide are added dropwise to a solution of 28 ml (321 mmol) of oxalyl chloride in 120 ml of dichloromethane, previously cooled to -1O \n0\n C and the reaction medium is stirred at room temperature for 18h. 800 ml of ice are added and the medium is extracted with ethyl acetate. The organic phases are combined, washed with water, dried magnesium sulfate, filtered and concentrated in vacuo. 22g (84%) of 4-but-2-ynyloxybenzenesulfonyl chloride as a beige solid.\n\n\n\n\n\n\n \n2.3: N, N-bis-(2-chloro-éthyl)-méthanesulfonamide \n2.3: N, N-bis- (2-chloro-ethyl) -methanesulfonamide\n\n\n\n\n\n\n \n 8,6ml (62 mmoles) de triéthylamine sont additionnés à une solution de 5g (28 mmoles) du chlorhydrate de bis-(2-chloroéthyl)-amine dans 60ml de dichlorométhane. Les sels de chlorure de triéthylammonium précipitent et sont filtrés . 2,4ml (31 mmoles) de chlorure de méthanesulfonyle sont alors additionnés au filtrat obtenu et le milieu réactionnel est agité à température ambiante pendant 3h. Après addition d'eau, le produit est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. 5,8g (94%) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide sont obtenus sous forme d'un solide beige. \n\n 2.4: (S)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle Dans un tube de Schlenk, une solution de 5g (20 mmoles) de chlorhydrate de (S)-2-amino-3-tert- butoxycarbonylamino-propanoate de méthyle et 4,3g (20 mmoles) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide dans 65ml de N,N-Diisopropyléthylamine est chauffée à 127\n0\nC sous forte agitation pendant 18h. Après addition d'eau, le produit est extrait à l'acétate d'éthyle. Les phases organiques sont rassemblées, lavées à l'eau, séchées sur sulfate de magnésium, filtrées et concentrées sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 50/50. 3,3g (46%) de (S)-3-tert-butoxycarbonylamino-2- (4-méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n8.6 ml (62 mmol) of triethylamine are added to a solution of 5 g (28 mmol) of bis (2-chloroethyl) -amine hydrochloride in 60 ml of dichloromethane. The triethylammonium chloride salts precipitate and are filtered. 2.4 ml (31 mmol) of methanesulfonyl chloride are then added to the filtrate obtained and the reaction mixture is stirred at ambient temperature for 3 h. After addition of water, the product is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. 5.8 g (94%) of N, N-bis- (2-chloro-ethyl) -methanesulfonamide are obtained in the form of a beige solid.  2.4: (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propionic acid methyl ester In a Schlenk tube, a solution of 5 g (20 mmol) of (S) -hydrochloride Methyl 2-amino-3-tert-butoxycarbonylamino-propanoate and 4.3 g (20 mmol) of N, N-bis- (2-chloro-ethyl) methanesulfonamide in 65 ml of N, N-diisopropylethylamine is heated to 127 \n°\n C. C with vigorous stirring for 18h. After addition of water, the product is extracted with ethyl acetate. The organic phases are combined, washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 3.3 g (46%) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n2.5: Chlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle\n2.5: Methyl (S) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate hydrochloride\n\n\n\n\n\n\n \n15ml d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5-6N sont additionnés goutte à goutte à une solution de 2,7g (7,4 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4- méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dans 30ml de méthanol. Le milieu réactionnel est agité à 4O\n0\nC pendant 2h, concentré sous vide puis repris dans 20ml de méthanol et 150ml d'éther diéthylique. Le produit précipite, est filtré sous vide, rincé à l'éther diéthylique puis séché sous vide. 2,3g (100%) du chlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n15 ml of a solution of hydrochloric acid in isopropanol of concentration 5-6N are added dropwise to a solution of 2.7 g (7.4 mmol) of (S) -3-tert-butoxycarbonylamino-2- ( 4-methyl methanesulfonyl-piperazin-1-yl) -propanoate in 30 ml of methanol. The reaction medium is stirred at 40 \n°\n C. for 2 h, concentrated in vacuo and then taken up in 20 ml of methanol and 150 ml of diethyl ether. The product precipitates, is filtered under vacuum, rinsed with diethyl ether and then dried under vacuum. 2.3 g (100%) of methyl (S) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate hydrochloride are obtained in the form of a white solid.\n\n\n\n\n\n\n \n2.6: (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate méthyle \n2.6: (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate methyl\n\n\n\n\n\n\n \n 0,3ml (2 mmoles) de triéthylamine et 270mg (1 mmole) de chlorure de 4-but-2-ynyloxy- benzènesulfonyle (préparé comme décrit en 2.2) sont additionnés sur une solution de 300mg (1 mmole) du chlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 2.5) dans 8ml de dichlorométhane. Après agitation à température ambiante pendant 18h,de l'eau est additionné et le milieu réactionnel est extrait au dichlorométhane. Les phases organiques sont lavées à l'eau, séchées sur sulfate de magnésium, filtrées et concentrés. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 50/50. 400mg (85%) de (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4- méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sous forme d'un solide blanc. \n 0.3 ml (2 mmol) of triethylamine and 270 mg (1 mmol) of 4-but-2-ynyloxybenzenesulfonyl chloride (prepared as described in 2.2) are added to a solution of 300 mg (1 mmol) of the hydrochloride salt of Methyl 3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 2.5) in 8 ml of dichloromethane. After stirring at room temperature for 18 h, water is added and the reaction mixture is extracted with dichloromethane. The organic phases are washed with water, dried over magnesium sulphate, filtered and concentrated. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 400 mg (85%) of methyl (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate as a white solid.\n\n\n\n\n\n\n \n2.7: acide (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin-1-yl)- propanoïque \n2.7: (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) propanoic acid\n\n\n\n\n\n\n \n1 ,3ml (1 ,3 mmoles) d'une solution aqueuse d'hydroxyde de lithium de concentration 1 M sont additionnés sur une solution de 400mg (0,8 mmoles) de (S)-3-(4-but-2-ynyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dilué dans 10ml de tétrahydrofuranne préalablement refroidie à O\n0\nC. Le milieu réactionnel est agité à température ambiante pendant 2Oh. Après évaporation à sec, 1 ,5ml d'une solution aqueuse d'acide acétique de concentration 1 M sont additionnés pour obtenir un pH= 6. Le produit précipite, est filtré, rincé à l'eau \n\n puis à l'éther diéthylique et séché sous vide. 340mg (89%) d'acide (S)-3-(4-but-2-ynyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoïque sont obtenus sous forme d'un solide blanc. 2.8: (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-piperazin-1-yl)- propionamide \n1, 3 ml (1.3 mmol) of a 1M aqueous solution of lithium hydroxide are added to a solution of 400 mg (0.8 mmol) of (S) -3- (4-but-2- Methyl ynyloxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate diluted in 10 ml of tetrahydrofuran previously cooled to 0 \n°\n C. The reaction medium is stirred at room temperature for 20 h. After evaporation to dryness, 1.5 ml of an aqueous solution of acetic acid of 1 M concentration are added to obtain a pH = 6. The product precipitates, is filtered, rinsed with water  then with diethyl ether and dried under vacuum. 340 mg (89%) of (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) propanoic acid are obtained in the form of a white solid. . 2.8: (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) propionamide\n\n\n\n\n\n\n \n 120mg ( 0,9 mmoles) de 1-hydroxybenzotriazole et 170mg (0,9 mmoles) du chlorhydrate de 1-éthyl-3- (3-diméthylaminopropyl)carbodiinnide sont ajoutés à une solution de 340mg (0,7 mmoles) d' acide (S)- 3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoïque dans 8ml de diméthylformamide. Le milieu réactionnel est agité 30min puis 120mg (0,8 mmoles) de O-tert- butyldiméthysilyl-hydroxylamine dans 3ml de diméthylformamide sont additionnés. Le milieu réactionnel est ensuite agité à température ambiante pendant 2Oh puis hydrolyse par 2ml d'eau et 2ml d'une solution aqueuse 5% d'acide citrique. Après agitation pendant 30min, une solution aqueuse saturée d'hydrogénocarbonate de sodium est ajoutée jusqu'à pH=8 puis le milieu réactionnel est extrait par de l'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu est repris dans du dichlorométhane, filtré puis séché sous vide. 80mg (23%) de (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-piperazin-1-yl)- propionamide sont obtenus sous forme d'un solide blanc de point de fusion 15O\n0\nC. \n120 mg (0.9 mmol) of 1-hydroxybenzotriazole and 170 mg (0.9 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiinnide hydrochloride are added to a solution of 340 mg (0.7 mmol) of acid. (S) - 3- (4-But-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid in 8 ml of dimethylformamide. The reaction medium is stirred for 30 minutes and then 120 mg (0.8 mmol) of O-tert-butyldimethylsilyl-hydroxylamine in 3 ml of dimethylformamide are added. The reaction medium is then stirred at room temperature for 20 h and then hydrolyzed with 2 ml of water and 2 ml of a 5% aqueous solution of citric acid. After stirring for 30 min, a saturated aqueous solution of sodium hydrogencarbonate is added until pH = 8 and the reaction medium is extracted with ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated. The residue is taken up in dichloromethane, filtered and dried under vacuum. 80 mg (23%) of (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide are obtained in the form of a white solid of melting point 15O \n0\n C.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 1 ,86 (s, 3H); 2,55 (m, 4H); 2,83 (s, 3H); 2,85-2,88 (m, 1 H); 2,97-3,00 (m, 3H); 3,00-3,06 (m, 2H); 3,10-3,12 (t, J=4,8Hz, 1 H); 4,86 (s, 2H); 7,15 (d, J=9,2Hz, 2H); 7,51 (s, 1 H); 7,75 (d, J=9,2Hz, 2H); 8,94 (s, 1 H); 10,6 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 1, 86 (s, 3H); 2.55 (m, 4H); 2.83 (s, 3H); 2.85-2.88 (m, 1H); 2.97-3.00 (m, 3H); 3.00-3.06 (m, 2H); 3.10-3.12 (t, J = 4.8 Hz, 1H); 4.86 (s, 2H); 7.15 (d, J = 9.2 Hz, 2H); 7.51 (s, 1H); 7.75 (d, J = 9.2 Hz, 2H); 8.94 (s, 1H); 10.6 (s, 1H).\n\n\n\n\n\n\n \nExemple 3 : (S)-3-(4-benzyloxy-benzenesulfonylamino)-N-hydroxy-2-(4-methanesulfonyl- piperazin-1 -yl)-propionamide. \nExample 3: (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n3.1 : N,N-bis-(2-chloro-éthyl)-méthanesulfonamide \n3.1: N, N-bis- (2-chloro-ethyl) -methanesulfonamide\n\n\n\n\n\n\n \n 14,3ml (185 mmoles) de chlorure de méthane sulfonyle sont ajoutés lentement à une solution de 15g (84 mmoles) de chlorhydrate de bis(2-chloroéthylamine) commercial et 26ml (185 mmoles) de triéthylamine dans 200ml de dichlorométhane et 70ml de tétrahydrofuranne préalablement agitée pendant 15min puis filtrée pour enlever le chlorure de triéthylammonium. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h, extrait au dichlorométhane, lavé à l'eau. La phase organique est séchée sur sulfate de magnésium, filtrée, évaporée. Le résidu obtenu est lavé à l'éther diisopropylique, filtré puis séché sous vide. 15,3g (82%) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide sont obtenus sous forme d'un solide. \n 14.3 ml (185 mmol) of methanesulfonyl chloride are slowly added to a solution of 15 g (84 mmol) of commercial bis (2-chloroethylamine) hydrochloride and 26 ml (185 mmol) of triethylamine in 200 ml of dichloromethane and 70 ml of tetrahydrofuran previously stirred for 15 min and then filtered to remove triethylammonium chloride. The reaction medium is then stirred at ambient temperature for 18 h, extracted with dichloromethane and washed with water. The organic phase is dried over magnesium sulphate, filtered and evaporated. The residue obtained is washed with diisopropyl ether, filtered and then dried under vacuum. 15.3 g (82%) of N, N-bis- (2-chloro-ethyl) -methanesulfonamide are obtained in the form of a solid.\n\n\n\n\n\n\n \n3.2 : (S)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle\n3.2: Methyl (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \nUne solution de 9,6g (44 mmoles) de N,N-bis-(2-chloro-éthyl)-méthanesulfonamide et de 11 ,1g (44 mmoles) de chlorhydrate de 2-amino-3-tert-butoxy-propanoate de méthyle dans 90ml de diisopropyléthylamine est chauffée à 127\n0\nC pendant 18h. Le milieu réactionnel est évaporé à sec. 31g de résidu brut sont obtenus et purifiés par chromatographie sur gel de silice élues avec un mélange \n\n heptane / acétate d'éthyle 9/1 puis augmentation de la polarité jusqu'à 4/6. 5,5g (35%) de (S)-3-tert- butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus. \nA solution of 9.6 g (44 mmol) of N, N-bis- (2-chloro-ethyl) -methanesulfonamide and 11.1 g (44 mmol) of 2-amino-3-tert-butoxy-propanoate hydrochloride. methyl in 90 ml of diisopropylethylamine is heated at 127 \n0\n C for 18h. The reaction medium is evaporated to dryness. 31 g of crude residue are obtained and purified by chromatography on silica gel eluted with a mixture  heptane / ethyl acetate 9/1 and then increase the polarity up to 4/6. 5.5 g (35%) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained.\n\n\n\n\n\n\n \n3.3: dichlorhydrate de (S)-3-Amino-2-(4-methanesulfonyl-piperazin-1-yl)-propanoate de méthyle Une solution de 4g (11 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 2.4) dans 40ml de méthanol et 20ml d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5 ou 6M est agitée à 4O\n0\nC pendant 18h puis concentrée sous vide. Le résidu obtenu est repris dans 200ml d'éther diéthylique, filtré puis séché sous vide. 3,5g (94%) du dichlorhydrate de (S)-3-amino-2-(4- méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide beige. \n3.3: Methyl (S) -3-Amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride A solution of 4 g (11 mmol) of (S) -3-tert-butoxycarbonylamino-2- Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in Example 2.4) in 40 ml of methanol and 20 ml of a solution of hydrochloric acid in isopropanol of concentration 5 or 6M is stirred at 40 \n°\n C. for 18 h and then concentrated under vacuum. The residue obtained is taken up in 200 ml of diethyl ether, filtered and dried under vacuum. 3.5 g (94%) of methyl (S) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride are obtained in the form of a beige solid.\n\n\n\n\n\n\n \n3.4 : sel de sodium de l'acide 4-benzyloxy-benzènesulfonique \n3.4: sodium salt of 4-benzyloxybenzenesulfonic acid\n\n\n\n\n\n\n \n 64ml (539 mmoles) de bromure de benzyle sont additionnés à une solution de 50g (215 mmoles) de sel de sodium de l'acide 4-hydroxy-benzènesulfonique dihydraté dans 700ml d'isopropanol et 250ml (250 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M. Le milieu réactionnel est chauffé à 7O\n0\nC pendant 2Oh. Après concentration sous vide de l'isopropanol, le produit précipite et est filtré. 61g (100%) de sel de sodium de l'acide 4-benzyloxy-benzènesulfonique sont obtenus sous forme d'un solide blanc . 3.5 : chlorure de 4-benzyloxy-benzènesulfonyle \n64 ml (539 mmol) of benzyl bromide are added to a solution of 50 g (215 mmol) of sodium salt of 4-hydroxy-benzenesulfonic acid dihydrate in 700 ml of isopropanol and 250 ml (250 mmol) of an aqueous solution 1 M concentration of sodium hydroxide. The reaction medium is heated at 70 \n°\n C. for 20 h. After concentration of the isopropanol under vacuum, the product precipitates and is filtered. 61 g (100%) of sodium salt of 4-benzyloxybenzenesulfonic acid are obtained in the form of a white solid. 3.5: 4-Benzyloxybenzenesulfonyl chloride\n\n\n\n\n\n\n \n Une solution de 55ml (639 mmoles) de chlorure d'oxalyle dans 250ml de dichlorométhane est additionnée goutte à goutte à une solution de 61g (213 mmoles) de sel de sodium de l'acide A- benzyloxy-benzènesulfonique dans 200ml de diméthylformamide, en maintenant la température entre -2O\n0\nC et -1O\n0\nC. Après addition, le milieu réactionnel est lentement ramené à température ambiante puis agité pendant 18h, versé sur de la glace et extrait à l'acétate d'éthyle. La phase organique est lavée par de l'eau, par une solution aqueuse saturée de chlorure de sodium et concentrée sous vide. 54g (89%) de chlorure de 4-benzyloxy-benzènesulfonyle sont obtenus sous forme d'un solide blanc . \nA solution of 55 ml (639 mmol) of oxalyl chloride in 250 ml of dichloromethane is added dropwise to a solution of 61 g (213 mmol) of sodium salt of A-benzyloxy-benzenesulfonic acid in 200 ml of dimethylformamide, now the temperature between -2O \n0\n C and -1O \n0\n C. After addition, the reaction medium is slowly brought to room temperature and then stirred for 18h, poured on ice and extracted with ethyl acetate. The organic phase is washed with water, with a saturated aqueous solution of sodium chloride and concentrated in vacuo. 54 g (89%) of 4-benzyloxy-benzenesulfonyl chloride are obtained in the form of a white solid.\n\n\n\n\n\n\n \n3.6: (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n3.6: Methyl (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \n 1 ,1 ml (7,8 mmoles) de triéthylamine puis 730mg ( 2,6 mmoles) de chlorure de 4-benzyloxy- benzènesulfonyle dans 8ml de dichlorométhane sont additionnés à une solution de 800mg ( 2,4 mmoles) de dichlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dans 20ml de dichlorométhane et le milieu réactionnel est agité à température ambiante pendant 3h . Après addition d'eau, le produit est extrait au dichlorométhane. La phase organique est lavée à l'eau , séchée sur sulfate de magnésium, filtrée et concentrée. \n 1.1 ml (7.8 mmol) of triethylamine and then 730 mg (2.6 mmol) of 4-benzyloxybenzenesulfonyl chloride in 8 ml of dichloromethane are added to a solution of 800 mg (2.4 mmol) of dihydrochloride. ) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate in 20ml of dichloromethane and the reaction medium is stirred at room temperature for 3h. After addition of water, the product is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated.\n\n\n\n\n\n\n \n Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/ acétate d'éthyle 8/2. 0,9g (75%) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl- piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n\n 3.7 : acide (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin-1-yl)- propanoique \nThe residue obtained is purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 8/2. 0.9 g (75%) of methyl (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonylpiperazin-1-yl) -propanoate are obtained in the form of a white solid.  3.7: (S) -3- (4-Benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) propanoic acid\n\n\n\n\n\n\n \n 2,6ml ( 2,6 mmoles) d'une solution aqueuse d'hydroxyde de lithium de concentration 1 M sont additionnés à une solution de 900mg (1 ,8 mmoles) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2- (4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dans 20ml de tétrahydrofurane et 0,5ml d'eau. Le milieu réactionnel est agité à température ambiante pendant 18h puis le THF est évaporé sous vide. 2,8ml d'une solution aqueuse d'acide acétique de concentration 1 M puis 30ml d'eau sont additionnés et le produit précipite. La suspension est agitée 30min à 100\n0\nC puis ramenée à température ambiante, filtrée et séchée sous vide. 750mg (86%) d' acide (S)-3-(4-benzyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n2.6 ml (2.6 mmol) of a 1 M aqueous solution of lithium hydroxide are added to a solution of 900 mg (1.8 mmol) of (S) -3- (4-benzyloxy-benzenesulfonylamino) Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate in 20 ml of tetrahydrofuran and 0.5 ml of water. The reaction medium is stirred at ambient temperature for 18 h and then the THF is evaporated under vacuum. 2.8 ml of a 1 M aqueous solution of acetic acid and then 30 ml of water are added and the product precipitates. The suspension is stirred for 30 min at 100 \n°\n C. and then brought to ambient temperature, filtered and dried under vacuum. 750 mg (86%) of (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n3.8 : (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propionamide \n3.8: (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n224mg ( 1 ,7 mmoles) de 1-hydroxybenzotriazole et 318mg (1 ,7 mmoles) du chlorhydrate de 1-éthyl- 3-(3-diméthylaminopropyl) carbodiimide sont additionnés successivement à 750mg (1 ,5 mmoles) d'acide (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoique dans 20ml de diméthylformamide. Après agitation à température ambiante pendant 20min, une solution de 244mg (1 ,7 mmoles) de O-tert-butyldiméthylsilylhydroxylamine dans 3ml de diméthylformamide est ajoutée. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h puis 2ml d'une solution aqueuse saturée d'hydrogénocarbonate de sodium et enfin 2ml d'eau sont ajoutés. Après extraction à l'acétate d'éthyle, la phase organique est lavée avec une solution aqueuse saturée d'hydrogénocarbonate de sodium, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu brut obtenu est repris dans 15ml d'acétate d'éthyle , chauffé à 7O\n0\nC puis ramené à température ambiante, filtré, séché sous vide. \n224 mg (1, 7 mmol) of 1-hydroxybenzotriazole and 318 mg (1.7 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride are successively added to 750 mg (1.5 mmol) of ) -3- (4-Benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid in 20 ml of dimethylformamide. After stirring at ambient temperature for 20 min, a solution of 244 mg (1.7 mmol) of O-tert-butyldimethylsilylhydroxylamine in 3 ml of dimethylformamide is added. The reaction medium is then stirred at ambient temperature for 18 h and then 2 ml of a saturated aqueous solution of sodium hydrogencarbonate and finally 2 ml of water are added. After extraction with ethyl acetate, the organic phase is washed with a saturated aqueous solution of sodium hydrogencarbonate, dried over magnesium sulfate, filtered and concentrated. The crude residue obtained is taken up in 15 ml of ethyl acetate, heated at 70 \n°\n C. and then brought to ambient temperature, filtered and dried under vacuum.\n\n\n\n\n\n\n \n 300mg (34%) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 165\n0\nC. RMN \n1\nH (δ, DMSO) : 2,40-2,50 (m, 2H); 2,50-2,60 (m, 2H); 2,84 (s, 3H), 3,00-3,05 (m, 4H); 3,06-3,09 (m, 2H); 3,34 (s, 1 H); 5,19 (s, 2H); 7,19 (d, J=8,4Hz, 2H); 7,30-7,34 (m, 1 H); 7,35-7,47 (m, 5H); 7,73 (d, J=8,4Hz, 2H); 8,93 (s, 1 H); 10,65 (s, 1 H). \n300 mg (34%) of (S) -3- (4-benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide are obtained in the form of a white point solid. melting 165 \n0\n C. \n1\n H NMR (δ, DMSO): 2.40-2.50 (m, 2H); 2.50-2.60 (m, 2H); 2.84 (s, 3H), 3.00-3.05 (m, 4H); 3.06-3.09 (m, 2H); 3.34 (s, 1H); 5.19 (s, 2H); 7.19 (d, J = 8.4Hz, 2H); 7.30-7.34 (m, 1H); 7.35-7.47 (m, 5H); 7.73 (d, J = 8.4Hz, 2H); 8.93 (s, 1H); 10.65 (s, 1H).\n\n\n\n\n\n\n \nExemple 4 : (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy- 2-(4-méthanesulfonyl-pipérazin-1-yl)-propionamide. 4.1: (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle \nExample 4: (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide. 4.1: Methyl (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) propanoate\n\n\n\n\n\n\n \n 300mg (1 ,9 mmoles) de carbonate de potassium puis 0,2ml (3,1 mmoles) d' iodure de méthyle sont additionnés sur une solution de 800mg (1 ,6 mmoles) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2- (4-methanesulfonyl-pipérazin-1-yl)-propanoate méthyle (préparé comme décrit en 3.6) dans 15ml de diméthylformamide. Le milieu réactionnel est ensuite agité à température ambiante pendant 2Oh, \n\n hydrolyse puis dilué par de l'acétate d'éthyle. Le produit est extrait à l'acétate d'éthyle. Les phases organiques sont lavées avec de l'eau, séchées sur sulfate de magnésium et filtrées. \n300 mg (1, 9 mmol) of potassium carbonate and then 0.2 ml (3.1 mmol) of methyl iodide are added to a solution of 800 mg (1, 6 mmol) of (S) -3- (4-benzyloxy) benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate methyl (prepared as described in 3.6) in 15 ml of dimethylformamide. The reaction medium is then stirred at room temperature for 20 h,  hydrolyzed and then diluted with ethyl acetate. The product is extracted with ethyl acetate. The organic phases are washed with water, dried over magnesium sulphate and filtered.\n\n\n\n\n\n\n \nLe filtrat est concentré sous vide pour donner 820mg (100%) de (S)-3-(4-benzyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate méthyle sous la forme d'un solide blanc. \nThe filtrate is concentrated in vacuo to give 820 mg (100%) of (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate methyl as a solution. white solid.\n\n\n\n\n\n\n \n4.2: acide (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoique: \n4.2: (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid:\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 820mg (1 ,6 mmoles) de (S)-3-[(4-benzyloxy- benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle, 720mg (90%) d' acide (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoique sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 3.7, from 820 mg (1.6 mmol) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1) methyl-propanoate, 720mg (90%) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) -methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n4.3: (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propionamide \n4.3: (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 720mg (1 ,4 mmoles) d' acide (S)-3-[(4- benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoique, 360mg (49%) de (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 11O\n0\nC. RMN \n1\nH (δ, DMSO) : 2,58-2,63 (m, 2H); 2,65 (s, 3H); 2,67-2,73 (m, 2H); 2,86 (s, 3H); 2,98-3,05 (m, 4H); 3,05-3,09 (m, 1 H); 3,24-3,25 (m, 1 H); 3,28-3,31 (m, 1 H); 5,21 (s, 2H); 7,24 (d, J=8,9Hz, 2H); 7,34-7,44 (\nm\n, 3H); 7,48 (d, J=7,2Hz, 2H); 7,72 (d, J=8,9Hz, 2H); 8,99 (s, 1 H); 10,69 (s, 1 H). \nIn a manner analogous to Example 3.8, from 720 mg (1.4 mmol) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl) piperazine 1-yl) propanoic acid, 360 mg (49%) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) ) -propionamide are obtained in the form of a white solid of melting point 110 \n°\n C. \n1\n H NMR (δ, DMSO): 2.58-2.63 (m, 2H); 2.65 (s, 3H); 2.67-2.73 (m, 2H); 2.86 (s, 3H); 2.98-3.05 (m, 4H); 3.05-3.09 (m, 1H); 3.24-3.25 (m, 1H); 3.28-3.31 (m, 1H); 5.21 (s, 2H); 7.24 (d, J = 8.9Hz, 2H); 7.34-7.44 ( \nm\n , 3H); 7.48 (d, J = 7.2 Hz, 2H); 7.72 (d, J = 8.9Hz, 2H); 8.99 (s, 1H); 10.69 (s, 1H).\n\n\n\n\n\n\n \nExemple 5 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 5: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n5.1 : (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n5.1: Methyl (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \nUne solution de 2,0g (3,9 mmoles) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4- méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 3.6) dans 60ml d'éthanol, 30ml de dioxanne et 0,5ml d'acide acétique glacial est dégazée sous flux d'azote puis 200mg (10% massique) de palladium sur charbon 10% en suspension dans 3ml de dioxanne sont additionnés. Le milieu réactionnel est placé sous une atmosphère d'hydrogène et agité à température ambiante pendant 18h. Après filtration sur célite, le filtrat est hydrolyse puis le produit est extrait à l'acétate d'éthyle. La phase organique est lavée à l'eau puis par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium, filtrée, concentrée sous vide. 1 ,65g (100%) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n\n 5.2 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \nA solution of 2.0 g (3.9 mmol) of methyl (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in US Pat. Example 3.6) in 60 ml of ethanol, 30 ml of dioxane and 0.5 ml of glacial acetic acid is degassed under a stream of nitrogen and then 200 mg (10% by mass) of palladium on carbon 10% suspended in 3 ml of dioxane are added . The reaction medium is placed under a hydrogen atmosphere and stirred at room temperature for 18 h. After filtration on celite, the filtrate is hydrolyzed and the product is extracted with ethyl acetate. The organic phase is washed with water and then with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. 1.65 g (100%) of methyl (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.  5.2: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n 280mg (0,85 mmoles) de carbonate de césium suivis de 160mg (0,85 mmoles) de 4-chlorométhyl-2- méthyl-quinoline et de 15mg d' iodure de potassium sont additionnés sur une solution de 300mg (0,71 mmoles) de (S)-3-(4-Hydroxy-benzenesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle dans 10ml d'acétone. Le milieu réactionnel est agité à température ambiante pendant 18h, filtré, concentré sous vide. Le produit brut est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 40/60. 130mg (32%) de (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle sont obtenus sous la forme d'un solide blanc. \n 280 mg (0.85 mmol) of cesium carbonate followed by 160 mg (0.85 mmol) of 4-chloromethyl-2-methyl-quinoline and 15 mg of potassium iodide are added to a solution of 300 mg (0.71 mmol). ) methyl (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate in 10 ml of acetone. The reaction medium is stirred at room temperature for 18 h, filtered, concentrated in vacuo. The crude product is purified by chromatography on silica gel eluted with a 40/60 heptane / ethyl acetate mixture. 130 mg (32%) of methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained under the shape of a white solid.\n\n\n\n\n\n\n \n5.3 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique \n5.3: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 130mg (0,2 mmoles) de (S)-2-(4-méthanesulfonyl- pipéridin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 120mg (99%) d' acide (S)-2-(4-méthanesulfonyl-pipéridin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 130 mg (0.2 mmol) of (S) -2- (4-methanesulfonylpiperidin-1-yl) -3- [4- (2-methyl-quinolin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate, 120mg (99%) (S) -2- (4-methanesulfonyl-piperidin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n5.4 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n5.4: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 123mg (0,2 mmoles) d'acide (S)-2-(4- méthanesulfonyl-piperazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 90mg (69%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide de point de fusion 185\n0\nC. \nIn a similar manner to Example 3.8, from 123 mg (0.2 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid, 90mg (69%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a solid with a melting point of 185 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,54-2,60 (m, 4H); 2,72 (s, 3H); 2,88 (s, 3H), 2,88-2,93 (m, 1 H); 3,01-3,05 (m, 1 H); 3,06-3,12 (m, 4H); 3,13-3,16 (t, J=7Hz, 1 H); 5,76 (s, 2H); 7,38 (d, J=8Hz, 2H); 7,57 (s, 1 H); 7,61- 7,66 (m, 2H); 7,78-7,85 (m, 3H); 8,02 (d, J=8,2Hz, 1 H); 8,15 (d, J= 8,2Hz, 1 H); 8,98 (s, 1 H); 10,71 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.54-2.60 (m, 4H); 2.72 (s, 3H); 2.88 (s, 3H), 2.88-2.93 (m, 1H); 3.01-3.05 (m, 1H); 3.06-3.12 (m, 4H); 3.13-3.16 (t, J = 7 Hz, 1H); 5.76 (s, 2H); 7.38 (d, J = 8Hz, 2H); 7.57 (s, 1H); 7.61-7.66 (m, 2H); 7.78-7.85 (m, 3H); 8.02 (d, J = 8.2 Hz, 1H); 8.15 (d, J = 8.2 Hz, 1H); 8.98 (s, 1H); 10.71 (s, 1H).\n\n\n\n\n\n\n \nExemple 6 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 6: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n6.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle \n6.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 160mg (0,9 mmoles) de 4-chlorométhyl-2-méthyl- quinoline et de 300mg (0,7 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)- 2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ), 130mg (32%) de (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n\n 6.2 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylaminoj-propanoique \nAnalogous to Example 5.2, starting from 160 mg (0.9 mmol) of 4-chloromethyl-2-methylquinoline and 300 mg (0.7 mmol) of (S) -3- (4-hydroxy) benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 5.1), 130mg (32%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) Methyl 3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -propanoate are obtained as a white solid.  6.2: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 240mg (0,6 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 210mg (91 %) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 240 mg (0.6 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy)) Methyl benzenesulfonylamino] propanoate, 210 mg (91%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) benzenesulfonylamino] - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n6.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide \n6.3: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 210mg (0,4 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)-benzènesulfonylamino]-propanoique, 70mg (33%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide beige de point de fusion 148\n0\nC. \nAnalogous to Example 3.8, from 210 mg (0.4 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-yl) acid). ylmethoxy) -benzenesulfonylamino] -propanoic acid, 70mg (33%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) benzenesulfonylamino) ] -propionamide are obtained in the form of a beige solid with a melting point of 148 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,45 (m, 2H); 2,60 (m, 2H); 2,85 (s, 3H); 2,90-3,05 (m, 4H); 3,06-3,15 (m, 2H); 3,35 (s, 1 H); 5,66 (s, 2H); 7,30 (d, J=8,4Hz, 2H); 7,50-7,60 (m, 4H); 7,70 (d, J=6,2Hz, 1 H); 7,77 (d, J=8.2Hz, 2H); 7,95-8,05 (m, 2H); 8,10 (d, J=6,4Hz, 1 H); 8,94 (s, 1 H); 10,70 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.45 (m, 2H); 2.60 (m, 2H); 2.85 (s, 3H); 2.90-3.05 (m, 4H); 3.06-3.15 (m, 2H); 3.35 (s, 1H); 5.66 (s, 2H); 7.30 (d, J = 8.4Hz, 2H); 7.50-7.60 (m, 4H); 7.70 (d, J = 6.2 Hz, 1H); 7.77 (d, J = 8.2 Hz, 2H); 7.95-8.05 (m, 2H); 8.10 (d, J = 6.4Hz, 1H); 8.94 (s, 1H); 10.70 (s, 1H).\n\n\n\n\n\n\n \nExemple 7 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy- benzènesulfonylamino)-propionamide. 7.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoate de méthyle \nExample 7: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide. 7.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 0,1 ml (1 ,3 mmoles) de 1-bromopropane et de 400mg (0,95 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) , 220mg (50%) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \n In a similar manner to Example 5.2, from 0.1 ml (1.3 mmol) of 1-bromopropane and 400 mg (0.95 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) - Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 5.1), 220 mg (50%) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3 Methyl (4-propoxybenzenesulfonylamino) propanoate are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n7.2 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propanoique \n7.2: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoic acid\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 220mg (0,5 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoate de méthyle, 190mg (90%) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoique sont obtenus sous forme d'un solide blanc. \n\n7.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide \nIn a similar manner to Example 3.7, from 220 mg (0.5 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoate. methyl, 190 mg (90%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoic acid are obtained in the form of a white solid.  7.3: (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 190mg (0,4 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoique, 30mg (16%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide sont obtenus sous forme d'un solide blanc de point de fusion 137\n0\nC. \nIn a similar manner to Example 3.8, from 190 mg (0.4 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) - Propane, 30 mg (16%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide are obtained in the form of a white solid. melting point 137 \n°\n C.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 0,91 (t, J=7,3Hz, 3H); 1 ,63-1 ,73 (m, 2H); 2,45 (m, 2H); 2,55 (m, 2H); 2,77 (s, 3H); 2,82 (m, 1 H); 2,83-2,95 (m, 4H); 2,95-3,05 (m, 2H); 3,94 (t, J=6,4Hz, 2H); 7,03 (d, J=8,7Hz, 2H); 7,38 (m, 1 H); 7,65 (d, J=8,7Hz, 2H); 8,85 (s, 1 H); 10,58 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 0.91 (t, J = 7.3 Hz, 3H); 1.63-1.73 (m, 2H); 2.45 (m, 2H); 2.55 (m, 2H); 2.77 (s, 3H); 2.82 (m, 1H); 2.83-2.95 (m, 4H); 2.95-3.05 (m, 2H); 3.94 (t, J = 6.4Hz, 2H); 7.03 (d, J = 8.7 Hz, 2H); 7.38 (m, 1H); 7.65 (d, J = 8.7 Hz, 2H); 8.85 (s, 1H); 10.58 (s, 1H).\n\n\n\n\n\n\n \nExemple 8 : (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide. \nExample 8: (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n8.1 : (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle \n8.1: Methyl (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 205mg (1 mmole) de 3-(bromométhyl)benzonitrile et de 400mg (0,95 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 5.1 ), 295mg (58%) de (S)-3-[4-(3- cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 5.2, from 205 mg (1 mmol) of 3- (bromomethyl) benzonitrile and 400 mg (0.95 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) -2- Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in Example 5.1), 295 mg (58%) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino) Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained as a white solid.\n\n\n\n\n\n\n \n8.2 : acide (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoique \n8.2: (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 295mg (0,5 mmoles) de (S)-3-[4-(3-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 270mg (94%) d'acide (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl- pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 3.7, from 295 mg (0.5 mmol) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate, 270 mg (94%) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n8.3 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propionamide \n8.3: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 264mg (0,5 mmoles) d'acide (S)-3-[4-(3-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoique, 107mg (40%) de (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide sont obtenus sous forme d'une poudre beige de point de fusion 108\n0\nC. \nAnalogously to Example 3.8, from 264 mg (0.5 mmol) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl) piperazine 1-yl) -propanoic acid, 107mg (40%) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) ) -propionamide are obtained in the form of a beige powder with a melting point of 108 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,55 (m, 4H); 2,84 (s, 3H); 2,95-3,05 (m, 4H); 3,10 (t, J=6,4Hz, 1 H); 3,34 (m;\n \n1\n H NMR (δ, DMSO): 2.55 (m, 4H); 2.84 (s, 3H); 2.95-3.05 (m, 4H); 3.10 (t, J = 6.4Hz, 1H); 3.34 (m;\n\n\n\n\n\n\n \n2H); 5,26 (s, 2H); 7,22 (d, J=8,6Hz, 2H); 7,50 (s, 1 H); 7,64 (t, J=7,6Hz, 1 H); 7,76 (d, J=8,6Hz, 2H);\n2H); 5.26 (s, 2H); 7.22 (d, J = 8.6 Hz, 2H); 7.50 (s, 1H); 7.64 (t, J = 7.6 Hz, 1H); 7.76 (d, J = 8.6 Hz, 2H);\n\n\n\n\n\n\n \n7,83 (t, J=8Hz, 2H); 7,96 (s, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n\n Exemple 9 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide. \n7.83 (t, J = 8Hz, 2H); 7.96 (s, 1H); 8.93 (s, 1H); 10.66 (s, 1H).  Example 9: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n9.1 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle \n9.1: Methyl (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 400mg (1 mmole) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) et de 205mg (1 ,1 mmoles) de 4-(bromométhyl)benzonitrile, 229mg (45%) de (S)-3-[4-(4- cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a manner similar to Example 5.2, from 400 mg (1 mmol) of methyl (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate ( prepared as described in 5.1) and 205 mg (1.1 mmol) of 4- (bromomethyl) benzonitrile, 229 mg (45%) of (S) -3- [4- (4-cyano-benzyloxy) benzenesulfonylamino] -2 Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n9.2 : acide (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoique \n9.2: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 229mg (0,4 mmoles) de (S)-3-[4-(4-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 202mg (91 %) d'acide (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl- pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 229 mg (0.4 mmol) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate, 202 mg (91%) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n9.3 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propionamide \n9.3: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir d'acide 197mg (0,4 mmoles) de (S)-3-[4-(4-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoique, 81 mg (40%) de (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide sont obtenus sous forme d'une poudre beige de point de fusion 109\n0\nC. \nAnalogously to Example 3.8, from 197 mg (0.4 mmol) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin) -1-yl) -propanoic acid, 81 mg (40%) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1- yl) - propionamide are obtained in the form of a beige powder of melting point 109 \n°\n C.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 2,50-2,60 (m, 4H); 2,84 (s, 3H); 2,96 -3,01 (m, 4H); 3,09 (t, J=7Hz, 1 H); 3,34 (s, 2H); 5,32 (s, 2H); 7,22 (d, J=8,8Hz, 2H); 7,50 (m, 1 H); 7,66 (d, J=8,1 Hz, 2H); 7,75 (d, J=8,8Hz, 2H); 7,89 (d, J=8,1 Hz, 2H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.50-2.60 (m, 4H); 2.84 (s, 3H); 2.96 - 3.01 (m, 4H); 3.09 (t, J = 7Hz, 1H); 3.34 (s, 2H); 5.32 (s, 2H); 7.22 (d, J = 8.8 Hz, 2H); 7.50 (m, 1H); 7.66 (d, J = 8.1Hz, 2H); 7.75 (d, J = 8.8 Hz, 2H); 7.89 (d, J = 8.1Hz, 2H); 8.93 (s, 1H); 10.66 (s, 1H).\n\n\n\n\n\n\n \nExemple 10 : 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzène sulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle. \nExample 10 Benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene sulfonylamino] -ethyl} -piperazine-1-carboxylate.\n\n\n\n\n\n\n \n10.1 : bis-(2-chloroéthyl)-carbamate de benzyle \n10.1: Benzyl bis (2-chloroethyl) carbamate\n\n\n\n\n\n\n \n 13,2ml (92 mmoles) de chloroformate de benzyle sont ajoutés lentement à une solution, refroidie à O\n0\nC, de 15g (84 mmoles) de chlorhydrate de bis(2-chloroéthylamine), 26ml (185 mmoles) de triéthylamine dans 200ml de dichlorométhane et 70ml de tétrahydrofuranne préalablement agitée pendant 15min puis filtrée pour enlever le chlorure de triéthylammonium. Le milieu réactionnel est agité à température ambiante pendant 18h. Après addition d'eau, le milieu réactionnel est extrait à l'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée, évaporée. 20g de résidu brut sont obtenus et purifiés par chromatographie sur gel de silice élues avec un mélange \n\n heptane / acétate d'éthyle 8/2. 6g (26%) de bis-(2-chloroéthyl)-carbamate de benzyle sont ainsi obtenus. \n13.2 ml (92 mmol) of benzyl chloroformate are slowly added to a solution, cooled to 0 \n°\n C., of 15 g (84 mmol) of bis (2-chloroethylamine) hydrochloride, 26 ml (185 mmol) of triethylamine in 200 ml of dichloromethane and 70 ml of tetrahydrofuran previously stirred for 15 min and then filtered to remove triethylammonium chloride. The reaction medium is stirred at ambient temperature for 18 h. After addition of water, the reaction medium is extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and evaporated. 20 g of crude residue are obtained and purified by chromatography on silica gel eluted with a mixture  heptane / ethyl acetate 8/2. 6 g (26%) of benzyl bis- (2-chloroethyl) carbamate are thus obtained.\n\n\n\n\n\n\n \n10.2 : 4-((S)-2-tert-butoxycarbonylamino-1-méthoxycarbonyl-éthyl)-pipérazine-1 -carboxylate de benzyle \n10.2: 4 - ((S) -2-tert-butoxycarbonylamino-1-methoxycarbonyl-ethyl) -piperazine-1-benzylcarboxylate\n\n\n\n\n\n\n \n Une solution de 5,5g (20 mmoles) de bis-(2-chloroéthyl)-carbamate de benzyle et 5,1g (20 mmoles) de chlorhydrate de 2-amino-3-tert-butoxy-propanoate de méthyle dans 40ml de diisopropyléthylamine est chauffée à 127\n0\nC pendant 18h. Après refroidissement, le milieu réactionnel est évaporé à sec. 17g de résidu brut sont obtenus et purifiés par chromatographie sur gel de silice élues avec un mélange heptane / acétate d'éthyle 9/1 jusqu'à 4/6. 1 ,6g (19%) de 4-((S)-2-tert-butoxycarbonylamino-1- méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle. \nA solution of 5.5 g (20 mmol) of benzyl bis (2-chloroethyl) carbamate and 5.1 g (20 mmol) of methyl 2-amino-3-tert-butoxy-propanoate hydrochloride in 40 ml of diisopropylethylamine is heated at 127 \n0\n C for 18h. After cooling, the reaction medium is evaporated to dryness. 17 g of crude residue are obtained and purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 9/1 to 4/6. 1, 6g (19%) of benzyl 4 - ((S) -2-tert-butoxycarbonylamino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate.\n\n\n\n\n\n\n \n10.3 : dichlorhydrate de 4-(2-amino-1-méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle Une solution de 1 ,45g (3,4 mmoles) de 4-((S)-2-tert-butoxycarbonylamino-1-méthoxycarbonyl-éthyl)- pipérazine-1-carboxylate de benzyle dans 3,5ml d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5-6N et 10ml de méthanol est chauffée à 4O\n0\nC pendant 3h puis évaporée. Le résidu est repris dans l'éther diéthylique, filtré. 1 ,2g (90%) de dichlorhydrate de 4-(2- amino-1-méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide. \n10.3: Benzyl 4- (2-amino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate dihydrochloride A solution of 1.45 g (3.4 mmol) of 4 - ((S) -2-tert-butoxycarbonylamino Benzyl 1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate in 3.5 ml of a solution of hydrochloric acid in isopropanol of concentration 5-6N and 10 ml of methanol is heated at 40 \n°\n C. for 3 h and then evaporated . The residue is taken up in diethyl ether, filtered. 1.2 g (90%) of benzyl 4- (2-amino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate dihydrochloride are obtained in the form of a solid.\n\n\n\n\n\n\n \n10.4 : 4-[(S)-2-(4-hydroxy-benzènesulfonylamino)-1-méthoxycarbonyl-éthyl]-pipérazine-1-carboxylate de benzyle \nBenzyl 10,4: 4 - [(S) -2- (4-hydroxy-benzenesulfonylamino) -1-methoxycarbonyl-ethyl] -piperazine-1-carboxylate\n\n\n\n\n\n\n \n 2,1 ml (15 mmoles) de triéthylamine puis 920mg (5 mmoles) de chlorure de 4-hydroxy- benzènesulfonyle dans 20ml de dichlorométhane sont additionnés goutte à goutte à une solution de 1 ,1g (3 mmoles) de dichlorhydrate de 4-(2-amino-1-méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle dans 30ml de dichlorométhane, préalablement refroidie à O\n0\nC. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h. Après addition d'eau, le milieu réactionnel est extrait par du dichlorométhane. La phase organique est à l'eau puis séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le résidu brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 50/50. 60mg (46%) de 4-[2-(4-hydroxy- benzènesulfonylamino)-1-méthoxycarbonyl-éthyl]-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide blanc. \n2.1 ml (15 mmol) of triethylamine and then 920 mg (5 mmol) of 4-hydroxybenzenesulfonyl chloride in 20 ml of dichloromethane are added dropwise to a solution of 1.1 g (3 mmol) of dihydrochloride of Benzyl 2-amino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate in 30 ml of dichloromethane, previously cooled to 0 \n°\n C. The reaction medium is then stirred at ambient temperature for 18 hours. After addition of water, the reaction medium is extracted with dichloromethane. The organic phase is with water then dried over magnesium sulfate, filtered and concentrated under vacuum. The crude residue obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 60 mg (46%) of benzyl 4- [2- (4-hydroxybenzenesulfonylamino) -1-methoxycarbonyl-ethyl] -piperazine-1-carboxylate are obtained as a white solid.\n\n\n\n\n\n\n \n10.5 : 4-{(S)-1-méthoxycarbonyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1 -carboxylate de benzyle \nBenzyl 10.5: 4 - {(S) -1-methoxycarbonyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} piperazine-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 260mg (1 ,4 mmoles) de 4-chlorométhyl-2-méthyl- quinoline et de 600mg (1 ,3 mmoles) de 4-[(S)-2-(4-hydroxy-benzènesulfonylamino)-1- méthoxycarbonyl-éthyl]-pipérazine-1 -carboxylate de benzyle, 320mg (40%) de 4-{(S)-1- méthoxycarbonyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}-pipérazine-1- carboxylate de benzyle sont obtenus sous forme d'un solide blanc. \n\n 10.6 : 4-{(S)-1-carboxy-2-[4-(2-méthyl-quinolin-4-ylméthoxy benzènesulfonylamino]-éthyl}-pipérazine- 1 -carboxylate de benzyle \nIn a similar manner to Example 5.2, from 260 mg (1.4 mmol) of 4-chloromethyl-2-methylquinoline and 600 mg (1.3 mmol) of 4 - [(S) -2- (4 benzylated-hydroxy-benzenesulfonylamino) -1-methoxycarbonyl-ethyl] -piperazine-1-carboxylate, 320mg (40%) of 4 - {(S) -1-methoxycarbonyl-2- [4- (2-methyl-quinolin)} Benzyl 4-ylmethoxy) -benzenesulfonylamino] -ethyl} -piperazine-1-carboxylate are obtained as a white solid.  Benzyl 10.6: 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxybenzenesulfonylamino] -ethyl} -piperazine-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 160mg (0,25 mmoles) de 4-{(S)-1-méthoxycarbonyl- 2-[4-(2-méthylquinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}-pipérazine-1 -carboxylate de benzyle, 135mg (87%) de 4-{(S)-1-carboxy-2-[4-(2-méthyl-quinolin-4-ylméthoxy benzènesulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide beige. 10.7 : 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-ethyl}- piperazine-1 -carboxylate de benzyle \n Analogously to Example 3.7, from 160 mg (0.25 mmol) of 4 - {(S) -1-methoxycarbonyl-2- [4- (2-methylquinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl } -piperazine-1-benzylcarboxylate, 135mg (87%) of 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -ethyl} -piperazine Benzyl 1-carboxylate is obtained in the form of a beige solid 10.7: 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} benzyl piperazine-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 135mg (0,2 mmoles) de 4-{(S)-1-carboxy-2-[4-(2- méthyl-quinolin-4-ylméthoxy benzènesulfonylamino]-éthyl}-pipérazine-1 -carboxylate de benzyle, 115mg (82%) de 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide blanc de point de fusion 162\n0\nC. \nIn a similar manner to Example 3.8, from 135 mg (0.2 mmol) of 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxy-benzenesulfonylamino] -ethyl} } -piperazine-1-benzylcarboxylate, 115mg (82%) 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} - Benzyl piperazine-1-carboxylate are obtained in the form of a white solid having a melting point of 162 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,35-2,45 (m, 4H); 2,70 (s, 3H); 2,80-2,90 (m, 1 H); 2,95-3,05 (m, 1 H); 3-05-3,10 (m, 1 H); 3,25-3,40 (m, 4H); 5,05 (s, 2H); 5,74 (s, 2H); 7,29-7,40 (m, 7H); 7,55 (m, 1 H); 7,60-7,70 (m, 2H); 7,79 (d, J=8,8Hz, 3H); 8,01 (d, J=8Hz, 1 H); 8,14 (d, J=8Hz, 1 H); 8,91 (s, 1 H); 10,67 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.35-2.45 (m, 4H); 2.70 (s, 3H); 2.80-2.90 (m, 1H); 2.95-3.05 (m, 1H); 3-05-3.10 (m, 1H); 3.25-3.40 (m, 4H); 5.05 (s, 2H); 5.74 (s, 2H); 7.29-7.40 (m, 7H); 7.55 (m, 1H); 7.60-7.70 (m, 2H); 7.79 (d, J = 8.8 Hz, 3H); 8.01 (d, J = 8Hz, 1H); 8.14 (d, J = 8 Hz, 1H); 8.91 (s, 1H); 10.67 (s, 1H).\n\n\n\n\n\n\n \nExemple 11 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 11: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n11.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \n11.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n 0,23ml (1 ,4 mmoles) de diéthylazodicarboxylate sont ajoutés lentement à une solution de 400mg (0,9 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 5.1) , 193mg (1 ,0 mmole) de (2-phényl-pyridin-4- yl)-méthanol et 373mg (1 ,4 mmoles) de triphénylphosphine dans 4ml de tétrahydrofuranne. Le mélange réactionnel est agité une heure à température ambiante puis évaporé à sec. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 60/40. 318mg (57%) de (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4- ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'une poudre blanche. \n 0.23 ml (1.4 mmol) of diethylazodicarboxylate are added slowly to a solution of 400 mg (0.9 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate (prepared as described in Example 5.1), 193 mg (1.0 mmol) of (2-phenyl-pyridin-4-yl) -methanol and 373 mg (1.4 mmol) of triphenylphosphine in 4ml of tetrahydrofuran. The reaction mixture is stirred for one hour at ambient temperature and then evaporated to dryness. The residue obtained is purified by chromatography on silica gel eluted with a 60/40 heptane / ethyl acetate mixture. 318 mg (57%) of methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained under form of a white powder.\n\n\n\n\n\n\n \n712 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)- benzènesulfonylamino]-propanoique \n712: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 317mg (0,5 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, \n\n 298mg (96%) d'acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)- benzènesulfonylannino]-propanoique sont obtenus sous forme d'un solide blanc. \nAnalogous to Example 3.7, from 317 mg (0.5 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (2-phenylpyridin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate  298 mg (96%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylannino] -propanoic acid are obtained under form of a white solid.\n\n\n\n\n\n\n \n11.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-piperazin-1-yl)-3-[4-(2-phenyl-pyridin-4-ylmethoxy)- benzenesulfonylaminoj-propionamide \n11.3: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 293mg (0,5 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 64mg (21 %) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl- pyridin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'une poudre blanche de point de fusion 100\n0\nC. \nIn a similar manner to Example 3.8, from 293 mg (0.5 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl) -2- pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid, 64mg (21%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl) pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white powder having a melting point of 100 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,52-2,59 (m, 4H); 2,84 (s, 3H); 2,85-2,90 (m, 1 H); 2,90-3,00 (m, 1 H); 3,00-3,08 (m, 4H); 3,10 (t, J=7,0Hz, 1 H); 5,35 (s, 2H); 7,26 (d, J=8,9Hz, 2H); 7,42 (m, 1 H); 7,45-7,55 (m, 4H); 7,78 (d, J=8,8Hz, 2H); 8,03 (s, 1 H); 8,10 (d, J=7,0Hz, 2H); 8,69 (d, J=5,0Hz, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.52-2.59 (m, 4H); 2.84 (s, 3H); 2.85-2.90 (m, 1H); 2.90-3.00 (m, 1H); 3.00-3.08 (m, 4H); 3.10 (t, J = 7.0 Hz, 1H); 5.35 (s, 2H); 7.26 (d, J = 8.9Hz, 2H); 7.42 (m, 1H); 7.45-7.55 (m, 4H); 7.78 (d, J = 8.8 Hz, 2H); 8.03 (s, 1H); 8.10 (d, J = 7.0 Hz, 2H); 8.69 (d, J = 5.0 Hz, 1H); 8.93 (s, 1H); 10.66 (s, 1H).\n\n\n\n\n\n\n \nExemple 12 : (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 12: (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n12.1 : (R)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle De manière analogue à l'exemple 3.2, à partir de 3,8g (17 mmoles) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide (préparé comme décrit en 3.1 ) et 4g (16 mmoles) de chlorhydrate de 2- (R) amino-3-tert-butoxy-propanoate de méthyle commercial, 2,6g (46%) de (R)-3-tert- butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide jaune clair. \n12.1: Methyl (R) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate Analogously to Example 3.2, from 3.8 g (17 mmol) of N N-bis- (2-chloroethyl) methanesulfonamide (prepared as described in 3.1) and 4g (16 mmol) of commercial methyl 2- (R) amino-3-tert-butoxypropanoate hydrochloride, 2, 6 g (46%) of methyl (R) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a light yellow solid.\n\n\n\n\n\n\n \n12.2 : dichlorhydrate de (R)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle\n12.2: Methyl (R) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.3, à partir de 2,5g ( 7 mmoles) de (R)-3-tert-butoxycarbonylamino- 2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 2,3g (100%) du dichlorhydrate de (R)-3- amino-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus. \nIn a similar manner to Example 3.3, from 2.5 g (7 mmol) of methyl (R) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate, 2, 3 g (100%) of methyl (R) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride are obtained.\n\n\n\n\n\n\n \n12.3 : (R)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n12.3: Methyl (R) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 2,4g (8,4 mmoles) de chlorure de 4-benzyloxy- benzènesulfonyle (préparé comme décrit dans l'exemple 3.5) et de 2,3g (7,6 mmoles) de dichlorhydrate de (R)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 3g (77%) de (R)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide. \n In a similar manner to Example 3.6, from 2.4 g (8.4 mmol) of 4-benzyloxybenzenesulfonyl chloride (prepared as described in Example 3.5) and 2.3 g (7.6 mmol) of methyl (R) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride, 3 g (77%) of (R) -3- (4-benzyloxy-benzenesulfonylamino) -2 Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a solid.\n\n\n\n\n\n\n \n12.4 : (R)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n\n De manière analogue à l'exemple 5.1 , à partir de 3g (5,9 mmoles) de (R)-3-(4-benzyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 2g (80%) de (R)- 3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n12.4: Methyl (R) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate  In a manner similar to Example 5.1, starting from 3 g (5.9 mmol) of (R) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl, 2g (80%) of (R) - 3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n12.5 : (R) -2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \n12.5: Methyl-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 1g (2,4 mmoles) de (R)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle et de 500mg (2,6 mmoles) de 4-chlorométhyl-2-méthylquinoline, 740mg (53%) de (R) -2-(4-méthanesulfonyl-pipérazin- 1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide. \n In a manner similar to Example 5.2, from 1 g (2.4 mmol) of (R) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl and 500 mg (2.6 mmol) of 4-chloromethyl-2-methylquinoline, 740 mg (53%) of (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2) methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a solid.\n\n\n\n\n\n\n \n12.6 : acide (R) -2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique \n12.6: (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 740mg (1 ,3 mmoles) de (R) -2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 622mg (86%) d' acide (R) -2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique sont obtenus. \n Analogous to Example 3.7, from 740 mg (1.3 mmol) of (R) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (2-methyl-quinolin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate, 622 mg (86%) of (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained.\n\n\n\n\n\n\n \n12.7 : (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n12.7: (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 620mg (1 ,1 mmoles) d'acide (R) -2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 465mg (73%) de (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 3.8, from 620 mg (1.1 mmol) of (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid, 465 mg (73%) of (R) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] propionamide are obtained in the form of a white solid.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2.53 (m, 4H); 2,68 (s, 3H); 2,84 (s, 3H); 2,85 (m, 2H); 2,95-3,05 (m, 4H); 3,10 (m, 1 H); 5,72 (s, 2H); 7,35 (d, J=8,8Hz, 2H); 7,52 (m, 1 H); 7,57-7,62 (m, 2H); 7,75-7,82 (m, 3H); 7,98 (d, J=8,4Hz, 1 H); 8,11 (d, J=8,16Hz, 1 H); 8,93 (s, 1 H); 10,70 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.53 (m, 4H); 2.68 (s, 3H); 2.84 (s, 3H); 2.85 (m, 2H); 2.95-3.05 (m, 4H); 3.10 (m, 1H); 5.72 (s, 2H); 7.35 (d, J = 8.8 Hz, 2H); 7.52 (m, 1H); 7.57-7.62 (m, 2H); 7.75-7.82 (m, 3H); 7.98 (d, J = 8.4Hz, 1H); 8.11 (d, J = 8.16 Hz, 1H); 8.93 (s, 1H); 10.70 (s, 1H).\n\n\n\n\n\n\n \nExemple 13 : (S)-N-Hydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]- 2-piperazin-1 -yl-propionamide. \nExample 13: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide.\n\n\n\n\n\n\n \n13.1 : 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1 -carboxylate de benzyle: \nBenzyl 13.1: 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] ethyl} piperazine-1-carboxylate:\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 135mg ( 0,2 mmoles) de 4-{(S)-1-carboxy-2-[4-(2- méthyl-quinolin-4-ylméthoxybenzènesulfonylamino]-éthyl}-pipérazine-1 -carboxylate de benzyle (préparé comme décrit en 10.6), 1 15mg (82%) de 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin- \n\n 4-ylméthoxy)-benzènesulfonylannino]-éthyl}-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide blanc de point de fusion 162\n0\nC. \nIn a similar manner to Example 3.8, from 135 mg (0.2 mmol) of 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxybenzenesulfonylamino] -ethyl} benzyl -piperazine-1-carboxylate (prepared as described in 10.6), 15mg (82%) of 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin)}  Benzyl 4-ylmethoxy) -benzenesulfonylannino] ethyl} -piperazine-1-carboxylate are obtained in the form of a white solid having a melting point of 162 \n°\n C.\n\n\n\n\n\n\n \n13.2 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-pipérazin-1-yl- propionamide \n13.2: (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide\n\n\n\n\n\n\n \n 90mg (0,15 mmoles) de 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle sont placés en solution dans 5ml de dichlorométhane et 5ml d' acide trifluoroacétique. Le milieu réactionnel est ensuite agité à température ambiante pendant 96h. Après évaporation de l'acide trifluoroacétique, le résidu est repris 5ml de la solution aqueuse saturée d'hydrogénocarbonate de sodium et extrait au n-butanol. La phase organique est lavée à l'eau puis par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium filtrée et concentrée sous vide. Le produit brut obtenu est repris dans un mélange heptane/acétate d'éthyle 50/50, agité pendant 1 h puis filtré et séché sous vide. 50mg (70%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-pipérazin-1-yl- propionamide sont obtenus sous forme d'un solide beige de point de fusion 225\n0\nC. \n90 mg (0.15 mmol) of benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} -piperazine-1-carboxylate are placed in solution in 5 ml of dichloromethane and 5 ml of trifluoroacetic acid. The reaction medium is then stirred at room temperature for 96h. After evaporation of the trifluoroacetic acid, the residue is taken up in 5 ml of saturated aqueous sodium hydrogencarbonate solution and extracted with n-butanol. The organic phase is washed with water and then with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate filtered and concentrated in vacuo. The crude product obtained is taken up in a 50/50 heptane / ethyl acetate mixture, stirred for 1 h, then filtered and dried under vacuum. 50 mg (70%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide are obtained in the form of a beige solid of melting point 225 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,35-2,45 (m, 4H); 2,67 (s, 3H); 2,70 (m, 4H); 2,80-3,00 (m, 2H); 3,15 (s, 1 H); 5,72 (s, 2H); 7,35 (d, J=8,6Hz, 2H); 7,70-7,80 (m, 3H); 7,98 (d, J=8,4Hz, 1 H); 8,12 (d, J=8,2Hz, 1 H). \n \n1\n H NMR (δ, DMSO): 2.35-2.45 (m, 4H); 2.67 (s, 3H); 2.70 (m, 4H); 2.80-3.00 (m, 2H); 3.15 (s, 1H); 5.72 (s, 2H); 7.35 (d, J = 8.6 Hz, 2H); 7.70-7.80 (m, 3H); 7.98 (d, J = 8.4Hz, 1H); 8.12 (d, J = 8.2 Hz, 1H).\n\n\n\n\n\n\n \nExemple 14 : chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2- méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 14: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide hydrochloride.\n\n\n\n\n\n\n \n0,2ml (1 ,3 mmoles) d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5-6N sont ajoutés à une solution de 301 mg (0,5 mmoles) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide (préparé comme décrit dans l'exemple 14) dans 10ml d'isopropanol. Après agitation à température ambiante pendant 1 h, le produit précipite. Par filtration, 927mg du chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'une poudre blanche. Ce solide est recristallisé dans un mélange isopropanol- eau 30ml / 5ml. 176mg (52%) du chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- 3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'une poudre blanche de point de fusion 209\n0\nC. \n0.2 ml (1.3 mmol) of a solution of hydrochloric acid in isopropanol of concentration 5-6N are added to a solution of 301 mg (0.5 mmol) of (S) -N-hydroxy-2 (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide (prepared as described in Example 14) in 10 ml of isopropanol. After stirring at room temperature for 1 hour, the product precipitates. By filtration, 927 mg of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide hydrochloride are obtained in the form of a white powder. This solid is recrystallized from an isopropanol / water mixture 30 ml / 5 ml. 176 mg (52%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) - 3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] hydrochloride propionamide are obtained in the form of a white powder having a melting point of 209 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,67 (m, 4H); 2,87 (s, 3H); 2,93 (s, 3H); 3,00-3,15 (m, 4H); 3,22 (m, 1 H); 3,35- 3,90 (m, 2H); 5,94 (s, 2H); 7,42 (d, J=8,7Hz, 2H); 7,64 (m, 1 H); 7,83-7,90 (m, 3H); 7,98 (m, 1 H); 8,05 (m, 1 H); 8,30 (d, J=7,6Hz; 1 H); 8,38 (d, J=8,5Hz, 1 H); 9,00 (m, 1 H); 10,75 (m, 1 H). \n \n1\n H NMR (δ, DMSO): 2.67 (m, 4H); 2.87 (s, 3H); 2.93 (s, 3H); 3.00-3.15 (m, 4H); 3.22 (m, 1H); 3.35- 3.90 (m, 2H); 5.94 (s, 2H); 7.42 (d, J = 8.7 Hz, 2H); 7.64 (m, 1H); 7.83-7.90 (m, 3H); 7.98 (m, 1H); 8.05 (m, 1H); 8.30 (d, J = 7.6 Hz, 1H); 8.38 (d, J = 8.5 Hz, 1H); 9.00 (m, 1H); 10.75 (m, 1H).\n\n\n\n\n\n\n \nExemple 15 : 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de tert-butyle , di trifluoroacétate. \n\n 15.1 : 3-{4-[(S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-2-méthoxycarbonyl-éthylsulfamoyl]- phénoxyméthyl}-2-méthyl-indole-1-carboxylate de tert-butyle \nExample 15: tert-Butyl 3- {4 - [(S) -2-hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate , di trifluoroacetate.  15.1: tert-butyl 3- {4 - [(S) -2- (4-methanesulfonyl-piperazin-1-yl) -2-methoxycarbonyl-ethylsulfamoyl] phenoxymethyl} -2-methylindole-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 400mg (0,95 mmoles) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 5.1 ) et de 248mg (0,95 mmoles) de 3-hydroxyméthyl-2-méthyl-indole-1- carboxylate de tert-butyle commercial, 326mg (52%) de 3-{4-[(S)-2-(4-méthanesulfonyl-pipérazin-1-yl)- 2-méthoxycarbonyl-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de tert-butyle sont obtenus sous forme d'une poudre beige. 15.2 : 3-{4-[(S)-2-carboxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-éthylsulfamoyl]-phénoxymethyl}-2- méthyl-indole-1 -carboxylate de tert-butyle \n In a manner analogous to Example 11.1, from 400 mg (0.95 mmol) of (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl (prepared as described in Example 5.1) and 248 mg (0.95 mmol) of commercial tert-butyl 3-hydroxymethyl-2-methyl-indole-1-carboxylate, 326 mg (52%) of 3- {4 Tert-Butyl [(S) -2- (4-methanesulfonyl-piperazin-1-yl) -2-methoxycarbonyl-ethylsulfamoyl] -phenoxymethyl} -2-methyl-indole-1-carboxylate are obtained in the form of a beige powder. 15.2: 3- {4 - [(S) -2-carboxy-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-tert-butylcarboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 325mg (0,5 mmoles) de 3-{4-[(S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-2-méthoxycarbonyl-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole- 1 -carboxylate de tert-butyle, 179mg (100%) de 3-{4-[(S)-2-carboxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1 -carboxylate de tert-butyle sont obtenus sous forme d'une poudre jaune. \n Analogous to Example 3.7, from 325 mg (0.5 mmol) of 3- {4 - [(S) -2- (4-methanesulfonyl-piperazin-1-yl) -2-methoxycarbonyl-ethylsulfamoyl] tert-Butylphenylphenol-2-methyl-indole-1-carboxylate, 179 mg (100%) of 3- {4 - [(S) -2-carboxy-2- (4-methanesulfonyl-piperazin-1-yl) tert-butyl-ethylsulfamoyl] -phenoxymethyl-2-methyl-indole-1-carboxylate are obtained in the form of a yellow powder.\n\n\n\n\n\n\n \n15.3 : Ditrifluoroacétate de 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxymethyl}-2-méthyl-indole-1 -carboxylate de tert-butyle \n15.3: 3- {4 - [(S) -2-Hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate trifluoroacetate of tert- butyl\n\n\n\n\n\n\n \n45mg (0,3 mmoles) de O-tert-butyldiméthylsilylhydroxylamine en solution dans 1 ml de diméthylformamide sont ajoutés à une solution de 179mg (0,3 mmoles) de 3-{4-[(S)-2-carboxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-éthylsulfamoyl]-phénoxymethyl}-2-méthyl-indole-1 -carboxylate de tert- butyle, 41 mg (0,3 mmoles) de 1-hydroxybenzotriazole et 58mg (0,3 mmoles) du chlorhydrate de 1- éthyl-3-(3-diméthylaminopropyl) carbodiimide dans 3ml de diméthylformamide. Le mélange réactionnel est agité 18h à température ambiante. Après addition d'eau puis extraction à l'acétate d'éthyle, les phases organiques sont rassemblées, lavées avec une solution saturée d'hydrogénocarbonate de sodium puis séchées sur sulfate de sodium, filtrées et évaporées. Le résidu est purifié par HPLC préparative (colonne Gemini C6 phenyl, 150x3mm, 3μm ; détecteur UV : 190- 420nm ; débit : 0 ,3ml/mn ; solvant A : CH\n3\nCN + 0,02% acide trifluoroacétique ; solvant B : eau + 0,02% acide trifluoroacétique). \n45 mg (0.3 mmol) of O-tert-butyldimethylsilylhydroxylamine dissolved in 1 ml of dimethylformamide are added to a solution of 179 mg (0.3 mmol) of 3- {4 - [(S) -2-carboxy-2- Tert-butyl (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl-2-methyl-indole-1-carboxylate, 41 mg (0.3 mmol) of 1-hydroxybenzotriazole and 58 mg (0.3 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride in 3 ml of dimethylformamide. The reaction mixture is stirred for 18h at room temperature. After addition of water and extraction with ethyl acetate, the organic phases are combined, washed with saturated sodium hydrogencarbonate solution and then dried over sodium sulfate, filtered and evaporated. The residue is purified by preparative HPLC (Gemini C6 phenyl column, 150x3mm, 3μm, UV detector: 190-420nm, flow rate: 0.3ml / min, solvent A: CH \n3\n CN + 0.02% trifluoroacetic acid, solvent B: water + 0.02% trifluoroacetic acid).\n\n\n\n\n\n\n \nGradient : \nGradient:\n\n\n\n\n\n\n \n Temps Composition \n Composition time\n\n\n\n\n\n\n \n 0.0 min A = 5% B = 95% \n 0.0 min A = 5% B = 95%\n\n\n\n\n\n\n \n 20.0 min A = 98% B = 2% \n 20.0 min A = 98% B = 2%\n\n\n\n\n\n\n \n30.0 min A = 98% B = 2% \n30.0 min A = 98% B = 2%\n\n\n\n\n\n\n \n Temps de rétention : 14,6mn, M + 1 = 666,1. \n Retention time: 14.6 min, M + 1 = 666.1.\n\n\n\n\n\n\n \n Après concentration des différentes fractions, 21 mg (10%) de ditrifluoroacétate de 3-{4-[(S)-2- hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl- indole-1 -carboxylate de tert-butyle sont obtenus. \n\n Exemple 16 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-yl méthoxy)-benzènesulfonylamino]-propionamide. \nAfter concentration of the various fractions, 21 mg (10%) of 3- {4 - [(S) -2-hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} ditrifluoroacetate 1-methyl-indole-1-tert-butylcarboxylate are obtained.  Example 16: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n16.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle \n16.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 440mg (2,5 mmoles) de 4-chlorométhyl-quinoline et de 950mg (2,2 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin- 1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ), 550mg (43%) de (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \n In a manner analogous to Example 5.2, starting with 440 mg (2.5 mmol) of 4-chloromethylquinoline and 950 mg (2.2 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) -2 Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 5.1), 550 mg (43%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- Methyl 4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained as a colorless oil.\n\n\n\n\n\n\n \n16.2 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque \n16.2: (S) -2- (4-Methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 550mg (1 ,0 mmole) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 450mg (83%) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide blanc . \n Analogous to Example 3.7, from 550 mg (1.0 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy)). methyl benzenesulfonylamino] propanoate, 450 mg (83%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) benzenesulfonylamino] - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n16.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n16.3: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 450mg (0,8 mmoles) d' acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoïque 260mg (56%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 18O\n0\nC. \nIn a manner similar to Example 3.8, from 450 mg (0.8 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-) ylmethoxy) -benzenesulfonylamino] -propanoic acid 260mg (56%) (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) benzenesulfonylamino] -propionamide are obtained in the form of a white solid of melting point 18O \n0\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,52-2,54 (m, 4H); 2,84 (s, 3H); 2,87 (m, 1 H); 2,97 (m, 1 H); 2,98-3,05 (m, 4H), 3,11 (t, J=7Hz, 1 H); 5,78 (s, 2H); 7,34 (d, J=8,8Hz, 2H); 7,52 (m, 1 H); 7,66-7,72 (m, 2H); 7,78-7,84 (m, 3H); 8,10 (d, J=8,3Hz, 1 H); 8,19 (d, J=8,2Hz, 1 H); 8,93 (s, 1 H); 8,94 (s, 1 H); 10,67 (s, 1 H). Exemple 17 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 2.52-2.54 (m, 4H); 2.84 (s, 3H); 2.87 (m, 1H); 2.97 (m, 1H); 2.98-3.05 (m, 4H), 3.11 (t, J = 7Hz, 1H); 5.78 (s, 2H); 7.34 (d, J = 8.8 Hz, 2H); 7.52 (m, 1H); 7.66-7.72 (m, 2H); 7.78-7.84 (m, 3H); 8.10 (d, J = 8.3 Hz, 1H); 8.19 (d, J = 8.2 Hz, 1H); 8.93 (s, 1H); 8.94 (s, 1H); 10.67 (s, 1H). Example 17: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n 17.1 : Sel de sodium de l'acide 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonique \n 17.1: Sodium salt of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonic acid\n\n\n\n\n\n\n \n 100g (438 mmoles) du chlorhydrate de 4-chlorométhyl-2-méthyl-quinoline sont additionnés sur une solution de 77g (395 mmoles) du sel de sodium de l'acide 4-hydroxy-benzènesulfonique et de 84ml (84 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M dans 800ml d'isopropanol. Le milieu réactionnel est chauffé à 7O\n0\nC pendant 5h puis à 4O\n0\nC pendant 18h. \n100 g (438 mmol) of 4-chloromethyl-2-methyl-quinoline hydrochloride are added to a solution of 77 g (395 mmol) of the sodium salt of 4-hydroxy-benzenesulfonic acid and 84 ml (84 mmol) of an aqueous solution of 1 M sodium hydroxide in 800 ml of isopropanol. The reaction medium is heated at 70 \n°\n C. for 5 h and then at 40 \n°\n C. for 18 h.\n\n\n\n\n\n\n \nAprès évaporation de l'isopropanol, le produit obtenu est filtré, rincé à l'isopropanol et à l'éther diéthylique puis séché sous vide. 114g (75%) du sel de sodium de l'acide 4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonique sont obtenus sous forme d'un solide blanc . \n\n17.2 : Chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle \nAfter evaporation of the isopropanol, the product obtained is filtered, rinsed with isopropanol and diethyl ether and then dried under vacuum. 114 g (75%) of the sodium salt of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonic acid are obtained as a white solid.  17.2: 4- (2-Methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride\n\n\n\n\n\n\n \n 76g (216 mmoles) du sel de sodium de l'acide 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonique dans 500ml de diméthylformamide sont additionnés goutte à goutte à une solution de 55ml (649 mmoles) de chlorure d'oxalyle dans 100ml de dichlorométhane, préalablement refroidie à -1O\n0\nC. Après addition, le milieu réactionnel est agité à température ambiante pendant 18h. Le milieu réactionnel est ensuite versé dans 11 de glace puis extrait à l'acétate d'éthyle. Les phases organiques sont rassemblées, lavées à l'eau puis avec une solution aqueuse saturée de chlorure de sodium, séchées de sulfate de magnésium, filtrées et concentrées sous vide. 77g (92%) du chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle sont obtenus sous forme d'un solide beige . \n76 g (216 mmol) of the sodium salt of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonic acid in 500 ml of dimethylformamide are added dropwise to a solution of 55 ml (649 mmol) of sodium chloride. oxalyl in 100ml of dichloromethane, previously cooled to -1O \n0\n C. After addition, the reaction mixture is stirred at room temperature for 18h. The reaction medium is then poured into ice and then extracted with ethyl acetate. The organic phases are combined, washed with water and then with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. 77 g (92%) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride are obtained as a beige solid.\n\n\n\n\n\n\n \n17.3 : benzyl-bis-(2-chloro-éthyl)-amine \n17.3: benzyl-bis- (2-chloro-ethyl) -amine\n\n\n\n\n\n\n \n 21g (152 mmoles) de carbonate de potassium puis 8ml (67 mmoles) de bromure de benzyle sont ajoutés à une solution de 10g (56 mmoles) de chlorhydrate de bis-(2-chloro-éthyl)-amine dans 130ml d'acétonitrile puis le milieu réactionnel est chauffé à 6O\n0\nC pendant 24h. Après filtration, le filtrat est concentré sous vide. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 90/10 pour donner 8,5g (65%) de benzyl-bis-(2-chloro-éthyl)-amine. \n21 g (152 mmol) of potassium carbonate and then 8 ml (67 mmol) of benzyl bromide are added to a solution of 10 g (56 mmol) of bis (2-chloroethyl) amine hydrochloride in 130 ml of acetonitrile then the reaction medium is heated at 60 \n°\n C. for 24 hours. After filtration, the filtrate is concentrated in vacuo. The crude residue is purified by chromatography on silica gel eluted with a 90/10 heptane / ethyl acetate mixture to give 8.5 g (65%) of benzyl-bis- (2-chloro-ethyl) -amine.\n\n\n\n\n\n\n \n17.4 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle \n17.4: methyl (S) -2- (4-benzylpiperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate\n\n\n\n\n\n\n \nUne solution de 5,9g (23 mmoles) du chlorhydrate de (S)-2-amino-3-tert-butoxycarbonylamino- propanoate de méthyle commercial et de 9,6g (23 mmoles) de benzyl-bis-(2-chloro-éthyl)-amine dans 50ml de N,N-diisopropyléthylamine est chauffée à 127\n0\nC pendant 3h30. Après évaporation de la N, N- diisopropyléthylamine, le milieu réactionnel est hydrolyse puis extrait par de l'acétate d'éthyle. La phase organique est lavée par une solution aqueuse d'hydroxyde de sodium de concentration 1 N, par de l'eau puis séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 50/50. 8,9g (64%) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle sont obtenus sous forme d'une huile jaune. 17.5 : trichlorhydrate de (S)-3-amino-2-(4-benzyl-pipérazin-1-yl)-propanoate de méthyle \nA solution of 5.9 g (23 mmol) of commercial methyl (S) -2-amino-3-tert-butoxycarbonylaminopropanoate hydrochloride and 9.6 g (23 mmol) of benzyl-bis (2-chloro) ethyl) amine in 50 ml of N, N-diisopropylethylamine is heated at 127 \n°\n C. for 3 h 30 min. After evaporation of the N, N-diisopropylethylamine, the reaction medium is hydrolyzed and then extracted with ethyl acetate. The organic phase is washed with an aqueous sodium hydroxide solution of 1 N concentration, with water then dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 8.9 g (64%) of methyl (S) -2- (4-benzyl-piperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate are obtained in the form of a yellow oil. 17.5: Methyl (S) -3-amino-2- (4-benzylpiperazin-1-yl) -propanoate trihydrochloride\n\n\n\n\n\n\n \n 8,9g ( 23,5 mmoles) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle sont placés en solution dans 60ml de méthanol et dans 20ml d'acide chlorhydrique isopropanolique de concentration 5-6N . Le milieu réactionnel est agité à 4O\n0\nC pendant 18h puis concentré sous vide. 9,0g (100%) du trichlorhydrate de (S)-3-amino-2-(4-benzyl-pipérazin-1-yl)- propanoate de méthyle sont obtenus sous forme d'un solide beige. \n8.9 g (23.5 mmol) of methyl (S) -2- (4-benzyl-piperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate are placed in solution in 60 ml of methanol and in 20 ml of isopropanolic hydrochloric acid 5-6N concentration. The reaction medium is stirred at 40 \n°\n C. for 18 h and then concentrated in vacuo. 9.0 g (100%) of methyl (S) -3-amino-2- (4-benzylpiperazin-1-yl) -propanoic trihydrochloride are obtained in the form of a beige solid.\n\n\n\n\n\n\n \n17.6 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle. \n17.6: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionic acid methyl ester.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,0g (2,6 mmoles) du trichlorhydrate de (S)-3-amino- 2-(4-benzyl-pipérazin-1-yl)-propanoate de méthyle et de 1 ,1g (2,8 mmoles) de chlorure de 4-(2- \n\n méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle sous forme de chlorohydrate, 750mg (50%) de (S)-2- (4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide beige. 17.7 : acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoïque. \nAnalogously to Example 3.6, from 1.0 g (2.6 mmol) of methyl (S) -3-amino-2- (4-benzylpiperazin-1-yl) -propanoate trihydrochloride and of 1.1 g (2.8 mmol) of 4- (2-  methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chlorohydrate form, 750mg (50%) (S) -2- (4-benzyl-piperazin-1-yl) -3- [4- (2-methyl-quinoline) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained as a beige solid. 17.7: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 750mg (1 ,3 mmoles) de (S)-2-(4-benzyl-pipérazin-1- yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 680mg (93%) d'acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoïque sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 3.7, from 750 mg (1.3 mmol) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-methyl-quinolin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate, 680 mg (93%) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) -benzenesulfonylamino] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n17.8 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n17.8: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 680mg (1 ,2 mmoles) d'acide (S)-2-(4-benzyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique, 250mg\n In a similar manner to Example 3.8, from 680 mg (1.2 mmol) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic, 250mg\n\n\n\n\n\n\n \n(36%) de (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion\n(36%) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white solid of melting point\n\n\n\n\n\n\n \n188\n0\nC. \n188 \n0\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,33 (m, 4H); 2,49 (m, 4H); 2,73 (s, 3H); 2,80-2,90 (m, 1 H); 3,00-3,10 (m, 2H); 2,46 (m, 2H); 5,77 (s, 2H); 7,25-7,40 (m, 7H); 7,50(m, 1 H); 7,61-7,67 (m, 2H); 7,78-7,85 (m, 3H); 8,04\n \n1\n H NMR (δ, DMSO): 2.33 (m, 4H); 2.49 (m, 4H); 2.73 (s, 3H); 2.80-2.90 (m, 1H); 3.00-3.10 (m, 2H); 2.46 (m, 2H); 5.77 (s, 2H); 7.25-7.40 (m, 7H); 7.50 (m, 1H); 7.61-7.67 (m, 2H); 7.78-7.85 (m, 3H); 8.04\n\n\n\n\n\n\n \n(d, J=8Hz, 1 H); 8,17 (d, J=8,2Hz, 1 H); 8,95 (s, 1 H); 10,65 (s, 1 H). \n(d, J = 8Hz, 1H); 8.17 (d, J = 8.2 Hz, 1H); 8.95 (s, 1H); 10.65 (s, 1H).\n\n\n\n\n\n\n \nExemple 18 : (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 18: (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n18.1 : bis-(2-chloro-éthyl)-(4-fluoro-benzyl)-amine \n18.1: bis- (2-chloro-ethyl) - (4-fluoro-benzyl) -amine\n\n\n\n\n\n\n \n De manière analogue à l'exemple 17.3, à partir de 5g (28 mmoles) du chlorhydrate de bis-(2-chloro- éthyl)-amine et de 3,8ml (31 mmoles) de 1-bromométhyl-4-fluoro-benzène, 6,9g (98%) de bis-(2- chloro-éthyl)-(4-fluoro-benzyl)-amine sont obtenus. \n In a similar manner to Example 17.3, from 5 g (28 mmol) of bis (2-chloroethyl) amine hydrochloride and 3.8 ml (31 mmol) of 1-bromomethyl-4-fluoro-benzene 6.9 g (98%) of bis- (2-chloro-ethyl) - (4-fluoro-benzyl) -amine are obtained.\n\n\n\n\n\n\n \n18.2 : (S)-3-tert-butoxycarbonylamino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle\n18.2: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propanoate\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.4, à partir de 7,1g (28 mmoles) du chlorhydrate de (S)-2-amino- 3-tert-butoxycarbonylamino-propanoate de méthyle et de 6,9g (28 mmoles) de bis-(2-chloro-éthyl)-(4- fluoro-benzyl)-amine, 5,3g (48%) de (S)-3-tert-butoxycarbonylamino-2-[4-(4-fluoro-benzyl)-pipérazin-1- yl]-propanoate de méthyle sont obtenus sous forme d'une huile. \nIn a manner analogous to Example 17.4, starting from 7.1 g (28 mmol) of methyl (S) -2-amino-3-tert-butoxycarbonylamino-propanoate hydrochloride and 6.9 g (28 mmol) of bis - (2-chloro-ethyl) - (4-fluoro-benzyl) -amine, 5.3 g (48%) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-fluoro-benzyl) - Methyl piperazin-1-yl] -propanoate is obtained in the form of an oil.\n\n\n\n\n\n\n \n18.3 : trichlorhydrate de (S)-3-amino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle\n18.3: Methyl (S) -3-amino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propanoate trihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.5, à partir de 5,3g (13,4 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propanoate de méthyle, 5,4g (100%) de \n\n trichlorhydrate de (S)-3-amino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide beige. \nAnalogous to Example 17.5, from 5.3 g (13.4 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl) ] methylpropanoate, 5.4g (100%) of  Methyl (S) -3-amino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propanoate trihydrochloride are obtained as a beige solid.\n\n\n\n\n\n\n \n18.4 : (S)-2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \n18.4 Methyl (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,5g ( 3,7 mmoles) du trichlorhydrate de (S)-3- amino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle et de 1 ,6g (4, I mmoles) de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle chlorohydrate (préparé comme décrit en 17.2), 1 ,0g (46%) de (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n Analogously to Example 3.6, from 1.5 g (3.7 mmol) of (S) -3-amino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl trihydrochloride Methyl propanoate and 1.6 g (4.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in 17.2), 1.0 g (46%) Methyl (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n18.5 : acide (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque \n18.5: (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 1 ,1g (1 ,7 mmoles) de (S)-2-[4-(4-fluoro-benzyl)- pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle 1 ,0g (100%) d'acide (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 1.1 g (1.7 mmol) of (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4] Methyl (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoate 1.0 g (100%) of (S) -2- [4- (4-fluoro-benzyl) -piperazin-1- (4-fluoro-benzyl) -piperazin) yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained as a white solid.\n\n\n\n\n\n\n \n18.6 : (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n18.6: (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, 990mg (1 ,7 mmoles) d'acide (S)-2-[4-(4-fluoro-benzyl)- pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique, 330mg\n Analogous to Example 3.8, 990 mg (1.7 mmol) of (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4- methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid, 330mg\n\n\n\n\n\n\n \n(33%) de (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 18O\n0\nC. \n(33%) (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) - benzenesulfonylamino] -propionamide are obtained in the form of a white solid of melting point 18O \n0\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,20-2-30 (m, 4H); 2,35-2,45 (m, 4H); 2,66 (s, 3H); 2,72-2,80 (m, 1 H); 2,87-3,00 (m, 2H); 3,38 (s, 2H); 5,70 (s, 2H); 7,10 (t, J=8,8Hz, 2H); 7,26-7,33 (m, 4H); 7,56-7,60(m, 2H); 7,73- 7,78 (m, 3H); 7,97 (d, J=8,4Hz, 1 H); 8,10 (d, J=8,2Hz, 1 H). Exemple 19 : (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-yl-méthoxy)- benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 2,20-2-30 (m, 4H); 2.35-2.45 (m, 4H); 2.66 (s, 3H); 2.72-2.80 (m, 1H); 2.87-3.00 (m, 2H); 3.38 (s, 2H); 5.70 (s, 2H); 7.10 (t, J = 8.8 Hz, 2H); 7.26-7.33 (m, 4H); 7.56-7.60 (m, 2H); 7.73-7.78 (m, 3H); 7.97 (d, J = 8.4Hz, 1H); 8.10 (d, J = 8.2 Hz, 1H). Example 19: (S) -2- (4-Ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-yl-methoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n19.1 : bis-(2-chloro-éthyl)-éthyl-amine \n19.1: bis- (2-chloro-ethyl) -ethyl-amine\n\n\n\n\n\n\n \n 24ml (330 mmoles) de chlorure de thionyle sont additionnés goutte à goutte à une solution de 20g (150 mmoles) de 2-[éthyl-(2-hydroxy-éthyl)-amino]-éthanol dans 200ml de dichlorométhane préalablement refroidie à O\n0\nC puis le milieu réactionnel est agité à température ambiante pendant 2Oh. Après addition d'une solution aqueuse saturée d'hydrogénocarbonate de sodium, le produit est extrait au dichlorométhane. La phase organique obtenue est ensuite lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. 19,5g (76%) de bis-(2-chloro-éthyl)-éthyl-amine sous la forme d'une huile. \n\n 19.2 : (S)-3-tert-butoxycarbonylamino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle\n24 ml (330 mmol) of thionyl chloride are added dropwise to a solution of 20 g (150 mmol) of 2- [ethyl- (2-hydroxyethyl) amino] ethanol in 200 ml of dichloromethane previously cooled to \n0.degree.\n And then the reaction medium is stirred at room temperature for 20 h. After addition of a saturated aqueous sodium hydrogencarbonate solution, the product is extracted with dichloromethane. The organic phase obtained is then washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo. 19.5 g (76%) of bis (2-chloroethyl) ethylamine in the form of an oil.  19.2: Methyl (S) -3-tert-butoxycarbonylamino-2- (4-ethyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \nUne solution de 5,0g (19,6 mmoles) de chlorhydrate de (S)-2-amino-3-tert-butoxycarbonylannino- propanoate de méthyle commercial et 3,3g (19,6 mmoles) de bis-(2-chloro-éthyl)-éthyl-amine dans 50ml de N,N-diisopropyléthylamine est chauffée à 127\n0\nC pendant 5h. Après évaporation d'un maximum de diisopropyléthylamine, le milieu réactionnel est dilué par de l'acétate d'éthyle, lavé avec une solution aqueuse d'hydroxyde de sodium de concentration 1 N. La phase organique obtenue est ensuite lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 30/70. 2,5g (40%) de (S)-3-tert-butoxycarbonylamino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'une huile. \nA solution of 5.0 g (19.6 mmol) of commercial methyl (S) -2-amino-3-tert-butoxycarbonylaminopropanoate hydrochloride and 3.3 g (19.6 mmol) of bis (2-chloro) -ethyl-ethyl-amine in 50ml of N, N-diisopropylethylamine is heated at 127 \n0\n C for 5h. After evaporation of a maximum of diisopropylethylamine, the reaction medium is diluted with ethyl acetate, washed with an aqueous solution of sodium hydroxide of 1N concentration. The organic phase obtained is then washed with water, dried over magnesium sulphate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 30/70 heptane / ethyl acetate mixture. 2.5 g (40%) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-ethyl-piperazin-1-yl) -propanoate are obtained in the form of an oil.\n\n\n\n\n\n\n \n19.3 : trichlorhydrate de (S)-3-amino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle \n19.3: methyl (S) -3-amino-2- (4-ethyl-piperazin-1-yl) -propanoic trihydrochloride\n\n\n\n\n\n\n \n 2,5g (7,9 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle sont placés dans 20ml de méthanol et 10ml d'acide chlorhydrique isopropanolique de concentration 5-6N. Le milieu réactionnel est chauffé à 4O\n0\nC pendant 3h puis évaporé à sec. Le résidu est repris dans 50ml d'éthanol, agité 1 h à température ambiante puis filtré. 1 ,4g (54%) de trichlorhydrate de (S)-3-amino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide beige. \n2.5 g (7.9 mmol) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-ethyl-piperazin-1-yl) -propanoate are placed in 20 ml of methanol and 10 ml of isopropanol hydrochloric acid. 5-6N concentration. The reaction medium is heated at 40 \n°\n C. for 3 h and then evaporated to dryness. The residue is taken up in 50 ml of ethanol, stirred for 1 h at room temperature and then filtered. 1.4 g (54%) of methyl (S) -3-amino-2- (4-ethyl-piperazin-1-yl) -propanoic trihydrochloride are obtained in the form of a beige solid.\n\n\n\n\n\n\n \n19.4 : (S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle \n19.4 Methyl (S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 700mg ( 2,1 mmoles) du trichlorhydrate de (S)-3- amino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle et de 900mg (2,3 mmoles) du chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit en 17.2), 740mg (67%) de (S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 3.6, from 700 mg (2.1 mmol) of methyl (S) -3-amino-2- (4-ethyl-piperazin-1-yl) -propanoic trihydrochloride and 900 mg of (2.3 mmol) 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in 17.2), 740 mg (67%) of (S) -2- (4-ethyl) Methyl -piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n19.5 : acide ((S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque \n19.5: ((S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir 740mg (1 ,4 mmoles) de (S)-2-(4-éthyl-pipérazin-1-yl)-3- [4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 630mg (87%) d'acide ((S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoïque sont obtenus sous forme d'un solide blanc. \n Analogously to Example 3.7, from 740 mg (1.4 mmol) of (S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4) Methyl (methoxy) -benzenesulfonylamino] -propanoate, 630 mg (87%) of ((S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) -benzenesulfonylamino] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n19.6 : (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n19.6: (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 630mg (1 ,2 mmoles) d'acide (S)-2-(4-éthyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique, 60mg (8%) \n\n de (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène- sulfonylamino]-propionannide sont obtenus sous forme d'un solide blanc de point de fusion 15O\n0\nC. RMN \n1\nH (δ, DMSO) : 2,49 (s, 3H); 2,55-2,65 (m, 2H); 2,69 (s, 3H); 2,70-2,90 (m, 6H); 2,90-3,00 (m, 2H); 3,13 (t, J=7,3Hz, 1 H); 3,20-3,35 (m, 2H); 3,36 (s, 2H); 5,72 (s, 2H); 7,35 (d, J=8,9Hz, 2H); 7,58- 7,62 (m, 3H); 7,74-7,81 (m, 3H); 7,98 (d, J=7,9Hz, 1 H); 8,12 (d, J=8,3Hz, 1 H); 9,03 (s, 1 H), 10,82 (s, 1 H). \nIn a similar manner to Example 3.8, from 630 mg (1.2 mmol) of (S) -2- (4-ethylpiperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid, 60mg (8%)  (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionannide are obtained in the form of a white solid of melting point 150 \n°\n C. \n1\n H NMR (δ, DMSO): 2.49 (s, 3H); 2.55-2.65 (m, 2H); 2.69 (s, 3H); 2.70-2.90 (m, 6H); 2.90-3.00 (m, 2H); 3.13 (t, J = 7.3 Hz, 1H); 3.20-3.35 (m, 2H); 3.36 (s, 2H); 5.72 (s, 2H); 7.35 (d, J = 8.9Hz, 2H); 7.58-7.62 (m, 3H); 7.74-7.81 (m, 3H); 7.98 (d, J = 7.9Hz, 1H); 8.12 (d, J = 8.3 Hz, 1H); 9.03 (s, 1H), 10.82 (s, 1H).\n\n\n\n\n\n\n \nExemple 20 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- 2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propionamide. \nExample 20: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- (4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propionamide.\n\n\n\n\n\n\n \n20.1 : bis-(2-chloro-éthyl)-(4-thfluorométhyl-benzyl)-amine \n20.1: bis- (2-chloro-ethyl) - (4-thfluoromethyl-benzyl) -amine\n\n\n\n\n\n\n \n De manière analogue à l'exemple 32.3, à partir 5,0g (28 mmoles) du chlorhydrate bis-(2-chloro-éthyl)- amine et de 7,4g (31 mmoles) de 1-bromométhyl-4-trifluorométhyl-benzène, 5g (59%) d'un mélange de bis-(2-chloro-éthyl)-(4-trifluorométhyl-benzyl)-amine sont obtenus sous forme d'une huile incolore. \n In a similar manner to Example 32.3, starting from 5.0 g (28 mmol) of bis (2-chloroethyl) amine hydrochloride and 7.4 g (31 mmol) of 1-bromomethyl-4-trifluoromethylbenzene. 5 g (59%) of a mixture of bis- (2-chloro-ethyl) - (4-trifluoromethyl-benzyl) -amine are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n20.2 : (S)-3-tert-butoxycarbonylamino-2-[4-(4-thfluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle \n20.2: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-thfluoromethyl-benzyl) -piperazin-1-yl] -propanoate\n\n\n\n\n\n\n \n Une solution de 4,2g (16,5 mmoles) du chlorhydrate de (S)-2-amino-3-tert-butoxycarbonylamino- propanoate de méthyle et 4,95g (16,5 mmoles) de bis-(2-chloro-éthyl)-(4-trifluorométhyl-benzyl)-amine dans 25ml de N,N-Diisopropyléthylamine est chauffée à 127\n0\nC pendant 6h. Après évaporation d'un maximum de diisopropyléthylamine, le milieu réactionnel est dilué avec de l'acétate d'éthyle et lavé par une solution aqueuse d'hydroxyde de sodium de concentration 1 N. La phase organique obtenue est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 60/40. 4,0g (55%) de (S)-3-tert-butoxycarbonylamino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]- propanoate de méthyle sont obtenus sous forme d'une huile. \nA solution of 4.2 g (16.5 mmol) of methyl (S) -2-amino-3-tert-butoxycarbonylaminopropanoate hydrochloride and 4.95 g (16.5 mmol) of bis (2-chloro) ethyl) - (4-trifluoromethyl-benzyl) -amine in 25ml of N, N-Diisopropylethylamine is heated at 127 \n0\n C for 6h. After evaporation of a maximum of diisopropylethylamine, the reaction medium is diluted with ethyl acetate and washed with a 1N aqueous solution of sodium hydroxide. The organic phase obtained is washed with water and dried. on magnesium sulfate, filtered and concentrated in vacuo. The crude residue is purified by chromatography on silica gel eluted with a 60/40 heptane / ethyl acetate mixture. 4.0 g (55%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate are obtained in the form of an oil.\n\n\n\n\n\n\n \n20.3 : trichlorhydrate de (S)-3-amino-2-[4-(4-thfluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle \n20.3: Methyl (S) -3-amino-2- [4- (4-thfluoromethyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.5, à partir de 4g (9,1 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle, 3,8g (93%) de trichlorhydrate de (S)-3-amino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous la forme d'un solide beige. 20.4 : (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)- pipérazin-1 -yl]-propanoate de méthyle \nAnalogously to Example 17.5, from 4 g (9.1 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - methyl propanoate, 3.8 g (93%) of methyl (S) -3-amino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride are obtained in the form of a beige solid. Methyl 20.4: (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) piperazin-1-yl] propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,0g ( 2,2 mmoles ) de trichlorhydrate de (S)-3- amino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle et de 1 ,2g (3,1 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 910mg (65%) de (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- \n\n benzènesulfonylannino]-2-[4-(4-trifluoronnéthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \nIn a similar manner to Example 3.6, from 1.0 g (2.2 mmol) of (S) -3-amino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl) dihydrochloride ] -methyl propanoate and 1.2 g (3.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 910 mg (65%). %) of (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -  Benzenesulfonylannino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n20.5 : acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-thfluorométhyl- benzyl)-pipérazin-1-yl]propanoïque \n20.5: (S) -3- [4- (2-Methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-thfluoromethyl-benzyl) -piperazin-1-yl] propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 910mg (1 ,4 mmoles) de (S)-3-[4-(2-méthyl-quinolin-\n In a similar manner to Example 3.7, from 910 mg (1.4 mmol) of (S) -3- [4- (2-methyl-quinolin)\n\n\n\n\n\n\n \n4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle, 790mg (88%) d'acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-\nMethyl 4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate, 790 mg (88%) of (S) -3- [4- 2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4-\n\n\n\n\n\n\n \n(4-trifluorométhyl-benzyl)-pipérazin-1-yl]propanoïque sont obtenus sous forme d'un solide blanc. \n(4-Trifluoromethyl-benzyl) -piperazin-1-yl] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n20.6 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4- trifluorométhyl-benzyl)-pipérazin-1-yl]-propionamide \n20.6: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 790mg (1 ,2 mmoles) d'acide (S)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]- propanoique, 550mg (68%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 148\n0\nC. \nIn a manner analogous to Example 3.8, starting from 790 mg (1.2 mmol) of (S) -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-Trifluoromethyl-benzyl) -piperazin-1-yl] -propanoic acid, 550 mg (68%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-Trifluoromethyl-benzyl) -piperazin-1-yl] -propionamide are obtained in the form of a white solid with a melting point of 148 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,21 (m, 4H); 2,38 (m, 4H); 2,58 (s, 3H); 2,69-2,75 (m, 1 H); 2,85-2,93 (m, 1 H);\n \n1\n H NMR (δ, DMSO): 2.21 (m, 4H); 2.38 (m, 4H); 2.58 (s, 3H); 2.69-2.75 (m, 1H); 2.85-2.93 (m, 1H);\n\n\n\n\n\n\n \n2,93-2,98 (m, 1 H); 3,42 (s, 2H); 5,63 (s, 2H); 7,25 (d, J=9Hz, 2H); 7,40 (d, J=8Hz, 3H); 7,47-7,53 (m, 2H); 7,57 (d, J=8,1 Hz, 2H); 7,65-7,72 (m, 3H); 7,90 (d, J=7,9Hz, 1 H); 8,03 (d, J=7,8Hz, 1 H); 8,83 (s,\n2.93-2.98 (m, 1H); 3.42 (s, 2H); 5.63 (s, 2H); 7.25 (d, J = 9Hz, 2H); 7.40 (d, J = 8Hz, 3H); 7.47-7.53 (m, 2H); 7.57 (d, J = 8.1 Hz, 2H); 7.65-7.72 (m, 3H); 7.90 (d, J = 7.9 Hz, 1H); 8.03 (d, J = 7.8 Hz, 1H); 8.83 (s,\n\n\n\n\n\n\n \n1 H), 10,56 (s, 1 H). \n1H), 10.56 (s, 1H).\n\n\n\n\n\n\n \nExemple 21 : (S)-N-hydroxy-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 21: (S) -N-Hydroxy-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n21.1 : bis-(2-chloro-éthyl)-(4-méthyl-benzyl)-amine \n21.1: bis- (2-chloro-ethyl) - (4-methyl-benzyl) -amine\n\n\n\n\n\n\n \n De manière analogue à l'exemple 17.3, à partir de 5,0g (28 mmoles) du chlorhydrate de bis-(2-chloro- éthyl)-amine et de 5,7g (31 mmoles) de 1-bromométhyl-4-méthyl-benzène, 4,9g (71 %) de bis-(2- chloro-éthyl)-(4-méthyl-benzyl)-amine sont obtenus. \n In a similar manner to Example 17.3, starting from 5.0 g (28 mmol) of bis (2-chloroethyl) amine hydrochloride and 5.7 g (31 mmol) of 1-bromomethyl-4-methyl benzene, 4.9 g (71%) of bis- (2-chloro-ethyl) - (4-methyl-benzyl) -amine are obtained.\n\n\n\n\n\n\n \n212 : (S)-3-tert-butoxycarbonylamino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle De manière analogue à l'exemple 17.4, à partir de 5,1g (20 mmoles) du chlorhydrate de (S)-2-amino- 3-tert-butoxycarbonylamino-propanoate de méthyle commercial et de 4,9g (20 mmoles) de bis-(2- chloro-éthyl)-(4-méthyl-benzyl)-amine, 4,1g (53%) de (S)-3-tert-butoxycarbonylamino-2-[4-(4-méthyl- benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile. 13 : trichlorhydrate de (S)-3-amino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle\n212: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate Analogously to Example 17.4, starting from 5.1 g (20 mmol) commercial methyl (S) -2-amino-3-tert-butoxycarbonylamino-propanoate hydrochloride and 4.9 g (20 mmol) bis (2-chloro-ethyl) - (4-methyl); benzyl) -amine, 4.1 g (53%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-methylbenzyl) piperazin-1-yl] -propanoate are obtained in the form of of an oil. 13: Methyl (S) -3-amino-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 19.3, à partir de 4,1g (10,5 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle, 3,95g (94%) de \n\n trichlorhydrate de (S)-3-amino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide crème. \nAnalogous to Example 19.3, from 4.1 g (10.5 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-methyl-benzyl) -piperazin-1-yl) ] -methyl propanoate, 3.95g (94%) of  Methyl (S) -3-amino-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride are obtained as a cream solid.\n\n\n\n\n\n\n \n214 : (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-méthyl-benzyl)- pipérazin-1 -yl]-propanoate de méthyle. \n214: Methyl (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-methyl-benzyl) piperazin-1-yl] -propanoate.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,0g (2,5 mmoles) du trichlorhydrate de (S)-3- amino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle et de 1 ,3g (3,5 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 950mg (63%) de (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 3.6, from 1.0 g (2.5 mmol) of (S) -3-amino-2- [4- (4-methyl-benzyl) -piperazin-1-yl trihydrochloride ] -methyl propanoate and 1.3 g (3.5 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 950 mg (63%). %) Methyl (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n215 : acide ((S)-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque. \n215: ((S) -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid.\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 950mg (1 ,6 mmoles) de (S)-2-[4-(4-méthyl-benzyl)- pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle, 880mg (95%) d'acide ((S)-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide crème. 216 : (S)Η-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-méthyl- benzyl)-pipérazin-1-yl]-propionamide. \nAnalogous to Example 3.7, from 950 mg (1.6 mmol) of (S) -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- ( Methyl 2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate, 880 mg (95%) of ((S) -2- [4- (4-methyl-benzyl) -piperazin-1-yl] 3- [4- (2-Methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid are obtained in the form of a cream solid 216: (S) Η-hydroxy-3- [4- (2-methyl) -quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-methylbenzyl) piperazin-1-yl] propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 880mg (1 ,5 mmoles) d'acide (S)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)benzènesulfonylamino]-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoique, 150mg (17%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4- méthyl-benzyl)-pipérazin-1-yl]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 17O\n0\nC. \nIn a manner similar to Example 3.8, starting from 880 mg (1.5 mmol) of (S) -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoic acid, 150 mg (17%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propionamide are obtained in the form of a white solid with a melting point of 170 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,25 (m, 4H); 2,25 (s, 3H); 2,43 (m, 4H); 2,67 (s, 3H); 2,80 (m, 1 H); 2,95-3,05 (m, 2H); 3,37 (m, 2H); 5,71 (s, 2H); 7,10 (q, J=8Hz, 4H); 7,33 (d, J=8,9Hz, 2H); 7,43 (m, 1 H); 7,56-7,61 (m, 2H); 7,73-7,79 (m, 3H); 7,98 (d, J=8,3Hz, 1 H); 8,1 1 (d, J=8,2Hz, 1 H); 8,89 (s, 1 H); 10,59 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.25 (m, 4H); 2.25 (s, 3H); 2.43 (m, 4H); 2.67 (s, 3H); 2.80 (m, 1H); 2.95-3.05 (m, 2H); 3.37 (m, 2H); 5.71 (s, 2H); 7.10 (q, J = 8Hz, 4H); 7.33 (d, J = 8.9Hz, 2H); 7.43 (m, 1H); 7.56-7.61 (m, 2H); 7.73-7.79 (m, 3H); 7.98 (d, J = 8.3 Hz, 1H); 8.1 (d, J = 8.2 Hz, 1H); 8.89 (s, 1H); 10.59 (s, 1H).\n\n\n\n\n\n\n \nExemple 22 : (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-N-hydroxy-2- (4-méthanesulfonyl-pipérazin-1-yl)-propionamide. \nExample 22: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n22.1 : Benzoisoxazol-3-yl-méthanol. \n22.1 Benzoisoxazol-3-yl-methanol.\n\n\n\n\n\n\n \n589mg (3,0 mmoles) de 1 ,2-benzoisoxazole-3-carboxylate d'éthyle en solution dans 10ml de tétrahydrofuranne sont ajoutés à une suspension de 129mg (3,5 mmoles) d'hydrure de lithium aluminium dans 5ml de tétrahydrofuranne. Le mélange réactionnel est agité une heure à 6O\n0\nC puis traité par l'addition goutte à goutte de 2ml de méthanol, filtré sur célite, rincé à l'acétate d'éthyle. Les phases organiques sont rassemblées, séchées sur sulfate de sodium et évaporées. Le résidu obtenu \n\n est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 60/40. 180mg (39%) de benzoisoxazol-3-yl-méthanol sont obtenus sous forme d'un solide blanc. \n589 mg (3.0 mmol) of ethyl 1,2-benzoisoxazole-3-carboxylate dissolved in 10 ml of tetrahydrofuran are added to a suspension of 129 mg (3.5 mmol) of lithium aluminum hydride in 5 ml of tetrahydrofuran. The reaction mixture is stirred for 1 hour at 60 \n°\n C. and then treated with the dropwise addition of 2 ml of methanol, filtered through celite and rinsed with ethyl acetate. The organic phases are combined, dried over sodium sulphate and evaporated. The residue obtained  is purified by chromatography on silica gel eluted with a 60/40 heptane / ethyl acetate mixture. 180 mg (39%) of benzoisoxazol-3-yl-methanol are obtained in the form of a white solid.\n\n\n\n\n\n\n \n22.2 : (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoate de méthyle. \n22.2: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) -propionic acid methyl ester.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 494mg (1 ,2 mmoles) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) et de 175mg (1 ,2 mmoles) de benzoisoxazol-3-yl-méthanol, 459mg (71 %) de (S)-3-[4- (benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'une huile. \n In a manner analogous to Example 11.1, starting from 494 mg (1.2 mmol) of (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl (prepared as described in 5.1) and 175 mg (1.2 mmol) of benzoisoxazol-3-yl-methanol, 459 mg (71%) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino) Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained as an oil.\n\n\n\n\n\n\n \n22.3 : acide (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propanoique. \n22.3: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonylpiperazin-1-yl) propanoic acid.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 458mg (0,8 mmoles) de (S)-3-[4-(benzoisoxazol-3- ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 283mg (63%) d'acide (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4- méthanesulfonyl-pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, starting from 458 mg (0.8 mmol) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate, 283 mg (63%) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n22.4 : (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propionamide. \n22.4: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonylpiperazin-1-yl) propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 283mg (0,5 mmoles) d'acide (S)-3-[4- (benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-éthanesulfonyl-pipérazin-1-yl)-propanoique, 231 mg (80%) de (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide beige de point de fusion 107\n0\nC. \nIn a similar manner to Example 3.8, from 283 mg (0.5 mmol) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-ethanesulfonyl) piperazine -1-yl) -propanoic acid, 231 mg (80%) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1- yl) -propionamide are obtained in the form of a beige solid with a melting point of 107 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,53-2,55 (m, 4H); 2,88 (s, 3H); 2,90-2,93 (m, 2H); 3,00-3,10 (m, 4H); 3,13 (t, J=6,9Hz,1 H); 5,77 (s, 2H); 7,35 (d, J=8,8Hz, 2H); 7,49 (t, J=7,5Hz, 1 H); 7,57 (m, 1 H); 7,75 (t, J=7,4Hz, 1 H); 7,78-7,87 (m, 3H); 8,01 (d, J=8Hz, 1 H); 8,96 (m, 1 H); 10,67 (m, 1 H). Exemple 23 : (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 2.53-2.55 (m, 4H); 2.88 (s, 3H); 2.90-2.93 (m, 2H); 3.00-3.10 (m, 4H); 3.13 (t, J = 6.9Hz, 1H); 5.77 (s, 2H); 7.35 (d, J = 8.8 Hz, 2H); 7.49 (t, J = 7.5Hz, 1H); 7.57 (m, 1H); 7.75 (t, J = 7.4 Hz, 1H); 7.78-7.87 (m, 3H); 8.01 (d, J = 8Hz, 1H); 8.96 (m, 1H); 10.67 (m, 1H). Example 23: (S) -N-Hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n23.1 : (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle. \n23.1: Methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-yl-propanoate.\n\n\n\n\n\n\n \n 2g (25% massique) de palladium sur charbon 10% sont additionnés à une solution de 8g (21 mmoles) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle (préparé comme décrit dans l'exemple 17.4) dans 120ml d'éthanol, préalablement dégazée sous flux d'azote. Le milieu réactionnel est ensuite placé sous une pression atmosphérique d'hydrogène pendant 24h puis filtré sur célite et abondamment rincé au dichlorométhane. Après concentration sous vide, 6,1g (100%) de (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle sont obtenus. \n 2 g (25% by weight) of 10% palladium on carbon are added to a solution of 8 g (21 mmol) of (S) -2- (4-benzyl-piperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate. methyl (prepared as described in Example 17.4) in 120 ml of ethanol, previously degassed under a stream of nitrogen. The reaction medium is then placed under atmospheric pressure of hydrogen for 24 h and then filtered through Celite and thoroughly rinsed with dichloromethane. After concentration under vacuum, 6.1 g (100%) of methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-ylpropanoate are obtained.\n\n\n\n\n\n\n \n23.2 : (S)-3-tert-butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)-propanoate de méthyle. \n\n 1 ,2ml ( 8,3 mmoles) de triéthylamine puis 0,8ml (7,6 mmoles) de chlorure d'isobutyryle sont additionnés à une solution de 2,0g ( 6,9 mmoles) de (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl- propanoate de méthyle dans 20ml de dichlorométhane, préalablement refroidie à O\n0\nC. Après agitation à température ambiante pendant 1 h30, de l'eau est additionnée. Le milieu réactionnel est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le résidu brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 50/50. 2,0g (81 %) de ((S)-3-tert-butoxycarbonylamino-2-(4- isobutyryl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'une huile incolore. 23.3 : acide (S)-3-tert-butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)-propanoïque. \n23.2: Methyl (S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) -propanoate.  1.2 ml (8.3 mmol) of triethylamine and 0.8 ml (7.6 mmol) of isobutyryl chloride are added to a solution of 2.0 g (6.9 mmol) of (S) -3-tert- methyl butoxycarbonylamino-2-piperazin-1-yl-propanoate in 20 ml of dichloromethane, previously cooled to 0 \n°\n C. After stirring at room temperature for 1 h 30, water is added. The reaction medium is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude residue obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 2.0 g (81%) of methyl ((S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) -propanoate are obtained in the form of a colorless oil. S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) propanoic acid.\n\n\n\n\n\n\n \n 10ml (10 mmoles) d'une solution aqueuse d'hydroxyde de lithium de concentration 1 N sont additionnés à une solution de 2,0g (5,6 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4-isobutyryl- pipérazin-1-yl)-propanoate de méthyle dans 40ml de tétrahydrofuranne et 8ml d'eau puis le milieu réactionnel est agité à température ambiante pendant 2Oh. Après addition d'une solution aqueuse d'acide acétique de concentration 1 N, le produit est extrait au n-butanol. La phase organique est séchée sur sulfate de magnésium, filtrée, concentrée sous vide. 1 ,5g (78%) d'acide (S)-3-tert- butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)propanoïque sont obtenus sous forme d'un solide blanc. 23.4 : (S)-2-allyloxycarbamoyl-2-(4-isobutyryl-pipérazin-1-yl)-éthyl]-carbamate de tert-butyle. \n 10 ml (10 mmol) of a 1 N aqueous solution of lithium hydroxide are added to a solution of 2.0 g (5.6 mmol) of (S) -3-tert-butoxycarbonylamino-2- (4- methyl isobutyryl-piperazin-1-yl) -propanoate in 40 ml of tetrahydrofuran and 8 ml of water and then the reaction medium is stirred at ambient temperature for 20 h. After addition of a 1N aqueous solution of acetic acid, the product is extracted with n-butanol. The organic phase is dried over magnesium sulfate, filtered and concentrated in vacuo. 1.5 g (78%) of (S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) propanoic acid are obtained as a white solid. 23.4: (S) -2-allyloxycarbamoyl-2- (4-isobutyryl-piperazin-1-yl) -ethyl] -carbamate tert-butyl ester.\n\n\n\n\n\n\n \n 1 ,4g (4,4 mmoles) de O-(benzotriazol-1-yl)-N,N, N',N'-tétraméthyluroniumtétrafluoroborate puis 2,3ml (13,1 mmoles) de diisopropyléthylamine sont ajoutés à une solution de 1 ,5g (4,4 mmoles) d'acide (S)- 3-tert-butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)-propanoïque dans 20ml de diméthylformamide. Après agitation à température ambiante pendant 15min, une solution de 500mg (4,6 mmoles) de chlorhydrate de O-allyl-hydroxylamine et de 0,8ml (4,6 mmoles) de diisopropyléthylamine dans 10ml de diméthylformamide est ajoutée. Le milieu réactionnel est agité à température ambiante pendant 2Oh, hydrolyse par une solution aqueuse saturée d'hydrogénocarbonate de sodium puis dilué par de l'acétate d'éthyle. La phase organique est lavée par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. 1 ,45g (83%) de [(S)-2-allyloxycarbamoyl-2-(4-isobutyryl-pipérazin-1-yl)-éthyl]- carbamate de tert-butyle sont obtenus sous forme d'une huile incolore. \n 1.4 g (4.4 mmol) of O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyluroniumtetrafluoroborate and then 2.3 ml (13.1 mmol) of diisopropylethylamine are added to a solution of 1 5 g (4.4 mmol) of (S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) -propanoic acid in 20 ml of dimethylformamide. After stirring at room temperature for 15 min, a solution of 500 mg (4.6 mmol) of O-allyl-hydroxylamine hydrochloride and 0.8 ml (4.6 mmol) of diisopropylethylamine in 10 ml of dimethylformamide is added. The reaction medium is stirred at ambient temperature for 20 h, hydrolyzed with a saturated aqueous solution of sodium hydrogencarbonate and then diluted with ethyl acetate. The organic phase is washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. 1.45 g (83%) of tert-butyl [(S) -2-allyloxycarbamoyl-2- (4-isobutyryl-piperazin-1-yl) -ethyl] carbamate are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n23.5 : dichlorhydrate de (S)-N-allyloxy-3-amino-2-(4-isobutyryl-pipérazin-1-yl)-propionamide. \n23.5: (S) -N-Allyloxy-3-amino-2- (4-isobutyryl-piperazin-1-yl) -propionamide dihydrochloride.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 19.3, à partir de 1 ,45g (3,6 mmoles) de [(S)-2-allyloxycarbamoyl-2- (4-isobutyryl-pipérazin-1-yl)-éthyl]-carbamate de tert-butyle, 1 ,4g (100%) de dichlorhydrate de (S)-N- allyloxy-3-amino-2-(4-isobutyryl-pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc. \n Analogous to Example 19.3, from 1.45 g (3.6 mmol) of [(S) -2-allyloxycarbamoyl-2- (4-isobutyryl-piperazin-1-yl) -ethyl] -carbamate from tert-butyl, 1.4 g (100%) of (S) -N-allyloxy-3-amino-2- (4-isobutyryl-piperazin-1-yl) -propionamide dihydrochloride are obtained in the form of a white solid .\n\n\n\n\n\n\n \n23.6 : (S)-N-allyloxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n\n 1 ,9g (5,1 mmoles) du chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonyle chlorohydrate (préparé comme décrit en 32.2) sont ajoutés à une solution de 1 ,3g (3,6 mmoles) de dichlorhydrate de (S)-N-allyloxy-3-amino-2-(4-isobutyryl-pipérazin-1-yl)- propionamide, 2,0ml (14,5 mmoles) de triéthylamine dans 15ml de dichlorométhane et 15ml de diméthylformamide , préalablement refroidie à O\n0\nC. Le milieu réactionnel est ensuite agité de O\n0\nC à température ambiante pendant 3h. Après addition d'eau, le milieu réactionnel est extrait au dichlorométhane. La phase organique est lavée par une solution aqueuse d'hydrogénocarbonate de sodium saturée, par de l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. \n23.6: (S) -N-Allyloxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.  1. 9 g (5.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonyl chloride hydrochloride hydrochloride (prepared as described in 32.2) are added to a solution of 1.3 g (3.6 g). mmol) of (S) -N-allyloxy-3-amino-2- (4-isobutyryl-piperazin-1-yl) propionamide dihydrochloride, 2.0ml (14.5 mmol) of triethylamine in 15ml of dichloromethane and 15ml of dimethylformamide, previously cooled to 0 \n°\n C. The reaction medium is then stirred at 0 \n°\n C. at ambient temperature for 3 hours. After addition of water, the reaction medium is extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium hydrogen carbonate solution, with water, dried over magnesium sulfate, filtered and concentrated.\n\n\n\n\n\n\n \nLe résidu brut obtenu est purifié par chromatographie sur colonne de silice élue avec un mélange dichlorométhane/ méthanol 97/3. 900mg (41 %) de (S)-N-allyloxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4- (2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc. \nThe crude residue obtained is purified by chromatography on a silica column eluted with a 97/3 dichloromethane / methanol mixture. 900mg (41%) of (S) -N-allyloxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white solid.\n\n\n\n\n\n\n \n23.7 : (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n23.7: (S) -N-hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n 33mg (0,06 mmoles) de palladium tétrakis triphénylphosphine puis 920mg (6,6 mmoles) de carbonate de potassium sont additionnés à une solution de 670mg (1 ,1 mmoles) de (S)-N-allyloxy-2-(4- isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide dans 15ml de méthanol puis le milieu réactionnel est chauffé à reflux pendant 8h. Après addition d'acétate d'éthyle, le milieu réactionnel est lavé par une solution aqueuse d'hydrogénocarbonate de sodium saturée. La phase organique est ensuite lavée par de l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le produit brut est repris dans 6ml d'éthanol et 12 ml d'eau puis chauffé à 8O\n0\nC jusqu'à solubilisation. Après refroidissement, la cristallisation est amorcée par évaporation d'un minimum d'éthanol. 120mg de produit sont obtenus par filtration et purifiés par chromatographie sur couche mince de silice préparative, élues avec un mélange dichlorométhane / méthanol 97/3. \n33 mg (0.06 mmol) of palladium tetrakis triphenylphosphine and then 920 mg (6.6 mmol) of potassium carbonate are added to a solution of 670 mg (1.1 mmol) of (S) -N-allyloxy-2- (4- isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide in 15 ml of methanol and the reaction medium is refluxed for 8 h. After addition of ethyl acetate, the reaction medium is washed with saturated aqueous sodium hydrogen carbonate solution. The organic phase is then washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product is taken up in 6 ml of ethanol and 12 ml of water and then heated at 80 \n°\n C. until solubilization. After cooling, the crystallization is initiated by evaporation of a minimum of ethanol. 120 mg of product are obtained by filtration and purified by preparative silica thin layer chromatography, eluted with a 97/3 dichloromethane / methanol mixture.\n\n\n\n\n\n\n \n 20mg (3%) de (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide sont finalement obtenus sous forme d'un solide beige. \n 20 mg (3%) of (S) -N-hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are finally obtained in the form of a beige solid.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 0,84 (s, 3H); 0,85 (s, 3H); 2,30-2,44 (m, 2H); 2,52 (m, 2H); 2,67 (s, 3H); 2,77 (m, 1 H); 2,85 (m, 2H); 2,95 (m, 1 H); 3,35 (m, 4H); 5,71 (s, 2H); 7,33 (d, J=8,9Hz, 2H); 7,43 (m, 1 H); 7,55- 7,62 (m, 2H); 7,72-7,82 (m, 3H); 7,98 (d, J=8,4Hz, 1 H); 8,11 (d, J=8,2Hz, 1 H); 8,96 (m, 1 H); 10,67 (m, 1 H). \n \n1\n H NMR (δ, DMSO): 0.84 (s, 3H); 0.85 (s, 3H); 2.30-2.44 (m, 2H); 2.52 (m, 2H); 2.67 (s, 3H); 2.77 (m, 1H); 2.85 (m, 2H); 2.95 (m, 1H); 3.35 (m, 4H); 5.71 (s, 2H); 7.33 (d, J = 8.9Hz, 2H); 7.43 (m, 1H); 7.55-7.62 (m, 2H); 7.72-7.82 (m, 3H); 7.98 (d, J = 8.4Hz, 1H); 8.11 (d, J = 8.2 Hz, 1H); 8.96 (m, 1H); 10.67 (m, 1H).\n\n\n\n\n\n\n \nExemple 24 : (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-l]-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 24: (S) -N-Hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy) ) benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n24.1 : (S)-3-tert-butoxycarbonylamino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle. \n24.1: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate.\n\n\n\n\n\n\n \n 479mg (3,0 mmoles) de chlorure de 2-méthyl-propane-1-sulfonyle sont additionnés à une solution de\n 479 mg (3.0 mmol) of 2-methyl-propane-1-sulfonyl chloride are added to a solution of\n\n\n\n\n\n\n \n800mg (2,8 mmoles) de (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle (préparé comme décrit dans l'exemple 23.1 ), 775μl (5,5 mmoles) de triéthylamine dans 8ml de dichlorométhane, préalablement refroidie à O\n0\nC. Le milieu réactionnel est agité à température \n\n ambiante pendant 18h puis de l'eau est additionnée et le milieu est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 5/5. 785mg (71 %) de (S)-3-tert-butoxycarbonylamino-2-[4-(2-méthyl-propane-1-sulfonyl)- pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \n800 mg (2.8 mmol) of methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-ylpropanoate (prepared as described in Example 23.1), 775 μl (5.5 mmol) of triethylamine in 8 ml of dichloromethane, previously cooled to 0 \n°\n C. The reaction medium is stirred at room temperature  ambient for 18h then water is added and the medium is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. The residue obtained is purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 5/5. 785 mg (71%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n24.2 : dichlorhydrate de (S)-3-amino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle. \n24.2: Methyl (S) -3-amino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate dihydrochloride.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.3, à partir de 785mg (1 ,9 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle,\n In a similar manner to Example 3.3, from 785 mg (1.9 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1 methyl-methylpropanoate,\n\n\n\n\n\n\n \n621 mg (85%) de dichlorhydrate de (S)-3-amino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]- propanoate de méthyle sont obtenus sous forme d'un solide. \n621 mg (85%) of methyl (S) -3-amino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate dihydrochloride are obtained in the form of a solid.\n\n\n\n\n\n\n \n24.3 : (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle. \n24.3: (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] - methyl propanoate.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 621 mg (1 ,6 mmoles) de dichlorhydrate de (S)-3- amino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle et de 876mg (2,3 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 643mg (64%) de (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin- 1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle \n In a manner similar to Example 3.6, from 621 mg (1.6 mmol) of (S) -3-amino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin) dihydrochloride were used. Methyl 1-yl] -propanoate and 876 mg (2.3 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 643 mg ( 64%) of (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino) ] -methyl propanoate\n\n\n\n\n\n\n \nsont obtenus sous forme d'une huile. \nare obtained in the form of an oil.\n\n\n\n\n\n\n \n24.4 : acide (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propanoique. \n24.4: (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] acid propanoic acid.\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 643mg (1 ,0 mmole) de (S)-2-[4-(2-méthyl-propane- 1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 395mg (63%) d' acide (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique sont obtenus sous forme d'un solide blanc. 24.5 : (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nIn a similar manner to Example 3.7, from 643 mg (1.0 mmol) of (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- Methyl 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate, 395 mg (63%) of (S) -2- [4- (2-methyl-propane-1-sulfonyl) acid) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained as a white solid. 24.5: (S) -N-hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy)); benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 390mg (0,6 mmoles) d'acide (S)-2-[4-(2-méthyl- propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 12mg (3%) de (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2- méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc. \n In a manner similar to Example 3.8, from 390 mg (0.6 mmol) of (S) -2- [4- (2-methylpropane-1-sulfonyl) -piperazin-1-yl] - 3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid, 12 mg (3%) of (S) -N-hydroxy-2- [4- (2-methyl-propane-1-yl) sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained as a white solid.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 1 ,01 (d, J=6,7Hz, 6H); 2,05 (m, 1 H); 2,49 (m, 4H); 2,67 (s, 3H); 2,86 (d, J=6,6Hz, 2H); 3,00-3,10 (m, 6H); 3,31 (m, 1 H); 5,71 (s, 2H); 7,34 (d, J=8,9Hz, 2H); 7,52 (m, 1 H); 7,57 (m, 2H); 7,76-7,80 (m, 3H); 7,98 (d, J=8,2Hz, 1 H); 8,10 (m, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n\n Exemple 25 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl- pyrazolo[1,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 1, 01 (d, J = 6.7Hz, 6H); 2.05 (m, 1H); 2.49 (m, 4H); 2.67 (s, 3H); 2.86 (d, J = 6.6Hz, 2H); 3.00-3.10 (m, 6H); 3.31 (m, 1H); 5.71 (s, 2H); 7.34 (d, J = 8.9Hz, 2H); 7.52 (m, 1H); 7.57 (m, 2H); 7.76-7.80 (m, 3H); 7.98 (d, J = 8.2 Hz, 1H); 8.10 (m, 1H); 8.93 (s, 1H); 10.66 (s, 1H).  Example 25: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n25.1 : 2-thfluorométhyl-pyrazolo[1,5-a]pyhdine-3-carboxylate d'éthyle. \n25.1: ethyl 2-thfluoromethyl-pyrazolo [1,5-a] pyhdine-3-carboxylate.\n\n\n\n\n\n\n \nUne solution de 2,1g (38 mmoles) de KOH dans 20ml d'eau puis 6,7g (30 mmoles) d'iodure de 1- amino-pyridinium sont ajoutés à une solution de 2,5g (15 mmoles) de 4,4,4-trifluoro-but-2-ynoate d'éthyle dans 25ml de dichlorométhane. Après agitation à température ambiante pendant 5h, de l'eau est additionnée et le milieu réactionnel est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 8/2. 2,8g (73%) de 2-trifluorométhyl-pyrazolo[1 ,5-α]pyridine-3-carboxylate d'éthyle sont obtenus sous forme d'un solide jaune. \nA solution of 2.1 g (38 mmol) of KOH in 20 ml of water and then 6.7 g (30 mmol) of 1-amino-pyridinium iodide are added to a solution of 2.5 g (15 mmol) of 4, Ethyl 4,4-trifluoro-but-2-ynoate in 25 ml of dichloromethane. After stirring at room temperature for 5 hours, water is added and the reaction mixture is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. The residue obtained is purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 8/2. 2.8 g (73%) of ethyl 2-trifluoromethyl-pyrazolo [1,5-a] pyridine-3-carboxylate are obtained in the form of a yellow solid.\n\n\n\n\n\n\n \n25.2 : (2-thfluorométhyl-pyrazolo[1 , 5-a]pyhdin-3-yl)-méthanol. \n25.2: (2-thfluoromethyl-pyrazolo [1,5-a] pyhdin-3-yl) -methanol.\n\n\n\n\n\n\n \nUne solution de 2,8g (11 mmoles) de 2-trifluorométhyl-pyrazolo[1 ,5-α]pyridine-3-carboxylate d'éthyle dans 50ml de tétrahydrofuranne est additionnée goutte à goutte à une suspension de 0,5g (12 mmoles) d'hydrure d'aluminium et de lithium dans 45ml de tétrahydrofuranne. Le milieu réactionnel est ensuite agité à 7O\n0\nC pendant 3h. Après addition goutte à goutte de 2,5ml de méthanol puis de 1 ,8ml d'une solution aqueuse d'hydroxyde de sodium de concentration 2N, le milieu réactionnel est agité 20mn à température ambiante puis filtré. Le filtrat est séché sur sulfate de magnésium, filtré et concentré sous vide. 2,3g (100%) de (2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-yl)-méthanol sont obtenus sous forme d'un solide. \nA solution of 2.8 g (11 mmol) of ethyl 2-trifluoromethyl-pyrazolo [1,5-a] pyridine-3-carboxylate in 50 ml of tetrahydrofuran is added dropwise to a suspension of 0.5 g (12 mmol ) of aluminum hydride and lithium in 45ml of tetrahydrofuran. The reaction medium is then stirred at 70 \n°\n C. for 3 hours. After dropwise addition of 2.5 ml of methanol and then 1.8 ml of a 2N aqueous solution of sodium hydroxide, the reaction medium is stirred for 20 minutes at ambient temperature and then filtered. The filtrate is dried over magnesium sulfate, filtered and concentrated in vacuo. 2.3 g (100%) of (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-yl) -methanol are obtained in the form of a solid.\n\n\n\n\n\n\n \n25.3 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-thfluorométhyl-pyrazolo[1, 5-a]pyridin-3- ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle. \n25.3: (S) -2- (4-Methanesulfonyl-piperazin-1-yl) -3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoate methyl.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 800mg (1 ,9 mmoles) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) et de 540mg (2,5 mmoles) de (2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-yl)-méthanol, 380mg (32%) de (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5- a]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 11.1, from 800 mg (1.9 mmol) of (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl (prepared as described in 5.1) and 540 mg (2.5 mmol) of (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-yl) -methanol, 380 mg (32%) of (S) - Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n25.4 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-thfluorométhyl-pyrazolo[1,5-α]pyhdin-3- ylméthoxy)-benzènesulfonylamino]-propanoique. \n25.4: (S) -2- (4-Methanesulfonyl-piperazin-1-yl) -3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyhdin-3-ylmethoxy) -benzenesulfonylamino] -propanoic acid .\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 380mg (0,6 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle, 237mg (64%) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2- trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propanoique \nAnalogously to Example 3.7, from 380 mg (0.6 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [ Methyl 1, 5-α] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoate, 237 mg (64%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4] - (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoic\n\n\n\n\n\n\n \nsont obtenus sous forme d'un solide blanc. \n\n25.5: (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-thfluorométhyl-pyrazolo[1,5- a]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide. \nare obtained in the form of a white solid.  25.5: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino ] -propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 230mg (0,4 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)- benzènesulfonylamino]-propanoique, 9mg (4%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide sous forme d'un solide blanc. \n In a manner similar to Example 3.8, from 230 mg (0.4 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl) -2- pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] propanoic acid, 9mg (4%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propionamide as a white solid.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,51-2,54 (m, 4H); 2,84 (s, 3H); 2,95 (m, 1 H); 2,97-3,04 (m, 4H); 3,10 (m, 1 H); 3,32 (m, 1 H); 5,45 (s, 2H); 7,20-7,25 (m, 3H); 7,49-7,51 (m, 2H); 7,76 (d, J=8,8Hz, 2H); 8,04 (m, 1 H); 8,87 (d, J=7Hz, 2H); 8,90 (m, 1 H). \n \n1\n H NMR (δ, DMSO): 2.51-2.54 (m, 4H); 2.84 (s, 3H); 2.95 (m, 1H); 2.97-3.04 (m, 4H); 3.10 (m, 1H); 3.32 (m, 1H); 5.45 (s, 2H); 7.20-7.25 (m, 3H); 7.49-7.51 (m, 2H); 7.76 (d, J = 8.8 Hz, 2H); 8.04 (m, 1H); 8.87 (d, J = 7Hz, 2H); 8.90 (m, 1H).\n\n\n\n\n\n\n \nExemple 26 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4- (propane-2-sulfonyl)-pipérazin-1-yl]-propionamide. 26.1 : (S)-3-tertbutoxycarbonylamino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle De manière analogue à l'exemple 20.2, à partir de 800mg (2,8 mmoles) de (S)-3- tertbutoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle (préparé comme décrit dans l'exemple 23.1 ) et de 342μl (3,1 mmoles) de chlorure de propane-2-sulfonyle, 700mg (64%) de (S)-3- tertbutoxycarbonylamino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile. \nExample 26: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propionamide. 26.1: Methyl (S) -3-tertbutoxycarbonylamino-2- [4- (propan-2-sulfonyl) -piperazin-1-yl] -propanoate Analogous to Example 20.2, from 800 mg (2.8 g) mmol) of methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-yl-propanoate (prepared as described in Example 23.1) and 342 μl (3.1 mmol) of propane-2-sulphonyl chloride, 700 mg (64%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoate are obtained in the form of an oil.\n\n\n\n\n\n\n \n26.2 : dichlorhydrate de (S)-3-amino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle De manière analogue à l'exemple 3.3, à partir de 700mg (1 ,8 mmoles) (S)-3-tertbutoxycarbonylamino- 2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle, 620mg (86%) du dichlorhydrate de (S)-3-amino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile. \n26.2: Methyl (S) -3-amino-2- [4- (propan-2-sulfonyl) -piperazin-1-yl] -propanoate dihydrochloride Analogous to Example 3.3, starting from 700 mg (1 Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoate, 620 mg (86%) of the (S) -3-dihydrochloride. Methyl amino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoate are obtained as an oil.\n\n\n\n\n\n\n \n26.3 : (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)- pipérazin-1 -yl]-propanoate de méthyle \n26.3: Methyl (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propan-2-sulfonyl) piperazin-1-yl] -propanoate\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.6, à partir de 620mg (1 ,5 mmoles) de dichlorhydrate de (S)-3- amino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle et de 830mg (2,1 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 505mg (54%) de (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \nIn a manner similar to Example 17.6, from 620 mg (1.5 mmol) of (S) -3-amino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] dihydrochloride, methyl propanoate and 830 mg (2.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 505 mg (54%) of Methyl 3- (4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (propan-2-sulfonyl) -piperazin-1-yl] -propanoate are obtained in the form of of a white solid.\n\n\n\n\n\n\n \n26.4 : acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propanoique \n26.4: (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 505mg (0,8 mmoles) de (S)-3-[4-(2-méthyl-quinolin- 4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle, \n\n135mg (27%) d' acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane- 2-sulfonyl)-pipérazin-1-yl]-propanoique sont obtenus sous forme d'un solide blanc. \nAnalogous to Example 3.7, from 505 mg (0.8 mmol) of (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- ( methyl propane-2-sulfonyl) -piperazin-1-yl] -propanoate,  135mg (27%) of (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl) ] -propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n26.5 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionamide \n26.5: (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 135mg (0,2 mmoles) d'acide (S)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoique, 24mg (17%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4- (propane-2-sulfonyl)-pipérazin-1-yl]-propionamide sont obtenus sous forme d'un solide blanc. \n Analogously to Example 3.8, from 135 mg (0.2 mmol) of (S) -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4] - (propan-2-sulfonyl) -piperazin-1-yl] propanoic acid, 24 mg (17%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino) ] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propionamide are obtained as a white solid.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 1 ,19 (d, J=6,8Hz, 6H); 2,45 (m, 4H); 2,68 (s, 3H); 2,80-2,90 (m, 1 H); 2,95-3,15 (m, 6H); 3,29 (m, 1 H); 5,72 (s, 2H); 7,34 (d, J=8,9Hz, 2H); 7,52 (m, 1 H); 7,57 (m, 2H); 7,76-7,80 (m, 3H); 7,98 (d, J=8,2Hz, 1 H); 8,10 (d, J=8,1 Hz, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 1.19 (d, J = 6.8 Hz, 6H); 2.45 (m, 4H); 2.68 (s, 3H); 2.80-2.90 (m, 1H); 2.95-3.15 (m, 6H); 3.29 (m, 1H); 5.72 (s, 2H); 7.34 (d, J = 8.9Hz, 2H); 7.52 (m, 1H); 7.57 (m, 2H); 7.76-7.80 (m, 3H); 7.98 (d, J = 8.2 Hz, 1H); 8.10 (d, J = 8.1 Hz, 1H); 8.93 (s, 1H); 10.66 (s, 1H).\n\n\n\n\n\n\n \nExemple 27 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy -3-[4-(2-trifluorométhyl-pyrazolo[1,5- α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 27: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n27.1 : chlorure de 4-hydroxy-benzènesulfonyle \n27.1: 4-hydroxy-benzenesulfonyl chloride\n\n\n\n\n\n\n \n Une solution de 7g (30 mmoles) du sel de sodium de l'acide 4-hydroxy-benzènesulfonique dihydrate dans 40ml de diméthylformamide est additionnée goutte à goutte à une solution de 15,5ml (181 mmoles) de chlorure d'oxalyle dans 120ml de dichlorométhane refroidie à -3O\n0\nC. Le milieu réactionnel est lentement ramené à température ambiante puis agité à température ambiante pendant 18h. Après addition de 200ml de glace, le milieu réactionnel est extrait à l'acétate d'éthyle. La phase organique est lavée par de l'eau, par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium, filtrée et concentrée. 6,2g (100%) de chlorure de 4-hydroxy-benzènesulfonyle sont obtenus sous forme d'une huile incolore. \nA solution of 7 g (30 mmol) of the sodium salt of 4-hydroxy-benzenesulphonic acid dihydrate in 40 ml of dimethylformamide is added dropwise to a solution of 15.5 ml (181 mmol) of oxalyl chloride in 120 ml of dichloromethane cooled to -30 \n°\n C. The reaction medium is slowly brought to ambient temperature and then stirred at ambient temperature for 18 hours. After addition of 200 ml of ice, the reaction medium is extracted with ethyl acetate. The organic phase is washed with water, with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, filtered and concentrated. 6.2 g (100%) of 4-hydroxy-benzenesulfonyl chloride are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n27.2 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-(4-hydroxy-benzènesulfonylamino)-propanoate de méthyle\n27.2: methyl (S) -2- (4-benzylpiperazin-1-yl) -3- (4-hydroxy-benzenesulfonylamino) propanoate\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.6, à partir de 5,8g (30 mmoles) de chlorure de 4-hydroxy- benzènesulfonyle et de 7,7g (20 mmoles) de trichlorhydrate de (S)-3-amino-2-(4-benzyl-pipérazin-1- yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 17.5), 2,25g (27%) de (S)-2-(4- benzyl-pipérazin-1-yl)-3-(4-hydroxy-benzènesulfonylamino)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \nIn a similar manner to Example 3.6, from 5.8 g (30 mmol) of 4-hydroxybenzenesulfonyl chloride and 7.7 g (20 mmol) of (S) -3-amino-2- ( Methyl 4-benzyl-piperazin-1-yl) -propanoate (prepared as described in Example 17.5), 2.25 g (27%) of (S) -2- (4-benzyl-piperazin-1-yl) Methyl 3- (4-hydroxy-benzenesulfonylamino) propanoate are obtained as a white solid.\n\n\n\n\n\n\n \n27.3 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1,5-a]pyridin-3-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle \n27.3: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoate methyl\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 500mg (1 ,1 mmoles) de (S)-2-(4-benzyl-pipérazin- 1-yl)-3-(4-hydroxy-benzènesulfonylamino)-propanoate de méthyle, et de 370mg (1 ,7 mmoles) de (2- trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-yl)-méthanol (préparé comme décrit dans l'exemple 25.2), 350mg (50%) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3- \n\n ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \nIn a manner analogous to Example 11.1, from 500 mg (1.1 mmol) of (S) -2- (4-benzyl-piperazin-1-yl) -3- (4-hydroxy-benzenesulfonylamino) -propanoate. methyl, and 370mg (1.7 mmol) of (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-yl) -methanol (prepared as described in Example 25.2), 350mg (50%) of (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-  Methyl ylmethoxy) -benzenesulfonylamino] -propanoate are obtained as a colorless oil.\n\n\n\n\n\n\n \n27.4 : acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1,5-α]pyridin-3-ylméthoxy)- benzènesulfonylamino]-propanoïque \n27.4: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 350mg (0,5 mmoles) de (S)-2-(4-benzyl-pipérazin-1- yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle, 165mg (48%) d' acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5- α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 350 mg (0.5 mmol) of (S) -2- (4-benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [ Methyl 1,5-α] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoate, 165 mg (48%) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4] (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n27.5 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-thfluorométhyl-pyrazolo[1,5-α]pyhdin-3- ylméthoxy)-benzènesulfonylamino]-propionamide \n27.5: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyhdin-3-ylmethoxy) -benzenesulfonylamino ] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 165mg (0,3 mmoles) d'acide (S)-2-(4-benzyl- pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]- propanoique, 50mg (29%) de (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-trifluorométhyl- pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 138\n0\nC. \nAnalogously to Example 3.8, from 165 mg (0.3 mmol) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-trifluoromethyl) -2- pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoic acid, 50 mg (29%) of (S) -2- (4-benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white solid having a melting point of 138 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,20 (m, 4H); 2,38 (m, 4H); 2,65-2,75 (m, 1 H); 2,86-2,98 (m, 2H); 3,35 (m, 2H); 5,37 (s, 2H); 7,10-7,25 (m, 8H); 7,35-7,44 (m, 2H); 7,68 (d, J=8,9Hz, 2H); 7,98 (d, J=9Hz, 1 H); 8,81\n \n1\n H NMR (δ, DMSO): 2.20 (m, 4H); 2.38 (m, 4H); 2.65-2.75 (m, 1H); 2.86-2.98 (m, 2H); 3.35 (m, 2H); 5.37 (s, 2H); 7.10-7.25 (m, 8H); 7.35-7.44 (m, 2H); 7.68 (d, J = 8.9Hz, 2H); 7.98 (d, J = 9Hz, 1H); 8.81\n\n\n\n\n\n\n \n(m, 2H); 10,52 (s, 1 H). \n(m, 2H); 10.52 (s, 1H).\n\n\n\n\n\n\n \nExemple 28 : Test enzymatique d'inhibition de TACE. Description du test \nExample 28 Enzymatic Test for TACE Inhibition Description of the test\n\n\n\n\n\n\n \n Les produits sont solubilisés dans du DMSO à une concentration de 10 mM. Une dilution sérielle de raison 3 sur 10 points est effectuée de façon à avoir une gamme de concentration allant de 10 μM à 0,5 nM final. \n The products are solubilized in DMSO at a concentration of 10 mM. A serial dilution of 3 out of 10 points is carried out so as to have a concentration range from 10 μM to 0.5 nM final.\n\n\n\n\n\n\n \nL'enzyme TACE est une production interne (réalisée selon la publication « protein Eng Des Sel 2006, 19., 155-161 ») et, est ajouté de façon à avoir un signal équivalent à 6 fois le bruit de fond en 2h à 37\n0\nC. La réaction s'effectue en milieu tamponné Tris 50 mM, 4% de glycérol, pH7,4. Le substrat fluorescent est MCA-Pro-Leu-Ala-Val-(Dpa)-Arg-Ser-Ser-Arg-NH2 (R&D System référence :ES003). Le substrat est clivé par l'enzyme entre l'alanine et la valine libérant ainsi un peptide fluorescent (excitation : 320nm, émission : 420nm). Le substrat est utilisé à 40μM. la réaction est réalisée dans un volume final de 10μl (4μl inhibiteur, 4μl substrat, 2μl enzyme) dans une plaque de 384 puits low volume (Corning référence : 3676). La plaque est incubée 2h à température ambiante, puis lue en fluorescence au Pherastar (BMG labtech). L\n1\nIC\n50\n est déterminée en utilisant un logiciel de traitement mathématique (XLfit). \n\n Test des produits \nThe TACE enzyme is an internal production (carried out according to the publication \"protein Eng Des Sel 2006, 19., 155-161\") and is added so as to have a signal equivalent to 6 times the background noise in 2 hours at 37. \n0\n C. The reaction is performed in 50 mM Tris buffered medium, 4% glycerol, pH 7.4. The fluorescent substrate is MCA-Pro-Leu-Ala-Val- (Dpa) -Arg-Ser-Ser-Arg-NH2 (R & D System reference: ES003). The substrate is cleaved by the enzyme between alanine and valine thus releasing a fluorescent peptide (excitation: 320 nm, emission: 420 nm). The substrate is used at 40 μM. the reaction is carried out in a final volume of 10 μl (4 μl inhibitor, 4 μl substrate, 2 μl enzyme) in a plate of 384 low-volume wells (Corning reference: 3676). The plate is incubated for 2 hours at room temperature and then read in fluorescence with Pherastar (BMG labtech). L \n1\n IC \n50\n is determined using mathematical processing software (XLfit).  Product testing\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Sur la base des résultats obtenus dans le test enzymatique TACE décrit ci-dessus, les composés revendiqués dans la présente invention sont des inhibiteurs de l'enzyme TNF-alpha converting enzyme (TACE) et de ce fait peuvent être des principes actifs potentiels pour le traitement de pathologies pour lesquelles diminuer la production de TNF alpha serait d'un grand intérêt. \n Based on the results obtained in the TACE enzymatic assay described above, the compounds claimed in the present invention are inhibitors of the enzyme TNF-alpha converting enzyme (TACE) and therefore may be potential active ingredients for treatment of diseases for which to decrease the production of TNF alpha would be of great interest.\n\n\n\n\n\n\n \nExemple 29 : test de sélectivité \nExample 29: selectivity test\n\n\n\n\n\n\n \nPrincipe du test : \nPrinciple of the test:\n\n\n\n\n\n\n \n Les molécules sont testées en dose réponse sur les enzymes suivants MMP1 , MMP3, MMP9, ADAM9 et ADAM10 suivant le même protocole que celui décrit pour l'enzyme TACE dans l'exemple 28 mais avec des substrats différents (MMP R&D System référence :P126-990 et ADAM R&D System référence :ES003). \n The molecules are tested in dose response on the following enzymes MMP1, MMP3, MMP9, ADAM9 and ADAM10 according to the same protocol as that described for the enzyme TACE in Example 28 but with different substrates (MMP R & D System reference: P126- 990 and ADAM R & D System Reference: ES003).\n\n\n\n\n\n\n \nLes enzymes sont achetées chez Calbiochem \nEnzymes are bought at Calbiochem\n\n\n\n\n\n\n \nTest des produits : \nProduct testing:\n\n\n\n\n\n\n \nIC50 (nM) \n\n\n\n\n\nIC50 (nM) \n \n\n\n\n\n\n\n \nSur la base des résultats obtenus dans le test de sélectivité décrit ci-dessus, ces composés sont également très sélectifs de TACE par rapport aux autres ADAMs et MMPs, c'est-à-dire qu'ils présentent des IC\n50\n pour d'autres ADAMs ou MMPs au moins 10 fois supérieures à celle obtenue pour TACE, et plus avantageusement au moins 100 fois supérieures. \nOn the basis of the results obtained in the selectivity test described above, these compounds are also very selective for TACE compared to other ADAMs and MMPs, ie they have IC \n50\n for others. ADAMs or MMPs at least 10 times higher than that obtained for TACE, and more preferably at least 100 times higher.\n\n\n\n\n\n\n \n Or, dans la mesure où il est connu que l'inhibition non sélective de ces familles d'enzymes induit des effets secondaires indésirables observés In Vivo, l'inhibition sélective de TACE par rapport à ces autres enzymes devrait permettre de réduire des effets secondaires indésirables lors de l'administration de ces molécules pour le traitement de pathologies pour lesquelles diminuer la production de TNF alpha serait d'un grand intérêt. \n\n However, since it is known that the non-selective inhibition of these families of enzymes induces undesirable side effects observed in vivo, the selective inhibition of TACE relative to these other enzymes should make it possible to reduce undesirable side effects. during the administration of these molecules for the treatment of pathologies for which to decrease the production of TNF alpha would be of great interest."
  }
]